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ABSTRACT 
 
Cell-penetrating peptides (CPPs) facilitate the delivery of cell-impermeable 
macrmolecules across the plasma membrane of live cells. CPPs act as biological Trojan 
horses by hijacking and inducing endocytosis to enter cells, which leads to entrapment of 
these peptides inside endocytic organelles. However, the endosomolytic activity displayed 
by CPPs is very low and cargos/CPP-cargo conjugates typically remain trapped inside 
endosomes. As a result, cargos often cannot reach their intracellular targets and fail to 
exert a biological response.  A possible solution to this problem is to increase the 
endosomolytic activity of CPPs by creating multivalent CPPs. This idea is based on the 
rationale that an increase in the local concentration of CPPs at the sites where CPPs 
interacts with their cellular components could lead to higher endosomolytic activity. 
Interestingly, the previous has been observed in nature. For example, viruses display 
multiple proteins on their surface in order to bind extracellular receptors efficiently, 
facilitate entry to cells and cause infection. In this work, I report a delivery methodology 
based on the CPP TAT, a peptide derived from the HIV-1 TAT protein. I demonstrate that 
a trimeric multivalent CPP, Fl-TAT3, penetrates live cells more efficiently that its dimeric 
and tetrameric counterparts and delivers different molecules inside cells. Moreover, I 
describe the generation of an improved multivalent endosomolytic agent, dfTAT. I show 
that dfTAT endosomolytic activity is highly efficient and can deliver proteins, peptides 
and cell-impermeable small molecules into the cytosolic space of live cells. I show that 
dfTAT-mediated delivery can be achieved in multiple cell types. Furthermore, dfTAT 
 iii
delivered multiple molecules inside cells simultaneously and more than once. 
Interestingly, the amount of cargo delivered into the cytosolic space of cells could be 
controlled. Remarkably, I demonstrate that dfTAT-mediated delivery did not significantly 
affect important cellular processes. In addition, I provide mechanistic insights involved in 
dfTAT cell penetration. I show that dfTAT escapes the endocytic pathway from late 
endosomes. Finally, I show that endosomal escape seems to require interactions between 
dfTAT and BMP, a phospholipid only found inside late endosomes. These collective 
insights should provide a basis for the development of improved delivery agents.   
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NOMENCLATURE 
 
Antp   antennapedia homeodomain 
ATCC  American Type Culture Collection 
BMP  bis(monoacylglycero)phosphate 
BSA   bovine serum albumin 
CPP   cell-penetrating peptide 
DCM  dichloromethane 
DIC  N,N-diisopropylcarbodiimide 
DIEA   N,N-Diisopropylethylamine 
DIGE  Differential in gel electrophoresis  
DMEM  Dulbecco's modified eagle medium 
DMF   dimethylformamide 
EGFP   enhanced green fluorescent protein 
FBS   fetal bovine serum 
FITC   fluorescein isothiocyanate 
Fl  carboxy-fluorescein 
FRET   Förster resonance energy transfer 
GTPase  guanosine triphosphate hydrolase 
HA2   haemagglutinin protein II 
HBTU  2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
 vii
HDF human dermal fibroblast 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  Human immunodeficiency virus 
HPLC   high-performance liquid chromatography 
HSPG   heparin sulfate proteoglycan 
IPTG   isopropyl _-D-1-thiogalactopyranoside 
kDa   kilo Dalton 
L-15   Leibovitz’s 15 
MALDI  matrix-assisted laser desorption/ionization 
MAP   model amphipathic peptide 
MPTP  mitochondrial permeability transition pore 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MVB   multivesicular bodies 
NLS  nuclear localization signal 
NMR   nuclear magnetic resonance 
p53   protein 53 
PAD   pro-apoptotic domain 
PBS   phosphate buffer saline 
PCI  photochemical internalization 
PCR   polymerase chain reaction 
PNA  peptide nucleic acid 
Ptd   phosphatidyl 
 viii
RBC   red blood cell 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPPS   solid-phase peptide synthesis 
TAT   Trans-Activator of Transcription 
TCEP   tris(2-carboxyethyl)phosphine 
TFA   Trifluoroacetic acid 
TMR  5(6)-carboxytetramethylrhodamine 
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1. INTRODUCTION 
 
1.1 History of macromolecule delivery inside live cells 
The plasma membrane of live cells is a biological barrier that controls the passage of 
molecules in and out of cells1. Although this barrier allows some small molecules and ions 
to cross in and out of the cell directly but not large and/or hydrophilic molecules2. The 
delivery of biologics into the cytosolic space of live cells is, therefore, not a trivial task. 
Several techniques such as microinjection, electroporation, transfection, chemical 
“nanoblasts”, liposome encapsulation, and virus-like particles have been utilized to allow 
hydrophilic macromolecules to enter cells3-5. However, these methods generally display 
one or more of the following: high cell toxicity, undesirable immunogenic effects 
requirement of high expertise and low delivery efficiency6-13. The latter makes these 
methods impractical. The development of a robust delivery methodology that allows 
macromolecule membrane translocation is, therefore, crucial, since the targets of these 
macromolecules/biologics are localized in the cytosolic space of cells.  A promising 
approach to solving this problem is using cell-penetrating peptides (CPPs) as delivery 
vectors. 
Back in 1988, the laboratories of Loewenstein and Pabo showed for the first time that 
a protein, trans-activator of transcription (Tat), from the human immunodeficiency virus 
type 1 (HIV-1) was able to penetrate live cells14, 15.  After incubating the 86-amino 
*Parts of this chaper are reprinted with permission from “Improving the Endosomal Escape of Cell-
Penetrating Peptides and Their Cargos: Strategies and Challenges” by Erazo-Oliveras,A+.; Muthukrishnan, 
N+.; Baker, R+.; Wang, T.-Y.; Pellois, J.-P. Pharmaceuticals  2012, 5, 1177-1209 doi:10.3390/ph5111177. 
+authors contributed equally. http://creativecommons.org/licenses/by/4.0/legalcode Copyright (2012) by 
Alfredo Erazo-Oliveras 
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acid Tat protein with HeLa cells for 8 hr, which had been transfected with pHIV-
LTRCAT, HIV-LTR (an important HIV-1 gene) was trans-activated. Transactivation of 
HIV-LTR, in turn, led to the production of RNA. It was not until a few years later that the 
laboratory of Frankel showed insights about the mechanism involved in Tat cellular 
penetration. Frankel and coworkers showed that the Tat protein was endocytosed after 
binding, in a non-specific manner, to the cell surface of live cells16. Although it appeared 
then that Tat cellular translocation was not biologically important, in part due to the lack 
of a specific receptor for this protein, its ability to penetrate cells made it a potentially 
useful delivery vehicle. In an attempt to better understand how Tat penetrates live cells, 
the laboratory of Lebleu discovered the CPP TAT. Lebleu and coworkers demonstrated 
that out of the 86 amino acids comprising Tat the small region 47YGRKKRRQRRR57 was 
essential for cellular internalization17. Together, all the evidence clearly indicated that a 
small peptide sequence could potentially be used to deliver macromolecules inside live 
cells. 
Over the past two decades, a number of peptide sequences have been shown to display 
a similar transduction activity as the CPP TAT. These CPP sequences include: penetratin, 
a 16-mer peptide derived from the third helix of Drosophila antennapedia homeoprotein 
(Antp)18; the VP22 peptide from the herpes simplex virus VP22 protein19, MPG, a peptide 
derived from the fusion of sequence of HIV gp41 and the hydrophilic nuclear localization 
sequence (NLS) of SV40 T-antigen20; transportan (TP), a chimeric peptide derived from 
the neuropeptide galanin and the wasp venom peptide mastoparan21; and the synthetic 
polyarginine (Rn) peptides22. Other well-known CPPs include CADY, Pep-1, MAP, 
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Xentry and PPTG123-27. CPPs usually display 30 or less amino acids and are polycationic 
or amphipathic in nature28, 29. CPPs-based delivery technologies are potentially useful for 
the delivery of therapeutics and the study of cellular processes both in cellulo and in vivo30, 
31. Therefore, it is important to better understand the mechanisms of CPP penetration and 
the CPP delivery activity. 
 
1.2 Development of CPPs as general delivery tools 
CPPs possess the ability to carry cell-impermeable macromolecules into live cells. For 
instance, full-length p53, an important tumor suppressor, and p53-derived peptides were 
delivered into the cytosolic space and nucleus of cancer cells in cellulo using TAT, VP22, 
penetratin and polyarginines32-35. Delivery of the cargos into cells bearing mutations in the 
p53 gene in their genome restored p53 activity and induced cell apoptosis. A major 
breakthrough in the field of CPP delivery came from one of the first attempts to establish 
the potential of utilizing CPPs to deliver macromolecules in vivo. The laboratory of Langel 
delivered a peptide nucleic acid (PNA) molecule (an artificial polymer utilized in antisense 
therapy) using CPPs36. A PNA molecule, complementary to the galanin receptor type 1 
mRNA, was delivered by penetratin and transportan into the superficial layers of the dorsal 
horn in a rat and suppressed the expression of galanin receptors. A year later, Dowdy and 
coworkers delivered biologically active β-galactosidase, a 120-kilodalton (kDa) protein, 
into most tissues of a mouse, including the brain37. CPPs have also been used to deliver 
small interfering RNA (siRNA) into live cells38-40. This is a prevalent topic in the delivery 
field, since this technology has the potential to treat multiple diseases in humans. Troy and 
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coworkers showed that a synthetic siRNA covalently attached to the CPP penetratin is 
taken up by primary mammalian hippocampal and sympathetic neurons41. This, in turn, 
led to the knockdown of specific genes and a considerable reduction in expression of the 
targeted protein products. In addition to protein, peptides and nucleic acids CPPs have 
been shown to deliver drugs, liposomes, quantum dots, fluorophores and magnetic 
nanoparticles42-46. All the current evidence regarding CPP-mediated delivery suggests that 
this technology is independent of the cell type utilized and the nature of the cargo47. This 
indicates that CPPs can serve as a general delivery tool.       
    
1.2.1 Potential problems of CPP-mediated macromolecule delivery 
There is strong evidence showing that different cargos can be delivered inside 
cells. However, while CPP-mediated endocytic uptake of cargos is typically efficient, it 
appears that the endosomolytic activity (disruption of endosomes and subsequent leakage 
of its contents) of CPPs is, in the contrary, very poor48. For instance, CPP-fluorophores 
and fluorescent CPP-protein conjugates display a punctate distribution inside cells 
consistent with endosomal entrapment when observed by fluorescence microscopy49-51. In 
many cases, no fluorescence signal is observed in the cytosolic space indicating that the 
CPP-cargo did not reached the cytosolic space and it remains trapped inside endosomes52. 
Furthermore, delivery of biologically active cargos inside cells with CPPs often fails to 
display significant cellular activities53. Interestingly, attaching reagents to CPPs that 
disrupt endosomes leads to a dramatic improvement in the cellular delivery and biological 
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activity of CPP-cargos54. To this day, this issue remains as the bottleneck of the delivery 
field. Therefore, the current challenge is to increase the endosomolytic activity of CPPs. 
 
1.3 Proposed mechanism of macromolecule delivery into live cells using CPPs 
Even though CPPs have been used extensively for more than two decades, the 
mechanism of CPP penetration remains unclear. This lack of understanding can be 
attributed, in one part, to laboratories utilizing different methodologies that are not 
comparable to study CPP delivery48, 55. Moreover, the use of cell fixation during these 
mechanistic studies has given rise to several cellular artifacts, which in turn, has caused 
the reevaluation of some of these findings. Finally, the different influences that affect: 
cargo size, the stereochemistry of the CPP sequence, the choice of strategy to attach cargo 
to the CPP (covalent, non-covalent, co-incubation) and the different concentrations of CPP 
used in delivery assays has on the mechanism of CPP-mediated delivery, making 
deciphering of these mechanisms a much harder task. However, the current evidence has 
allowed scientists in the delivery field to narrow down all the possible mechanisms of CPP 
delivery to two major ones. The first mechanism involves direct translocation of CPPs 
across the plasma membrane of cells via an energy-independent process56, 57. Several 
models have been proposed to describe the way the CPP interacts with and crosses the 
plasma membrane of live cells58, 59. The second major mechanism of CPP penetration 
involves a two-step process: endocytosis and endosomal release58, 60, 61. In this mechanism, 
the CPP is taken up by cells into an endocytic vesicle where it stays trapped until the CPP 
disrupts the endosomal membrane and escapes from the endocytic pathway to enter the 
	 6
cytosolic space of the cell. The exact molecular details of how CPPs disrupt the endocytic 
membrane and at what stage it escapes the endocytic pathway remains unclear. The current 
evidence that have already been established involving these two major mechanisms of 
CPP penetration will be discussed in detail.  
 
1.3.1 Direct membrane translocation of CPPs inside cells 
Certain CPPs have the ability to cross the membrane of cells directly. The specific 
details describing how the CPP crosses the plasma membrane have been described and 
divided into several different models, which include the carpet model, inverted micelle 
model and pore formation62. 
In the carpet model, the CPP first binds to the plasma membrane of cells. After the 
CPP surpasses a threshold concentration (refer to as an “extensive association”), a major 
destabilization of the plasma membrane allows the CPP to enter the cytosolic space59, 63, 
64. Destabilization of the plasma membrane takes place as a result of the reorganization of 
phospholipids and is believed to be only transient. 
The inverted micelle model was first described in a study of the cellular 
internalization of the peptide penetratin by Prochiantz and coworkers65. In this model, the 
interaction of the CPP with the plasma membrane leads to rearrangement of the 
phospholipids and formation of inverted hexagonal structures refer to as inverted micelles. 
The CPP localizes in the hydrophilic lumen of the inverted micelle until it destabilizes the 
membrane and consequently escapes into the cytosolic space. Nuclear magnetic resonance 
(NMR) studies using the CPP penetratin have shown that, indeed, CPPs can cause the 
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formation of these inverted micelle structures66. The inverted micelle model provides a 
plausible explanation for direct membrane translocation of small CPP-cargo conjugates 
since the CPP-cargo is not required to interact with the hydrophobic part of the cell 
membrane, and, in result, there is no need to overcome the high energetic barrier of such 
process. This notion is consistent with the idea that high molecular weight CPP-cargo 
conjugates are most likely not to cross membranes using these mechanisms67. 
The pore formation model is comes in as two different versions the toroidal and 
the barrel stave models62, 68. In both models, the direct translocation of the CPP across the 
membrane involves formation of a transient pore as a result of the CPP inserting into the 
membrane. In the toroidal model, the hydrophilic face of the CPP interacts with the 
phospholipid heads. This interaction leads to distortion and rearrangement of the plasma 
membrane. On the contrary, in the barrel stave model the hydrophobic face of an 
amphipathic CPP interacts with the fatty acid chain of the phospholipids and the 
hydrophilic face orients to the hydrophilic side and forms the pore. In both cases, the CPP 
reaches the cytosolic space after crossing the plasma membrane through the pore. 
All the models previously described display several similarities. The most obvious 
and probably most important is the requirement of the CPP to become in direct contact 
with the lipid bilayer of cells and cause disruption and a major reorganization of 
phospholipids. The latter, in most cases, only occurs after the CPP reaches a specific 
concentration (usually described as a high peptide/lipid ratio). However, these models 
share several differences that are important to mention. For example, in the pore formation 
model, the CPP makes direct contact with both faces of the lipid bilayer (hydrophilic and 
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hydrophobic) while in the carpet and inverted micelle models the CPP makes contact only 
with the hydrophilic face. Another example is the dramatic and extensive reorganization 
of the lipid bilayer that occurs in the case of the toroidal, carpet and inverted micelle 
models. In the contrary, in the barrel stave model, the CPP is thought not to cause 
significant membrane perturbations. Finally, the models that display pore formation evoke 
for the existence of a well-defined CPP structure in the membrane pore. In contrast, the 
carpet model predicts a highly disorganized CPP structure. 
All these models that were described, with exception of the inverted micelle model, 
can allow the translocation of high molecular CPP-cargo conjugates. Moreover, the 
requirement of the presence of amphipathic peptides that will allow some of the molecular 
events in these models to take place is a feature observed in many CPPs69. However, the 
low cell toxicity observed, in most cases, is not on par with the degree of membrane 
disruption that will need to occur in order for large CPP-cargo conjugates to cross the 
plasma membrane directly. This clearly indicates that direct membrane translocation is 
not the only mechanism involve in CPP penetration, especially during delivery of large 
CPP-cargo conjugates or when CPP-cargo conjugates are present at low concentrations.    
 
 
1.3.2 Entry of CPPs inside live cells by non-direct membrane translocation 
To this date, multiple studies have shown that CPPs can enter live cells utilizing 
several endocytic pathways70, 71. Moreover, the same CPPs have been reported to use 
different endocytic routes to gain access to the cell interior. Even though these 
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discrepancies have not been resolved, it is well established that all these CPPs share a 
common model of cellular entry. This model involves four major steps: i) binding of CPPs 
to the surface of cells, ii) uptake of CPPs by endocytosis into endocytic vesicles (leads to 
entrapment of CPPs inside vesicles), iii) trafficking of CPPs along the endocytic pathway 
and iv) escape of CPPs into the cytosolic space of cells (these step involves CPP-mediated 
disruption of endocytic vesicles) (Figure 1-1). This study will focus on this type of cellular 
translocation using the CPP TAT. 
 
1.3.3 Binding of CPPs to the surface of live cells 
Highly-positively charged CPPs have the ability to interact with negatively 
charged macromolecules72. As mentioned earlier, CPP-mediated delivery has been shown 
to be cell type independent. It has been proposed that association of CPPs with the surface 
of cells does not require interactions with cellular receptors47. Several studies have shown 
that the positively charged arginine residues in CPPs are essential for their activity73. The 
guanidinium group on the side chain of arginine residues can form bidentate hydrogen 
bonds with carboxylate, phosphate and sulfate anions74. On the contrary, the amino groups 
on the side chain of lysines can only form monodentate hydrogen bonds (one reason as to 
why polylysines) display a lower delivery efficiency than polyarginines and TAT). 
Moreover, the higher the number of arginine residues on a CPP (not just their presence, 
Arg v.s. Lys) increases their activity in vitro and in cellulo73, 75, 76. 
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Figure 1-1. Model of the trafficking of a CPP-cargo conjugate through the endocytic 
pathway. From left to right: A CPP-cargo binds to heparin sulfate proteoglycans (HSPGs) 
on the cell surface and induces endocytosis. Endocytosis leads to uptake and entrapment 
of the CPP-cargo inside an endocytic vesicle. The endosomal membrane contains the lipid 
phosphatidylserine (Ptd-Ser) in its outer leaflet. During endosomal maturation, a vacuolar 
H+-ATPase acidifies the lumen of endocytic organelles. The CPP-cargo reaches early 
endosomes (pH~6.5). Concurrently, hydrolases partially degrade HSPGs and release HS 
fragments. Upon further maturation, the CPP-cargo reaches multivesicular bodies, late 
endosomes (pH~5.5), and lysosomes (pH~4.5). The membrane of the intraluminal vesicles 
of late endosomes is enriched with BMP. HS is further degraded to smaller fragments. The 
CPP-cargo is susceptible to degradation due to the low pH and lysosomal hydrolases. 
 
 
 
 
CPPs have also been shown to display strong affinity towards proteoglycans (PGs), 
a protein-polysaccharide macromolecule hybrid present on the surface of cells 77. The two 
major types of PGs in cells are the transmembrane protein syndecans and the membrane 
lipid-linked glypicans78. The linear glycosaminoglycans (GAGs) on these PGs are heavily 
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substituted with sulfates and, in lesser amount, carboxylates. Binding of CPPs to heparan 
sulfate PGs (HSPGs) is believe to be, in most part, due to the presence of positively-
charged arginine residues in CPPs (Figure 1-1). Interestingly, studies have shown that 
delivery of CPPs depend greatly on HSPGs79. For example, the laboratory of Raines and 
Chernomordik demonstrated that the uptake of nonaarginine (R9) and TAT inside cells 
was significantly reduced in a cell line deficient in heparan sulfate (HS)49, 80. Other 
peptides have been shown to display similar behavior.  
This evidence and that of others has allowed to establish a model that explains the 
first step involved in CPP penetration (this model does not require the presence of a 
specific cell receptor). The positively charged arginine residues in CPPs strongly bind to 
negatively charged HSPGs through electrostatic interactions. These interactions allow the 
CPPs to dock on the surface of live cells until the second step, endocytosis of CPPs, 
ensues.  
 HSPGs are involved in many cellular processes such as: cytokine signaling, lipid 
metabolism, viral transcription activation, microbe invasiveness, cell growth, wound 
healing and angiogenesis81-85. Interestingly, HSPGs have also been shown to be involved 
in ligand catabolism86, 87. It has been shown that some ligands that bind HSPGs, became 
endocytosed and are targeted to lysosomes for degradation. In some cases, ligand-
mediated clustering at the cell surface precedes ligand internalization (endocytosis)86, 88. 
More importantly, both syndecans and glypicans are known to be actively endocytosed 
inside cells89, 90. This evidence shows a link between the first two steps of CPP penetration: 
binding of CPPs to HSPGs and CPP endocytosis. Most importantly, it suggests two modes 
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of CPP internalization. In the first one, CPPs bind to HSPGs, which could then trigger 
endocytosis and CPP internalization into endocytic vesicles. In the second one, the CPP 
binds to HSPGs and enters cells in a piggyback manner. The second step of CPP 
internalization will be discussed in detail next. 
  
1.3.4 Endocytic internalization and endosomal trafficking of CPPs 
One mechanism by which macromolecules are internalized into cells is 
endocytosis (Figure 1-1). There are various endocytic mechanisms, which can be divided 
into phagocytosis, a process that occurs only in certain cells (e.g. macrophages) and 
pinocytosis, an energy-dependent process that occurs in most cells91, 92. There is a 
consensus among the delivery community that CPPs can enter cells by pinocytosis. The 
most well-known types of pinocytosis include: cavelolae-mediated endocytosis, clathrin-
mediated endocytosis and macropinocytosis93-96. It has been shown that CPPs have the 
ability to hijack or induce different pinocytic mechanisms97, 98. 
Several studies have been carried out to better understand the role of pinocytosis 
and the influence of each different type of pinocytosis in CPP delivery. Pinocytosis is an 
energy-dependent process. Then, incubation of cells at 4 ºC inhibits every type of 
pynocytic uptake (cavelolae-mediated endocytosis, clathrin-mediated endocytosis and 
macropinocytosis). For example, Futaki and coworkers showed that uptake of an arginine-
rich CPP decreased significantly in HeLa cells incubated at 4 ºC using flow cytometry99. 
Similar results have been observed for the TAT peptide100. This type of experiment is 
normally carried out to distinguish between pinocytosis and direct membrane translocation 
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as the route of CPP penetration. Therefore, it is consensus in the delivery field that 
pinocytosis is a major route used by arginine rich CPPs to enter cells101. 
Other studies have focused on deciphering the exact pathway by which a particular 
CPP enters cells. However, these experiments are not without disadvantages and are often 
difficult to interpret. Yet, they have provided insightful mechanistic details involving CPP 
penetration. Inhibitors of cavelolae-mediated endocytosis, clathrin-mediated endocytosis 
and macropinocytosis have been used to selectively block a single pathway. It has been 
shown that uptake of TAT and TAT-cargo conjugates is significantly reduced when cells 
are incubated with amiloride, an inhibitor of macropinocytosis102. Similar results have 
been observed for polyarginine peptides103. While it is important to mention that these 
inhibitors are not one hundred percent specific104 and could still block, to a lesser extent, 
other pathways, they remain a very useful tool for in cellulo assays.  
Another approach employed to elucidate the route of CPP uptake is colocalization 
assays. These assays measure colocalization of CPPs with cellular protein markers found 
only in one specific type of endocytosis or fluorescent cargos known to enter cells by a 
specific route. Assays perform with penetratin showed colocalization of transferrin, a 
marker of clathrin-mediated endocytosis, with the peptide at early stages of the endocytic 
pathway105. On the other hand, TAT has been shown to colocalize with fluorescently 
labeled dextrans, a marker of macropinocytosis106. 
The evidence for CPP endocytosis discussed earlier is part of a large reservoir of 
data. CPPs have been utilized to deliver numerous cargos inside cells. In multiple cases, 
the cargo has been delivered in the form of a CPP-cargo conjugate. Covalent attachment 
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of a cargo to a CPP has been shown to alter the route of endocytosis utilized by the CPP 
(as mentioned before). Consequently, it is no surprise that multiple endocytic pathways 
has been shown to be involved for the same CPP. However, the most recognized model of 
uptake for the CPP TAT (focus of this study) is macropinocytosis107. 
To this date, macropinocytosis remains not fully characterized. Macropinocytosis 
is a form of fluid-phase endocytosis performed by all mammalian cells108. This process 
occurs at ruffling sites containing newly formed actin filaments109. Ruffling takes place in 
different cells at different extents. This, in turn, contributes to the observed varying rates 
of macropinocytosis among cell types. It has been shown that effector molecules such as: 
epidermal growth factor (EGF) and phorbol esters can induce membrane ruffling and, 
subsequently, macropinocytosis110, 111. On the other hand, these processes can be inhibited 
by amiloride and cytochalasins112. It has been shown that TAT can induce structural 
changes on actin filaments reminiscent of ruffling in vitro113. Moreover, TAT can induce 
macropinocytosis and increase the uptake of different cargos inside cells. However, the 
exact molecular details behind this process are still unknown. 
After ruffles take form (circular, cup-shaped or planar folds), they close into large 
endocytic vesicles called macropinosomes. Due to the unguided nature of this process, 
formation of vesicles does not always follow ruffling and sometimes the ruffles recede 
back to the cytosolic space114. The vesicles that do form pinch-off the plasma membrane 
and become intracellular vesicles that range in size from 0.5 - 5 µm in diameter115, 116. 
These vesicles are very large when compared to the vesicles formed by caveolae and 
clathrin-mediated endocytosis (50 nm and 100 nm, respectively)117, 118. This suggests that 
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cells will display a limit, with macropinocytosis at the top of the range, for the size of a 
particular cargo that can be internalized by each pathway.  
During endocytosis of CPPs, the endocytic vesicle formed, which contains CPPs will 
undergo a complex maturation process involving multiple synchronized dependent and 
independent steps119. Multiple endocytic vesicles displaying different characteristics will 
form during the maturation process (Figure 1-1). These vesicles have been well 
characterized and can be distinguish based on their morphology, intracellular localization, 
the rate with which they accumulate endocytic markers and the presence of specific 
endocytic protein markers. It is known that newly internalized CPPs and cargos are 
transported into early endosomes (EEs)119. The amount of lipids and proteins that are 
internalized, along with the CPPs, into EEs is enormous, and some of these materials are 
recycled back to the plasma membrane114. EE readily fuse with and move away from other 
EE allowing efficient trafficking. EE display a mosaic membrane that allows the 
recruitment of specialized proteins, like Rab5, and formation of protein-protein, protein-
lipid and lipid-lipid domains involve, in part, in the trafficking and maturation of these 
vesicles120. Maturation of EEs lead to formation of another type of endocytic vesicle, 
multivesicular bodies (MVBs)121, 122. These process initiates after EE detaches from 
tubular structures, and the vesicle moves away from the plasma membrane towards the 
nucleus along microtubules. Following further fusion events and invagination of the 
limiting endosomal membrane, intraluminal vesicles are formed within pre-existing EEs. 
The previous step marks the formation of MVBs. These vesicles, compared to EE, display 
lesser protein markers and gradually gain hydrolases from the trans-Golgi network 
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(TGN)123. At the end of their maturation process, MVBs sort and segregate protein 
receptors and lipids to intraluminal or limiting membranes. This last step leads to the 
formation of late endosomes (LEs)124, 125. LEs are morphologically different than MVBs. 
The population of late endosomes varies in size and contains sac-like and tubular vesicles. 
The protein and lipid composition of LEs is different than other endocytic organelles. LEs 
contain important proteins like Lamp1 and Rab7126, 127. These vesicles contain bis-
monoacylglycerophosphate (BMP), a phospholipid found only in LE128. BMP is highly 
enriched in the intraluminal vesicles of LEs and is thought to be necessary for the entry of 
some viruses into the cytosolic space of cells by back-fusion129, 130. BMP is very important 
since it has been shown to bind TAT with high affinity131. Furthermore, the presence of 
BMP increases TAT-mediated leakage and lipid mixing in vitro. During the final stages 
of the endocytic pathway, LEs fuse with lysosomes. Lysosomes represent the dead-end of 
the endocytic pathway132. These organelles contain acidic hydrolases, which are essential 
for lysosome function, that digest macromolecules. In order to reach the cytosolic space 
of cells and avoid degradation, CPPs have to escape the endocytic pathway (Figure 1-2). 
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Figure 1-2. CPP-cargo conjugate endosomal escape. From left to right: A CPP-cargo 
binds to HSPGs on the cell surface and enter cells, which leads to entrapment of the CPP-
cargo inside an endocytic vesicle. After the CPP-cargo reaches early endosomes, MVBs 
or late endosomes it can escape from the endocytic pathway (red arrows). This is the 
preferred point of exit for a CPP-cargo conjugate in order to avoid degradation. The CPP-
cargo is susceptible to degradation and, in order to avoid degradation and inactivation, it 
needs to escape the endocytic pathway before it reaches lysosomes. The endosomolytic 
activity of CPPs is low and endosomal escape is innefecient. Consequently, the amount of 
CPP-cargo delivered into the cytosolic space of cells is very low. 
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1.3.5 Escape of CPPs from the endocytic pathway: The limiting step 
Because endosomal release might determine the efficiency with which a cargo 
reaches the cytosol of cells, understanding the mechanisms involved in this step is 
important. To date, these mechanisms remain poorly defined. Part of the challenge 
associated with understanding how CPP-cargos escape from the endocytic pathway is that 
efficiency of endosomal escape is often poor48, 133. Cargos that typically require fewer 
copies to elicit a biological response certainly demonstrate that endosomal escape takes 
place (as is the case for TAT-Cre). However, cargos that require more copies inside cells 
for activity often fail to show significant biological effects. Several assays have been 
developed to assess the endosomal escape efficiency of CPPs. Fluorescence-based 
methods have revealed that CPPs conjugated to fluorescent cargos typically remain 
localized within the endocytic pathway52. Mass spectrometry approaches have also 
confirmed these results, though estimates vary widely depending on the conditions used103, 
134, 135. Maybe the most telling examples are not those in which delivery worked, but the 
applications where no cytosolic delivery is detected136-139. For instance, TAT has been 
conjugated to an ubiquitin cargo designed to be cleaved by cytosolic deubiquitinating 
enzymes upon escape from endosomes. However, upon incubation with cells, endocytosis 
was detected but cleavage of ubiquitin was not139. It was therefore concluded that the 
protein did not access the cytosol to any detectable extent. 
While many mechanisms have been proposed to explain plasma membrane 
translocation140, fewer have been offered to explain endosomal escape. First, it should be 
noted that mechanisms that imply the disruption of lipid bilayers are not only applicable 
	 19
to plasma membrane translocation but also to endosomal escape. A mechanism that has 
been proposed to explain how CPPs could translocate across the plasma membrane of cells 
involves the negatively charged phospholipid phosphatidylserine (Ptd-Ser). Positively 
charged CPPs are known to bind negatively charged phospholipids such as Ptd-Ser141, 142. 
This phospholipid is, however, found mainly in the inner leaflet of the plasma membrane 
of mammalian cells (Figure 1-1)143. The outer leaflet of the plasma membrane bilayer is, 
in contrast, composed of zwitterionic phospholipids for which CPPs have little affinity144, 
145. Nevertheless, it was proposed that CPPs and Ptd-Ser, positioned on either side of the 
lipid bilayer, might together form the equivalent of a membrane capacitor. This capacitor 
theoretically generates a membrane potential high enough to create a reversible 
electropore on a membrane146. This model also agrees with experimental data that has 
found a relatively enhanced ability of oligoarginine peptides to deliver cargo molecules 
across membranes when compared to oligolysine peptides73. The membrane capacitor 
model suggests that oligoarginines could bind the negatively charged phosphate groups in 
phospholipids better than oligolysines and form a more stable CPP-Ptd-Ser capacitor. 
Because the Ptd-Ser lipid asymmetry is presumably maintained within the endocytic 
pathway, such mechanisms could take place inside endosomes143. If this is true, a key 
question lies in determining how a CPP might permeabilize an endosome without acting 
first on the plasma membrane. A possible answer to this question could involve the 
difference in how CPPs access these different bilayers. As previously stated, positively 
charged CPPs interact with HSPGs present on the cell surface (Figure 1-1)147. The 
abundance of HS at the plasma membrane might therefore contribute to reducing the 
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concentration of CPP directly in contact with lipids. During endocytosis, HSPGs are 
presumably internalized with CPPs (Figure 1-1)80, 148. HSPGs therefore continue to have 
an inhibitory effect on the membrane disruption activity of CPPs149. However, HSPGs are 
gradually hydrolyzed during maturation within the endocytic pathway (Figure 1-1)150. HS 
hydrolysis and release from the membrane of endosomes could in turn favor the 
interaction between CPPs and endosomal lipid bilayers [30]. 
Several lines of evidence suggest that CPPs could disrupt the lipid bilayer of 
endocytic organelles more readily than that of the plasma membrane. For instance, 
positively charged CPPs preferentially bind negatively charged phospholipids over neutral 
ones151. Interestingly, the intraluminal lipid bilayers of late endosomes appear to be 
uniquely enriched in the negatively-charged phospholipid 
bis(monoacylglycero)phosphate (BMP), also known as lysobisphosphatidic acid (LBPA) 
(Figure 1-1)152, 153. Recently, TAT was shown to induce the leaky fusion of liposomes 
containing BMP131. TAT induces lipid mixing and membrane leakage in a BMP 
concentration-dependent manner and these activities were also greater at pH 5.5 than at 
physiological pH. This is important because pH 5.5 is characteristic of the acidic pH found 
in the lumen of late endosomes. The involvement of BMP in CPP-mediated delivery has 
not been demonstrated yet. However, cellular assays in which progression through the 
endocytic pathway is blocked with dominant negative Rab proteins have also suggested 
that TAT and polyarginine peptides only escape from the endocytic pathway upon 
reaching late endosomes103. Together, these results strongly suggest that BMP is a target 
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for CPPs and that fusion between the limiting membrane of late endosomes and that of 
intraluminal vesicles is involved in the escape of CPP-cargo to the cytosolic space of cells. 
 
1.4 Tools to improve CPP endosomal escape 
1.4.1 pH dependent membrane active peptides (PMAPs) 
PMAPs have been used in combination with CPPs to increase the endosomal escape 
of various cargos (Figure 1-3). This strategy is attractive because PMAP-CPP fusions can 
be genetically encoded or easily synthesized by SPPS. Chimeric hybrids of PMAPs and 
CPPs can therefore be readily obtained. HA2 derivatives are typically attached to the N-
terminus of CPPs because HA2 requires a free N-terminal glycine for full membrane 
activity154, 155. It has been shown that TAT-mediated delivery of cell-impermeable cargos 
into cells is enhanced by conjugation to PMAPs156. HA2-TAT and its derivatives have 
been attached to quantum dots, and such conjugates have been shown to stimulate 
macropinocytosis and endosomal escape in cultured cells157. Protein cargo delivery can 
also be enhanced by this method, and has potential for therapeutic applications. HA2 fused 
to the tumor suppressor protein p53 containing the poly-arginine CPP R11 (HA2- 
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Figure 1-3. Mechanism of PMAPs-mediated endosomal escape.  PMAPs undergo 
conformational change upon acidification. This typically involves a shift from a random 
coil to an ordered conformation such as a helix, in which hydrophobic moieties are on one 
face while the ionizable moieties are on the other. This ordered conformation leads to 
membrane binding, and brings conjugated CPPs and cargos into close proximity to the 
membrane. At sufficient concentrations, this binding eventually leads to lysis or 
membrane fusion resulting in cargo release. 
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p53-R11) was, for instance, more efficient in abrogating cancer cell growth than p53-R11 
alone158. While HA2 can be directly connected to the cargo, HA2-TAT has also been used 
in trans to increase the delivery of cargos co-incubated with cells. The principle is that 
HA2-TAT and a TAT-labeled cargo will accumulate together inside the endocytic 
pathway. HA2-TAT can then induce the endosomal escape of a TAT-cargo that would be 
present in the lumen of the same organelles. For example, a retro-inverso HA2-TAT, 
which is less susceptible to degradation within the cell, has been used to increase the 
delivery of TAT-Cre recombinase156.  
Interestingly, HA2-TAT derivatives can also increase the delivery efficiency of 
proteins that are not labeled by TAT or other CPPs. For instance, the derivative HA2E5-
TAT has been used to deliver fluorescent proteins not labeled with a CPP to the cytosol 
of cells by simple co-incubation159. The apoptosis-inducing peptide PAD was also 
delivered to cells efficiently when co-incubated with cells, and successful cytosolic 
delivery was assessed by induction of cellular apoptosis. Amiloride inhibited PAD-
mediated cell death in the presence of HA2E5-TAT, suggesting that HA2E5-TAT induces 
uptake of soluble cargo by macropinocytosis159. The strategy is therefore to take advantage 
of the fact that TAT can induce pinocytic uptake of cargo molecules that do not necessarily 
interact with cells but are simply present in the extracellular milieu. These cargo 
molecules, despite not containing TAT, also accumulate in the lumen of endocytic 
organelles that contain HA2-TAT. 
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1.4.2 Limitations and future challenges 
Ideally, PMAPs should only become active at acidic pH so as to prevent disruption 
of the plasma membrane or membranes of intracellular organelles once cytosolic delivery 
has been achieved. However, PMAPs exist in equilibrium between protonated and 
deprotonated forms at any pH (Figure 1-3)160. This can be illustrated by a modified 
version of the Henderson Hasselbach equation: 
pH = pKa + log (inactive peptide/active peptide) 
where inactive and active peptide is protonated and deprotonated, respectively. At any 
given pH a defined fraction of the peptides will be active. Thus, even at neutral pH, a 
sufficiently high concentration of total peptide can lyse RBCs145, 161. Concentrations above 
~5 μM HA2E5-TAT has been shown to be toxic to HeLa cells161. CPPs might, however, 
contribute to modulating the toxicity associated with PMAPs. As previously mentioned, 
CPPs can interact with HSPGs162, 163. Heparan, an HS analogue that binds to CPPs such 
as TAT (Figure 1-1), has been shown to inhibit the binding of HA2E5-TAT to RBCs and 
concomitantly inhibit hemolysis. The effect of heparan on HA2E5 mediated hemolysis is, 
on the other hand, negligible145. It is therefore interesting to speculate that interactions 
between HA2E5-TAT and HSPGs could reduce access of HA2E5–TAT to the plasma 
membrane lipid bilayer. These interactions could therefore protect cells from the lytic 
activity of the PMAP-CPP conjugate. On the other hand, interactions between HA2E5-
TAT and HS within the lumen of endosomes could inhibit endosomolysis.  
PMAPs can be readily conjugated to CPPs as well as cargo proteins (Figure 1-3). In 
principle, they interact with membranes in a pH-dependent manner, allowing them to 
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disrupt endosomal membranes only at appropriate concentrations. While they can enhance 
CPP-mediated delivery, PMAP-CPP conjugates present several challenges. How to 
incorporate PMAP-CPPs to achieve optimal delivery and minimal toxicity remains to be 
further explored. As illustrated before, how cargo conjugation affects PMAP-CPP activity 
remains in particular unclear. Endosomal retention of cargo fused to the PMAP-CPP 
construct, even after endosomal lysis, is a concern. This phenomenon seems to indicate 
that preferable designs should include cleavable linkers between PMAP-CPPs and their 
cargos. Such designs would, in principle, increase endosomal escape and cytosolic 
delivery. Finally, difficult handling of hydrophobic/amphipathic PMAPs and aggregation 
in aqueous solutions remains a problem.  
 
1.4.3 Photochemical internalization 
In 2004, two groups made the observation that fluorescently labeled CPPs could 
escape from endosomes upon irradiation with visible light (Figure 1-4). Arginine-rich 
CPPs labeled with fluorescein were released from endocytic compartments upon 
irradiation with laser light at 488 nm. Similar endosomal release was observed when the 
peptide was labeled with Alexa-Fluor 633, incubated with cells and irradiated with 633 
nm laser light164. This phenomenon has also been demonstrated when the CPPs are 
conjugated to proteins (Figure 1-4). For instance, the protein p53 labeled with the CPP 
R11 and with the fluorophore FITC was observed to accumulate in endosomes upon 
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Figure 1-4. Model for fluorophore-CPP mediated PCI. The Fl-CPP conjugates exist in 
equilibrium in a membrane bound and unbound state due to the membrane-targeting role 
of the peptide moiety. Upon light irradiation, the fluorophore moiety of the conjugate 
produces singlet oxygen by transfer of energy from its triplet state to molecular oxygen. 
When present in solution, the Fl-CPP conjugate is innocuous. But, in its membrane bound 
state, the singlet oxygen produced by the fluorophore reacts with membrane biomolecules 
and disrupts the membrane, causing release of endosomal contents. 
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incubation with cells. Repeated fluorescence imaging at 480 nm by confocal laser 
scanning microscopy, however, led to a redistribution of the FITC conjugate into the 
cytosolic and nuclear compartments of cells165. The use of fluorescently labeled CPPs for 
PCI has been extended to the cytosolic delivery of RNA molecules. Ohtsuki and co-
workers have fused an RNA binding protein U1A to the TAT peptide. This TatU1A 
construct was labeled with Alexa Fluor 546 or cyanine fluorophores at its C-terminus. The 
fluorescently labeled TatU1A construct could bind small hairpin RNA (shRNA) 
containing a U1A binding sequence and carry its cargo into the endocytic pathway of cells. 
Irradiation with light corresponding to the excitation wavelength of the fluorophores led 
to release of shRNA from endosomes into cytosol as measured by the cytosolic 
redistribution of fluorescence as well as by gene silencing mediated by the delivered 
shRNA. It was therefore shown that gene expression could be spatially and temporally 
controlled using light irradiation166.  
In addition to the fluorophores cited previously (i.e. xanthenes, Alexa fluor dyes, 
cyanines), CPP-photosensitizer conjugates have also been tested. For instance, aluminum 
phthalocyanine (AlPcS) has been attached to TAT to photo-induce endosomal release and 
cytosolic delivery167. Better uptake of the photosensitizer 5-[4-carboxyphenyl]-10,15,20-
triphenyl-2,3-dihydroxychlorin (TPC) was also seen when conjugated to oligoarginine 
R7168. The irradiation wavelength required to induce endosomal escape has to match the 
excitation spectra of the fluorophore and so far, light in the range of 480 to 670 nm has 
been successfully used164, 169-174. When irradiation is performed on a confocal laser 
scanning microscope, the fluorophores have to be subjected to multiple light exposures to 
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achieve significant endosomal release. Consequently, cytosolic redistribution typically 
happens on a time scale of minutes. In contrast, irradiation on an epifluorescence 
instrument can lead to cytosolic redistribution within milliseconds175. This has, for 
instance, been observed with TAT labeled with the fluorophore tetramethylrhodamine 
irradiated at 560 nm175. Presumably, these differences are due to the fact that while the 
whole cell is exposed to light when using epifluorescence, only small subcellular areas are 
exposed to light at once when a scanning laser is used. Together, these results nonetheless 
suggest that light can be dosed and that, unlike with other methods, endosomal release can 
in principle be precisely controlled. In addition, it appears that most if not all endocytic 
organelles containing Fluorophore-CPP conjugates lyse if sufficient light exposure is 
applied. The overall yield of cytosolic delivery using this methodology can therefore be 
very high. 
 
1.4.4 Limitations and future challenges 
A potential limitation of PCI and CPP-mediated PCI in particular, is the photo-toxicity 
associated with these methodologies. The photosensitizers used for PCI can cause cell 
death when exposed to sufficient light176. The light dose applied to achieve endosomal 
release must therefore carefully be controlled so as to avoid cell death during delivery176. 
Several reports have shown that CPP-mediated PCI can be accomplished without killing 
cells164, 177. However, R7-TPC causes apoptosis and necrotic cell damage at low and high 
concentrations, respectively168. Recently, rapid cell death was also found to occur during 
PCI with TMR-TAT. In particular, plasma membrane permeabilization and blebbing were 
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observed shortly after endosomal escape of TMR-TAT was initiated with light178. It is 
clear that delivering photolytic agents into the cytosol of cells can potentially have 
detrimental effects. One can imagine how a photolytic Fluorophore-CPP could, upon 
endosomal escape, reach the membrane of other intracellular organelles, damage these 
membranes during irradiation, and cause cell death. However, TMR-TAT is not 
phototoxic when directly microinjected into the cell’s cytosol178. Instead, endosomal lysis 
itself has been implicated in the cell death that accompanies PCI with TMR-TAT. In 
particular, irradiation causes the endosomal release of not only TMR-TAT but also of 
other molecules present in the lumen of these organelles178. The release of toxic material 
such as lysosomal hydrolases179 or iron180 might in principle take place. Recently, the 
release of calcium from endocytic vesicles photolysed with TMR-TAT has been 
implicated in cell-death. Release of calcium into the cytosol was followed by 
accumulation of calcium in the mitochondria, activation of the mitochondrial permeability 
transition pore (MPTP), and subsequent cell death178. Consequently, in tissue culture 
assays, rapid cell death was abolished with ruthenium red or cyclosporine A, inhibitors of 
mitochondrial calcium transport or of the MPTP, respectively178. 
In principle, CPP-mediated PCI could be used in vivo to deliver drugs to diseased cells 
by shining light only on selected tissues. PCI is particularly attractive for such applications 
because of the temporal and spatial control that it provides166. The in vivo potential of PCI 
has been demonstrated with photosensitizers181-183. However, CPP-mediated PCI has 
never been tested in vivo to my knowledge. Yet, one can envision how CPP-based agents 
might be complementary to other PCI photosensitizers. While peptides are prone to rapid 
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degradation in vivo and in cellulo, retro-inverso (ri) peptides can be used to extend the 
half-life of Fluorophore-CPPs. It has been observed that endocytosed TMR-TAT loses its 
photo-endosomolytic activity after only a few hours of incubation, presumably because of 
proteolytic degradation of the peptide within endocytic organelles184. In contrast, TMR-
riTAT remains active even after 8 h of incubation175. Another important issue for in vivo 
applications is related to the fact that visible light does not penetrate tissues deeply185. It 
is reported that red and near-infrared light penetrates tissues more deeply than light of 
shorter wavelengths185. Chromophores that absorb light above the 600 nm range should 
therefore be preferable for in vivo procedures. However, Fluorophore-CPPs conjugates 
containing Cy5, Cy5.5, Alexa 660, and Alexa 680 were reported to be dramatically less 
efficient at inducing the endosomal release of shRNA than fluorophores with shorter 
excitation wavelength166. Whether Fluorophore-CPP can be performed with red or near-
infrared chromophores therefore remains to be established. 
 
1.5  Multivalent CPPs for delivery of macromolecules inside live cells: another class 
of endosomolytic agents  with potential  improved features  
1.5.1 Multivalency: Concept and rationale for the increase of CPPs activity 
One way to increase the endosomolytic activity of CPPs is to create multivalent CPPs. 
This approach consists of presenting multiple copies of a CPP on a delivery vector so as 
to increase the local concentration of the CPP where the peptide interacts with cellular 
components. Several multivalent CPPs have been reported (Figure 1-5). 
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Figure 1-5. MCPP systems and their interactions with membranes. (a) Strategies used 
to generate MCPPs. From left to right: (1) The p53tet-CPP system involves connecting 
the tetramerization domain from the human tumor repressor protein p53 to a CPP. The 
peptide sequence is generated using SPPS. After purification of the peptide sequence, 
p53tet selfassembles into a tetramer producing a tetravalent CPP. (2) Loligomers are a 
“squid-like” MCPP system. The CPP is attached on the surface of a polylysine branch 
scaffold. The scaffold and the peptide are generated using SPPS. The number of branches 
of this MCPP system will depend on the number of Lys coupling steps. (3) The branched 
CPP system involves the generation of a peptide scaffold of Lys(ε-NH-Cys)Gly repeats to 
which a CPP-thioester is added using native chemical ligation (NCL). The peptides were 
generated using SPPS although production of recombinant peptide or protein thioesters is 
possible using intein fusions. A fluorophore was added on the N-terminal end of the 
scaffold peptide to serve as both an imaging agent and a small model cargo. (4) 
Dendrimers are MCPPs having a “tree-like” shape and are usually generated using 
divergent or convergent methods. CPPs have been attached to the surface of 
polyamidoamine (PAMAM), polypropylenimine (PPI) or polyethylenimine (PEI) 
dendrimers. The number of CPPs on dendrimers is among the highest observed for 
MCPPs. (b) A possible model for the mode of action of CPPs versus that of MCPPs. In 
this example, a CPP-cargo is present at the membrane of endosomes at a low local 
concentration, leading to poor endosomolytic activity. In contrast, a MCPP-cargo displays 
multiple copies of the CPP. This leads to efficient membrane interactions and a possible 
enhancement in membrane disruption. In some cases however, too many CPP copies 
might cause unproductive membrane interactions such as tight binding to HSPGs. This in 
turn might lead to poor cellular penetration. 
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Here, I survey the protocols used to generate multivalent CPPs and discuss the evidence 
suggesting that multivalent CPPs escape from endosomes more efficiently than their 
monomeric counterparts. 
 
1.5.2 Strategies to generate multivalent CPPs 
 Multiple synthetic protocols have been used to create multivalent CPPs (Figure 1-
5a). One strategy involves attaching a protein oligomerization domain to CPPs. For 
instance, the tetramerization domain of the human tumor suppressor p53 (p53tet), 
corresponding to amino acids 325–355, has been attached to the CPPs decaarginine and 
decalysine by solid phase peptide synthesis (SPPS)186, 187. The p53tet domain self-
assembles in solution and tetrameric CPP constructs were therefore obtained (Figure 1-
5a (1)). Notably, these compounds delivered DNA into cells more efficiently than 
decaarginine and decalysine alone. Multivalent CPPs have also been generated by 
attachment of the peptides to dendrimers74, 188-191. Dendrimers are highly branched 
molecules that display a tree-like shape (Figure 1-5a (2))192. The branches of dendrimers 
can be functionalized and, therefore, dendrimers can serve as a scaffold onto which CPPs 
can be chemically conjugated. Related approaches consist of attaching CPPs to peptide 
scaffolds. Branched “squid-like” peptide constructs known as loligomers have, for 
instance, been reported (Figure 1-5a (3))193-195. Loligomers containing eight CPP copies 
have been assembled by SPPS on branched polylysine scaffolds196. TAT has also been 
assembled on a peptide scaffold consisting of Lys(ε-NH-Cys)Gly repeats (Figure 1-5a 
(4)). In this example, TAT was functionalized with a C-terminal thioester and conjugated 
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to the cysteine residues of the scaffold by native chemical ligation197, 198. The MCPPs 
generated displayed 2, 3, and 4 TAT copies. Finally, CPPs containing cysteine residues 
have been dimerized by the straightforward formation of disulfide bridges (Figure 1-5a 
(5))199-201 
 
1.5.3 Delivery of cargos using multivalent CPPs 
 How the extracellular and intracellular behavior of multivalent CPPs compares to 
that of their monomeric counterparts is not clear. There is certainly growing evidence that 
multivalent CPPs transduce cargos into cells more efficiently than CPPs. The multivalent 
CPPs described in the previous paragraph have, for instance, been reported to deliver 
molecules such as DNA, proteins, peptides, polysaccharides or small organic fluorophores 
to a higher degree than CPPs198, 200-204. However, in the case of DNA transfection 
experiments, improvements in cytosolic delivery can be difficult to interpret. Positively-
charged multivalent CPPs form complexes with DNA that might be significantly different 
than those formed with CPPs. As a matter of fact, it has been proposed that branched CPPs 
might be more capable of “multitasking”, with a few branches of multivalent CPPs being 
in complex with its DNA cargo while other branches might interact with cellular 
components203. In contrast, a positively charged and monomeric CPP bound to negatively 
charged DNA might not be able to interact with other molecules as readily. Taking the 
example of DNA transfection again, multivalent CPPs/DNA complexes are typically 
endocytosed at higher levels than CPPs/DNA particles186, 193, 202. Since more multivalent 
CPPs and more DNA accumulate inside endosomes, more DNA is delivered into the 
	 34
cytosol and nucleus of cells. This would presumably happen even when multivalent CPPs 
and CPPs might have similar intrinsic endosomal escape activity. It is therefore often 
difficult to determine whether increased delivery by multivalent CPPs is due to enhanced 
endocytosis, enhanced endosomal release, or both. 
 
1.5.4 Limitations and future challenges 
Multivalent CPPs show great potential as endosomolytic compounds. However, 
several limitations of this class of compounds can be expected. First, synthesis protocols 
are often complex and multivalent CPPs cannot be generated as easily as their monomeric 
counterparts. In addition, convenient protocols for the conjugation of these systems to 
various cargos remain to be established. The in vivo utility of multivalent CPPs inside cells 
is also uncertain because of the potential immunogenicity of branched peptides in general. 
The possibility that CPPs might act as immunogens has already been discussed in the 
literature205, 206. Notably, multivalent CPPs share close structural resemblance with 
multiple antigenic peptides (MAPs)207. MAPs are known to induce strong immune 
responses in part because of enhanced molecular recognition by immune cells208. The 
latter is a result of the display of multiple short antigenic peptides in a polylysine 
dendrimer scaffold. The use of multivalent CPPs could therefore produce a non-desired 
cellular immune response due to the display of multiple, possibly immunogenic CPPs. 
One of the challenges ahead consists in understanding how multivalent CPPs mediate 
better delivery than monomeric peptides. To date, how the number of CPP copies impacts 
activity remains uncertain. As indicated in Figure 1-5b, few CPP branches might not 
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induce enough activity while too many might cause unproductive behavior. The effect of 
cargo conjugation also remains to be explored. It is, for instance, possible that the number 
of CPP branches required for optimal delivery depends on the types of cargo used. 
Structure-activity relationship studies should also reveal how the architecture of 
multivalent CPPs affects their interactions with lipid bilayers, their trafficking inside cells, 
and their endosomolytic activity. The mechanism of multivalent CPPs endosomal escape 
remains unknown. It is possible that displaying multiple copies of a CPP would change 
how the peptide is uptaken by cells (direct plasma translocation or endocytosis) and, if 
endocytosed, how does it escape from the endocytic pathway, when compared to its 
monomeric counterpart.  Mechanistic studies using DN-Rab proteins and endocytosis 
inhibitors should help decipher the route that multivalent CPPs utilize to penetrate cells. 
This in turn, could allow the development of more efficient delivery agents. 
 
1.6 The goal of my study 
Although previous studies showed that multivalent CPPs display an enhanced delivery 
of multiple different types of cargos, relative to their monomeric counterparts, very little 
is known about how they penetrate cells. Furthermore, the synthesis of multivalent CPPs 
and conjugation of cargos to these delivery vectors is complex. In order to establish the 
mechanism involved in multivalent CPPs penetration, I will utilize cells and liposomes as 
complementary models. A simple and controllable in vitro model, like liposomes, will 
allow me to study how multivalent CPPs interact with membranes that resemble different 
lipid bilayers that multivalent CPPs may encounter in a cell. Moreover, I will be able to 
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study the ability of multivalent CPPs to disrupt these membranes. This will allow me to 
establish, in a controlled environment, insights involved in multivalent CPPs cell 
penetration. Yet, liposomes fail to reproduce the activity displayed by multivalent CPPs 
in cells. To solve this problem, I will use living cells to look at the delivery activity of 
multivalent CPPs. Furthermore, with the help of cellular and molecular biology tools I 
will perform mechanistic studies using multivalent CPPs. The in cellulo studies will then 
complement the in vitro ones. Together, these will allow me to establish the mechanism 
of multivalent CPP cell penetration. Finally, my work will also focus on developing new 
simple and convenient strategies to generate multivalent CPPs, as well as, establishing 
new protocols for efficient and simple delivery of cargos. Altogether, the knowledge I will 
acquire will lay a solid foundation for the design of improved delivery agents with high 
therapeutic potential that can also prove to be very useful to study cellular processes in 
living cells.   
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2. GENERATION OF MULTIVALENT BRANCHED ENDOSOMOLYTIC 
REAGENTS OF THE PROTOTYPICAL CELL-PENETRATING PEPTIDE TAT: 
TOOLS FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE 
COMPOUNDS TO LIVE CELLS IN CIS (COVALENT CONJUGATION) OR TRANS 
(SIMPLE CO-INCUBATION)*198 
 
2.1 Introduction 
 In this chapter, I describe the synthesis and cellular delivery properties of 
multivalent and branched delivery systems consisting of the prototypical CPP TAT 
assembled onto peptide scaffolds using native chemical ligation. I test the hypothesis that 
branched multivalent TAT molecules would display an enhanced endosomolytic activity 
when compared to TAT and that these delivery agents could induce the release of cell-
impermeable macromolecules trapped inside endocytic organelles into the cytosolic space 
of live cells. This is based on the principle that multivalency results in an increase of the 
CPP's local concentration at the sites where the peptide interacts with cellular components 
(avidity effect) (Figure 1-5b)209, 210. It has been clearly established that such an approach 
can increase the endocytic uptake of cationic peptides, and that branched molecules can 
function and multitask in ways their linear homologues cannot186, 187, 203. Herein I show 
that upon displaying three TAT copies, this trimeric delivery agent (Fl-TAT3) escapes 
from the endocytic pathway. Moreover, Fl-TAT3  
*This chapter is reprinted with permission from “Generation of endosomolytic reagents by branching of 
cell-penetrating peptides: tools for the delivery of bioactive compounds to live cells in cis or trans” by 
Ángeles-Boza, A.+;Erazo-Oliveras, A.+; Lee, Y.-J. and Pellois, J.-P. Bioconjugate Chemistry 2010, 21 2164-
2167. doi: 10.1021/bc100130r. +authors contributed equally. Copyright (2010) by American Chemical 
Society. 
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seems to possess an endosomolytic activity much greater that its monomeric and dimeric 
counterparts (Fl-TAT and Fl-TAT2) and do not appear to show the unproductive 
membrane binding displayed by its tetrameric counterpart (Fl-TAT4). Moreover, I show 
that Fl-TAT3 can be utilized to deliver the small cargo fluorescein (Fl) in cis and two 
different cargos in trans, a fluorescently-labeled dextran (Dextran-tetramethylrhodamine) 
and a bioactive cell-impermeable peptide (pro-apoptotic domain, PAD). However, the 
mechanism of multivalent CPP endosomal escape remains unknown. 
 
2.2 Results 
2.2.1 Synthesis and purification of Fl-TATn peptides 
 My synthetic approach consists of assembling multiple CPPs onto scaffold 
peptides using native chemical ligation (NCL)197. The scaffold peptides contain several 
lysines that have been modified at the ε NH2 with a cysteine residue211. Each cysteine is 
available to react with a TAT peptide containing a C-terminal thioester (TAT-thioester) to 
generate branched multivalent species. The scaffold peptides were synthesized by solid-
phase peptide synthesis (SPPS) using standard Fmoc protocols (Figure 2-1). N number of 
lysine residues bearing methyl-trityl (Mtt) protecting groups at the ε NH2 were 
incorporated onto the Rink amide resin and separated by glycine residues to reduce steric 
hindrance during synthesis and NCL. The lysine side chains protecting groups were 
removed orthogonally with 2 % trifluoroacetic acid (TFA) and Boc-Cys(tButhio)-OH was 
coupled onto the exposed ε NH2. This was followed by removal of the N- 
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Figure 2-1. Synthesis scheme of the scaffold peptides using SPPS. Synthesis is 
performed in house using a glass vessel connected to a N2 line (providing agitation). 
Before step 1, the Rink amide resin is swollen in DMF and deprotected (Fmoc removal). 
In step 1, Fmoc-Gly-OH, HBTU and DIEA are added to the resin to couple the first amino 
acid to the resin. After coupling, the resin is washed thoroughly, deprotected and Fmoc-
Lys(Mtt)-OH is coupled to the resin as before. After coupling, the resin is washed and 
deprotected. The previous steps are repeated until the desired number of Gly and Lys are 
added to the resin. In step 2, Mtt (side chain protecting group) is selectively removed with 
1 % TFA in DCM, the amino acid Boc-Cys(Stbu)-OH is added, the resin is deprotected 
and the fluorophore is conjugated to the resin. In step 3, the StBu (side chain protecting 
group) is removed and the peptide is cleaved from the resin. This last step leads to the 
generation of the free scaffold peptide. 
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terminal Fmoc group and subsequent coupling of 5(6)-carboxyfluorescein (Fl) to the free 
amino group on the scaffold. TFA cleavage and preparative scale reverse phase high-
performance liquid chromatography (HPLC) purification afforded the scaffold peptides 
containing n sites for NCL. The products identity was confirmed using matrix-assisted 
laser desorption ionization time of flight (MALDI-TOF) mass spectrometry. TAT-
thioester was obtained by SPPS on a sulfamylbutyryl resin using reported protocols 
(Figure 2-2)212. The branched multivalent TAT compounds were obtained by reacting the 
scaffold peptides containing n cysteines with 3n equivalents of TAT-thioester at room 
temperature in aqueous buffer at pH 7.5. Formation of the products, Fl-TATn, was detected 
by HPLC as early as 1 h, and the reactions were complete in less than 12 h (Figure 2-3). 
The crude products were purified by preparative scale reverse phase HPLC and their 
identity was confirmed using MALDI-TOF (Figure 2-4, 2-5 and 2-6). 
  
2.2.2 Translocation of Fl-TATn peptides into live cells 
The cellular import of the multivalent compounds (Fl-TATn) was first investigated 
by live-cell fluorescence microscopy. The fluorescein molecule installed at the N-terminus 
of the peptides was used as both a fluorescent label and a model of a small molecule cargo. 
A fluorescein labeled TAT (Fl-TAT) was evaluated as a “non-branched” control. Fl-TAT, 
Fl-TAT2, and Fl-TAT3 were incubated with HeLa cells for 30 min at 1 or 5 μM. These 
concentrations were chosen because Fl-TAT is known to penetrate cells poorly under a 
concentration threshold of 5-10 μM102. I therefore considered that it would be possible to 
observe any enhancement of activity by Fl-TAT2  
	 41
 
 
 
 
 
Figure 2-2. Synthesis scheme of TAT-SR using SPPS. Synthesis is performed in house 
using a glass vessel connected to a N2 line (provide agitation). Before step 1, the Rink 
amide resin is swollen in DMF. In step 1, the resin is activated and the amino acids are 
coupled using standard SPPS protocols. In step 2, the peptide is cleaved to yield the 
peptide thioester. 
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Figure 2-3 HPLC analysis of the chemical reaction between Fl-(Kε(C)-G)3-NH2 and 
TAT-thioester. The species shown here were identified by mass spectrometry. 
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Figure 2-4 Characterization of Fl-TAT2. Chemical structure and expected molecular 
weight of Fl-TAT2 (top) and MALDI-TOF mass spectrum of Fl-TAT2 (bottom). The peak 
at 1911.76 corresponds to the doubly charged product. 
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Figure 2-5 Characterization of Fl-TAT3. Chemical structure and expected molecular 
weight of Fl-TAT3 (top) and MALDI-TOF mass spectrum of Fl-TAT3 (bottom). 
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Figure 2-6 Characterization of Fl-TAT4. Chemical structure and expected molecular 
weight of Fl-TAT4 (top) and MALDI-TOF mass spectrum of Fl-TAT4 (bottom). 
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Figure 2-7 Fluorescence and bright field images of HeLa cells incubated with Fl-
TATn (n=2,3 and 4). After incubation with cells, Fl-TAT2 is trapped inside endocytic 
organelles (punctate distribution (shown in scheme below image), 5 μM; same results were 
obtained for Fl-TAT at 5 μM) but Fl-TAT3 released into the cytosolic space (diffuse 
distribution in cytosol and nucleus.) at only 1 μM. Fl-TAT4 is bound to the plasma 
membrane. Some Fl-TAT3 remains inside endosomes, as shown in scheme but when it 
reaches the cytosolic space, Fl-TAT3 accumulates in the nucleolus. This is further 
evidence supporting that the peptide escaped from the endocytic pathway and is indeed 
inside cells. 
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and Fl-TAT3 as compared to Fl-TAT under conditions where the monomeric peptide 
shows low activity. After washing the cells with fresh media, cells were imaged by 
fluorescence confocal microscopy. In the case of Fl-TAT and Fl-TAT2, a punctate 
distribution consistent with accumulation of the compounds inside endocytic organelles 
was observed at both concentrations (1 and 5 µM) (Figure 2-7). No accumulation of the 
peptides in the cytosolic space of cells was detected. In contrast, Fl-TAT3 exhibited a clear 
diffuse and cytosolic distribution at 1 or 5 μM indicative of an increase in the translocation 
efficiency as compared to the monomeric and dimeric compounds. Importantly, this was 
not accompanied by an increase in cytotoxicity of Fl-TAT3 (see next paragraph and 
Figure 2-8). The transport of Fl-TAT3 into the cytosolic space of cells was inhibited by 
amiloride, an inhibitor of macropinocytosis. These results indicate that Fl-TAT3 is 
predominantly internalized by macropinocytosis and that it reaches the cytosolic space of 
cells by escaping from the endocytic pathway. Fl-TATn with n = 4, 5 and 6 were also 
tested but could not be washed from the cell surface to a satisfactory level after incubation 
and analysis of their transport properties was therefore difficult. These results are 
consistent with the work of Futaki and coworkers who have reported the synthesis of 
peptides with four branched chains of the type (Rn)4 (n = 1-6)213. (R2)4 was shown to 
internalized into cells with an efficiency similar to that of its linear homologue R8 while 
(R6)4 was found to only accumulate at the plasma membrane without being able to enter 
cells214. Likewise, Fl-TATn with n = 4, 5 and 6 (a single TAT peptide copy contains six R 
residues) might bind to cell-surface components to such an  
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Figure 2-8 Delivery of TMR-PAD into HeLa cells mediated by Fl-TAT and Fl-TAT3 
as measured by a reduction in cell viability. Fl-TAT (10 μM) or Fl-TAT3 (1 μM where 
highlighted with * or 3 μM otherwise) were co-incubated with TMR-PAD for 1 h.  
SYTOX® Blue staining was used to detect dead or dying cells 240 min after incubation 
with the peptides. Amiloride was used to inhibit macropinocytosis. Cell viability is 
expressed in % in comparison to an untreated sample. As observed, Fl-TAT and TMR-
PaD co-incubation did not lead to a significant change in cell viability. In the contrary, Fl-
TAT3, when co-incubated with TMR-PAD, led to a 40 % and 80 % reduction in cell 
viability when present in the media at 1 μM and 3 μM, respectively. These results represent 
the average cell viability and corresponding standard deviation from three experiments. 
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extent that, in this case, it leads to a membrane-bound state that is not productive. 
Accordingly, these reagents were not considered further in my experiments. 
 
2.2.3 Delivery of cell-impermeable macromolecules inside live cells using Fl-TAT3 
 To characterize the delivery activity of Fl-TAT3, I tested whether Fl-TAT3 might 
be capable of inducing the release of macromolecules from endosomes. This idea is based 
on the principle that, if Fl-TAT3 and a macromolecule are co-incubated and accumulate 
together within endocytic vesicles, Fl-TAT3 might cause leakage of the endosomal 
membrane and release of the macromolecule into the cytosolic space of cells159. This was 
first suggested by the observation that 70 kDa Dextran-tetramethylrhodamine (Dextran-
TMR), a marker of pinocytosis that typically accumulates inside endocytic vesicles when 
co-incubated with cells, was present into the cytosol of cells when co-incubated with Fl-
TAT3 (Figure 2-9). To test this working hypothesis further and evaluate the delivery of a 
bioactive macromolecule, the pro-apoptotic peptide KLAKLAKKLAKLAKNH2 (PAD) 
was used. PAD is cell-impermeable and has a negligible cytotoxicity towards mammalian 
cells215. However, if delivered into the cytosol of cells, PAD permeabilizes the 
mitochondrial membrane and induces apoptosis136, 216. Cell-death was therefore used as 
an indicator of the efficiency with which Fl-TAT3 might deliver PAD into live cells. PAD 
labeled with carboxytetramethylrhodamine (TMR-PAD, 10 μM) was co-incubated with 
Fl-TAT (1 to 10 μM) or Fl-TAT3 (1 to 3 μM) for 30 min. The import of TMR-PAD, Fl-
TAT and Fl-TAT3 into cells was monitored by confocal microscopy and cell viability was 
assessed  
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Figure 2-9 Fluorescence and bright field images of HeLa cells co-incubated with Fl-
TAT3 and Dextran-TMR. (A) Schematic representation of TMR-labeled dextran and Fl-
labeled trimeric TAT delivery inside a single cell. (B) Confocal fluorescence microscopy 
images of HeLa cells incubated with Fl-TAT3 (1 μM) and 70 kDa Dextran-TMR (10 μM), 
a marker of pinocytosis. As observed, Fl-TAT3 is able to deliver a macromolecule into the 
cytosolic space of live cells. The cells represented were not stained by SYTOX® Blue. 
This indicates that the membrane of these cells was not compromised. Scale bar: 10 μm. 
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by SYTOX® Blue staining. SYTOX® Blue, a high-affinity nucleic acid and cell-
impermeable dye, stains the nucleus of apoptotic or necrotic cells with a compromised 
plasma membrane without staining live cells217, 218. When TMR-PAD was co-incubated 
with Fl-TAT, TMR-PAD was present inside endocytic organelles but did not appear to 
enter the cytosol of cells (as monitored by TMR fluorescence, data not shown) regardless 
of the concentration of Fl-TAT used. In addition, the cells’ viability was not affected by 
treatment with these peptides (Figure 2-8). These results are consistent with a model 
where Fl-TAT cannot promote endosomal release of TMR-PAD and, as a result, TMR-
PAD is unable to induce cell-death. In contrast, cells incubated with Fl-TAT3 and TMR-
PAD showed a diffuse and cytosolic distribution for both TMR-PAD and Fl-TAT3 
(Figure 2-10). These cells were not stained by SYTOX® Blue 60 min post-incubation 
(Figure 2-10 (A)). However, 40 and 80 % of the cells became SYTOX® Blue positive 
240 min post-incubation when 1 or 3 μM Fl-TAT3 were used, respectively (Figure 2-8 
and 2-10 (B)). Progression to classic morphological changes such as membrane blebbing 
and nuclear fragmentation further confirmed that cells were undergoing apoptosis. 
Treatment with amiloride inhibited delivery of Fl-TAT3 and TMR-PAD into cells as well 
as cell-death (Figure 2-8 and 2-10 (C)). These results therefore indicate that the 
cytotoxicity observed when Fl-TAT3 and TMR-PAD are co-incubated arises from the 
delivery of TMR-PAD by Fl-TAT3 as opposed to cytotoxic effects that might arise when 
the peptides are combined and not related to the transport of TMR-PAD. Together, these 
results support a model where Fl-TAT3 and TMR-PAD are first internalized into cells by 
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endocytic mechanisms and where Fl-TAT3 then releases TMR-PAD into the cytosol of 
cells. 
 
 
 
 
Figure 2-10 Fluorescence and bright field images of HeLa cells co-incubated with Fl-
TAT3 and TMR-PAD. Cells were incubated with TMR-PAD (10 μM), Fl-TAT3 (3 μM), 
and with or without the macropinocytosis inhibitor amiloride. Cells were incubated with 
the peptides for 30 min and washed with fresh media, and SYTOX® Blue was added to 
detect dead cells. Images were acquired 60 or 240 min after addition of SYTOX® Blue. 
Blue nuclei in the SYTOX® Blue images represent dead or dying cells. Cells containing 
a cytosolic distribution of both TMR-PAD and Fl-TAT3 can be observed at 60 min. Scale 
bar: 100 μm. 
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2.2.4 The enhanced delivery activity of Fl-TAT3 is not a result of formation of 
aggregates containing n  ≥ 6 TAT copies 
 The NCL synthesis scheme that I used in this report generates Fl-TATn compounds 
that contain n free thiols. On one hand, these thiols could be used to attach molecular 
cargos through a disulfide bond to the multivalent delivery reagents. On the other hand, 
the thiols, when left unmodified, could promote the aggregation of Fl-TATn through the 
formation of intermolecular disulfide bridges. Such aggregates could participate in the 
cellular activities observed and lead me to believe that Fl-TAT3 possesses a higher 
endosomolytic activity when in reality the aggregates with n ≥ 6 TAT copies contribute 
with most of the observed activity.  
To test whether the thiols present in the Fl-TATn compounds could lead to 
aggregate formation through the formation of intermolecular disulfide bridges, the 
compounds (10 M in PBS, this concentration reflects the highest concentration used in 
the cell-based assays) were oxidized by bubbling O2 in the media for 1 hour. Formation 
of aggregates of higher molecular weights was monitored by HPLC analysis and mass 
spectrometry (data not shown). The HPLC profiles and mass spectrometry spectra of the 
oxidized Fl-TATn compounds were similar to those presented above and to the samples 
treated with the reducing agent TCEP (10 mM), indicating that no intermolecular disulfide 
bridges formed between the Fl-TATn molecules. Instead, intramolecular disulfide bridges 
might have formed. Given the close proximity of the cysteine residues in the Fl-TATn 
compounds, these intramolecular disulfide bonds would have a greater probability of 
formation than intermolecular disulfide bridges. These intramolecular disulfide bridges 
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might however not lead to a shift in HPLC retention time. The mass spectrometry analysis 
was also not accurate enough to unequivocally confirm the loss of 2 H that would 
accompany the formation of each disulfide bridge.  
In the case of Fl-TAT2 and Fl-TAT4, oxidation of the cysteines was confirmed by 
monitoring the reducing activity of the compounds. Fl-TAT2 and Fl-TAT4 were first 
reduced with immobilized tris(2-carboxyethyl)phosphine (TCEP) in PBS. The TCEP 
beads were filtered and the solution was immediately added to a solution of Aldrithiol-2 
(2,2’-dithiopyridine, 100 M). Aldrithiol forms a thiopyridone salt upon reduction and 
this is accompanied by an increase in absorbance at 350 nm. As expected, the reduced Fl-
TAT2 and Fl-TAT4 caused an increase in the absorbance of the solution at 350 nm (data 
not shown). In a parallel assay, the freshly reduced Fl-TAT2 and Fl-TAT4 were bubbled 
with O2 as described in the previous paragraph. In this case, addition of Aldrithiol did not 
cause an increase in the absorbance 350 nm (the absorbance of fluorescein at 490 nm was 
measured to confirm that the reduced and oxidized Fl-TATn compounds were used at the 
same concentration). These results therefore confirm that the reducing activity of Fl-TAT2 
and Fl-TAT4 was abolished after the oxidation step, further confirming that intracellular 
disulfide bonds are formed.  
In the case of Fl-TAT3, one can presume that one intramolecular disulfide bridge 
might form leaving one cysteine that could potentially form an intermolecular disulfide 
bond. The fact that I did not detect aggregates of high molecular weight might reflect the 
fact that intermolecular disulfide bond formation is sterically unfavorable. Indeed, Fl-
TAT3 had the ability to reduce Aldrithiol-2 even after the oxidation step, confirming that 
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a free thiol might remain even after bubbling oxygen (aldrithiol is a small molecule that 
presumably might have access to this free thiol).  
However, to unequivocally confirm that aggregates of the Fl-TAT3 compound 
were not involved in the unique delivery properties of this compound, the free thiol groups 
present in the molecule were capped with iodoacetamide. Furthermore, in vitro assays 
might not reproduce what happens inside cells and it is possible that aggregates form in 
the lumen of endosomes. To address this issue, the thiols of Fl-TAT3 were blocked with 
iodoacetamide to form an acetamidated analogue of Fl-TAT3. This product, Fl-TAT3-(S-
CH2-CO-NH2)3, cannot form disulfide bonds because the thiols are replaced by thioethers 
(Figure 2-11). To compare the delivery activity of Fl-TAT3-(S-CH2-CO-NH2)3 with that 
of Fl-TAT3, Fl-TAT3-(S-CH2-CO-NH2)3 (3 μM) and TMR-PAD (10 μM) were co-
incubated for 30 min with HeLa cells (Figure 2-12) and cell-viability was assessed by 
microscopy. While incubation with Fl-TAT3-(S-CH2-CO-NH2)3 alone resulted in a cell 
viability of 90 % (Figure 2-12 (top panel)), co-incubation with TMR-PAD resulted in a 
cell-viability of 25 % 240 min post-incubation (Figure 2-12 (middle panel)). Moreover, 
treatment with amiloride inhibited delivery of Fl-TAT3-(S-CH2-CO-NH2)3 and TMR-
PAD into cells as well as cell-death (Figure 2-12 (bottom panel)). These results are 
similar to those obtained with Fl-TAT3. This suggests that the delivery  
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Figure 2-11 Characterization of Fl-TAT3-(S-CH2-CO-NH2)3. Chemical structure and 
expected molecular weight of Fl-TAT3-(S-CH2-CO-NH2)3 (alkyl amide group shown in 
green) (top) and MALDI-TOF mass spectrum of Fl-TAT3-(S-CH2-CO-NH2)3 (bottom). 
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Figure 2-12 Fluorescence and bright field images of HeLa cells co-incubated with 
TMR-PAD and Fl-TAT3-(S-CH2-CO-NH2)3. (A) Cells were treated with Fl-TAT3-(S-
CH2-CONH2)3 (3 μM) and TMR-PAD (10 μM) and imaged after a 30 min co-incubation 
at 37°C (the objective used was 100X). The cells represented were not stained by 
SYTOX®Blue at this early timepoint. This indicates that the membrane of these cells 
was not compromised. Scale bar: 10 μm (B) Cells were incubated with TMR-PAD (10 
μM), Fl-TAT3-(S-CH2-CO-NH2)3 (3 μM), and with or without the macropinocytosis 
inhibitor, amiloride. Cells were incubated with the peptides for 30 min, washed with fresh 
media, and SYTOX® Blue was added to detect dead cells. Images were acquired 240 min 
after addition of SYTOX®Blue. Black nuclei in the SYTOX®Blue images represent 
dead or dying cells (images are represented as inverted monochrome). Scale bars: 100 μm. 
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activity of Fl-TAT3 is not a result of aggregation of the compound and that the presence 
of the thiols is not necessary to achieve delivery. 
   
2.3 Discussion 
The trimeric TAT (Fl-TAT3) delivery system is able to deliver cell-impermeable 
molecules inside cells. Delivery into the cytosolic space is achieved, presumably, by Fl-
TAT3-mediated endosomal escape. This is not surprising because it has been known for a 
long time that TAT monomer, Fl-TAT3 monomeric counterpart, penetrates cells by 
escaping from endocytic vesicles. Yet, I showed that the ability of Fl-TAT3 to deliver 
cargos intracellularly is inhibited by amiloride, an inhibitor of macropinocytosis219. 
Similar inhibitory effects have been observed for CPPs that utilize the endocytic pathway 
to deliver cargos into the cell220-222.    
Fl-TAT3 appears to have an endosomolytic activity much greater than its 
monomeric and dimeric counterparts without displaying the unproductive membrane 
binding observed for constructs containing more branches. It was surprising that the 
delivery activity of these constructs did not follow a constant increase dependent of TAT 
copies. Work done by Whitesides have shown that polyvalent interactions can be used for 
the design of inhibitors to block viral and bacterial infections and toxins209, 223, 224. The 
unproductive membrane binding observed could be explain by the presence of multiple 
simultaneous interactions between Fl-TATn (n >4) and HSPGs. Strong interaction 
between the peptide and HSPGs could block the interaction of the peptide with specific 
cellular components, lipids for example, required to cause cellular uptake and endosomal 
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escape. Yet, Fl-TAT3 can deliver the small molecule cargo fluorescein in cis at 
concentrations much lower than that required for Fl-TAT. In addition, it can also be used 
to achieve delivery of molecules displaying diverse structures and sizes in trans. Fl-TAT3 
delivered a 70-kDa fluorescently-labeled Dextran macromolecule and a bioactive but cell-
impermeable peptide. This is important because this demonstrates that a macromolecule 
does not need to be labeled with an extraneous delivery peptide to be delivered, thereby 
greatly simplifying delivery protocols for in vitro applications.  
The design of Fl-TAT3 used herein allows the delivery of a cargo in cis by 
covalently attaching a molecule to the N-terminus of the scaffold peptide. Alternatively, 
delivery of molecules inside cells by linking cargos to the free thiol groups (through 
disulfide bridges or thioether bond) in Fl-TAT3 could potentially be achieved as well. 
Interestingly, I show that blocking the free thiols of Fl-TAT3 with iodoacetamide does not 
affect its delivery activity. Moreover, the alkyl amide in Fl-TAT3-(S-CH2-CO-NH2)3 
(acetamidated Fl-TAT3) acts as a small model cargo. This delivery system could prove 
useful for situations that require covalent attachment of the cargo to the delivery system. 
Furthermore, linking the cargo to Fl-TAT3 through a disulfide bridge would allow 
cleavage of this bond in the reducing cytosol of cells which would render the cargo 
unmodified and free of potential interferences from Fl-TAT3 that could affect the cargo 
bioactivity. Establishing where Fl-TAT3 escapes from the endocytic pathway should also 
provide valuable insights regarding its endosomolytic activity. Future experiments will 
also focus on testing the applicability of this delivery method to other macromolecules 
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and exploring the effect of the structure and spatial orientation of the scaffold peptide on 
the delivery activity of the TAT trimer.  
 
2.4 Materials and methods 
2.4.1 Peptide synthesis and purification 
All amino acids and the Rink amide resin were obtained from Novabiochem (San 
Diego, CA) and used as received. Peptides were synthesized in-house by SPPS using 
standard Fmoc protocols. Fmoc-Lys(Boc)-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Gly-OH, 
Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, and Boc-
Cys(StBu) were used to assemble the peptides. Reactions were carried out in SPPS vessels 
at room temperature using a stream of dry N2 to provide agitation. Fmoc deprotection was 
performed by addition of piperidine in DMF (20 %, 5 mL) to the protected Fmoc-peptide 
resin (0.72 mmol). Deprotection was carried out for 1×3 min and 1×10 min. Coupling 
reactions were carried out for 2 h with a mixture of Fmoc-amino acid (2.88 mmol), HBTU 
(1.06 g, 2.80 mmol), and DIEA (1.25 mL, 7.2 mmol) in DMF. Upon completion of the 
reaction, the resin was washed with DMF. The peptides were analyzed and purified by 
reverse phase HPLC. HPLC analysis was performed on a Hewlett-Packard 1200 series 
instrument and a Vydac C18 column (5 micron, 4 x 150 mm). Flow rate was 1 mL/min 
and detection was at 214 nm and 450 nm. Semipreparative HPLC was performed on a 
Vydac C18 10 × 250 mm column. Flow rate was 4 mL/min and detection was at 214 nm 
and 450 nm. All runs used linear gradients of 0.1 % aqueous TFA (solvent A) and 90 % 
acetonitrile, 9.9 % water and 0.1 % TFA (solvent B). The correct identity of the peptides 
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was confirmed by time-offlight mass spectrometry performed with a Shimadzu/Kratos 
instrument (AXIMACFR, 
Shimadzu, Kyoto). 
 
2.4.2 Synthesis of Fl-(Kε(C)-G)n-NH2 
The Fl-(Kε(C)-G)n-NH2, n=2-6, peptides were assembled using a standard Fmoc 
solid phase peptide synthesis strategy. Fmoc-Gly-OH was first coupled to the Rink amide 
resin (0.72 mmol scale). Fmoc-Lys(Mtt)-OH and Fmoc-Gly-OH were the alternatively 
coupled to generate the peptides Fmoc-(Kε(Mtt)-G)n-Rink amide. The Mtt protecting 
groups were cleaved by treating the resin with 2% TFA in DCM for 30 min and Boc-
Cys(StBu)-OH (3 x n equivalents) was coupled onto the exposed ε amino groups in DMF 
containing DIEA and HBTU (3 x n eq.). This was followed by N-terminal Fmoc 
deprotection and subsequent overnight coupling of 5(6)-carboxyfluorescein (Fl, 1.1 eq) in 
DMF containing HBTU (1.1 eq.). The S-StBu groups on the Cys side chains were cleaved 
on the solid phase using 100 eq of PBu3 and 400 eq of H2O in DMF:DCM for 4 h. The 
peptides were cleaved from the resin with 92.5 % TFA, 2.5 % TIS, 2.5 % EDT, and 2.5 % 
H2O. The crude products were precipitated and washed with cold diethyl ether and then 
lyophilized to yield crude peptide solids that were purified by preparative scale reverse 
phase HPLC using a water/acetonitrile gradient in the presence of 0.1 % TFA. 
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2.4.3 Synthesis of TAT-thioester 
The TAT peptide thioester (GRKKRRQRRRG-thioester) was readily prepared by 
SPPS on the 4-sulfamylbutyryl-AM resin using reported protocols212. The resin was pre-
swollen in 10 volumes of dry methylene chloride for 1 h. During this period, Fmoc-Gly-
OH (4 equiv) along with 1-methylimidazole (4 equiv) was dissolved in a 4:1 mixture of 
dry methylene chloride (DCM) and dimethylformamide (DMF) under a blanket of inert 
gas. N,N-diisopropylcarbodiimide (DIC) was added and the solution was mixed for 5 min 
at room temperature. This acylation mixture was added to the drained resin. The resin was 
agitated with a stream of N2 for 18 h at room temperature and then drained. The resin was 
washed with DCM and DMF. The desired peptide is then formed via standard manual 
peptide synthesis. Boc-Gly-OH was used in the last coupling. The resin was washed with 
DMF and DCM. For activation of the resin prior to cleavage, a solution of iodoacetonitrile 
(25 equiv) and diisopropylethyl amine (10 equiv) in 3 mL of DMF and 1 mL of 
hexamethylphosphoric triamide was added to the drained resin. The resin was agitated 
with a stream of N2 for 18 h at room temperature. The solution was drained, and the resin 
was washed with DMF and DCM prior to immediate cleavage. The peptide was then 
cleaved from the activated resin with mercaptophenylacetic acid. First, 
mercaptophenylacetic acid (2.0 mmol for 0.1 mmol resin) was suspended in DCM (10 
mL) in a round-bottom flask flushed with argon. The mixture was cooled to 0 °C and 
DIEA (1.0 mmol) was added dropwise over 5 min. The resin pre-swollen in DCM was 
drained and treated with the thiol solution. The resin bed was stirred for 18 h at room 
temperature. The resin was drained and the filtrate collected. The resin was washed with 
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three additional portions of DCM, these being pooled with the original filtrate. The filtrate 
was concentrated in vacuo to provide a crude product. The residue was treated with 10 mL 
of a 95:2.5:2.5 TFA/water/triisopropylsilane (TIS) mixture to remove the side-chain 
protecting groups. The product was filtered to remove excess insoluble thiol, concentrated 
in vacuo, and precipitated and washed with cold diethyl ether. The peptide was purified 
by reversed-phase HPLC and analyzed by mass spectrometry. Expected mass: 1603.9 Da, 
observed mass: 1603.2 Da. 
 
2.4.4 Synthesis of Fl-TATn 
Fl-TATn was formed by addition of TAT-MPAA thioester (3 x n equivalents) to 
Fl-(Kε(C)-G)n-NH2 (1 mM) in 25 mM HEPES, 100 mM MESNa, and 10 mM TCEP at 
pH 7.5 (TAT-MPAA thioester exchanges to TAT-mercaptoethanesulfonate thioester 
under these conditions). After 16 hours of reaction at room temperature, the crude product 
was purified by preparative scale reverse phase HPLC using a water/acetonitrile gradient 
in the presence of 0.1 % TFA. 
 
2.4.5 Synthesis of Fl-TAT 
Fl-TAT (GRKKRRQRRRK(Fl)G-NH2) was prepared by SPPS on the Rink amide 
resin. Fmoc-G-R(Pbf)-K(Boc)-K(Boc)-R(Pbf)-R(Pbf)-Q(Trt)-R(Pbf)-R(Pbf)-R(Pbf)-
K(Mtt)-G was first assembled on the resin. The Mtt protecting group was cleaved by 
treating the resin with 2 % TFA in DCM for 30 min and 5(6)-carboxyfluorescein (Fl, 1.1 
eq.) was coupled onto the exposed ε amino groups in DMF containing DIEA and HBTU 
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(1.1 eq.). This was followed by N-terminal Fmoc deprotection with 20 % piperidine in 
DMF. The peptide was cleaved from the resin with 92.5 % TFA, 2.5 % TIS, 2.5 % EDT, 
and 2.5 % H2O. The crude product was precipitated and washed with cold diethyl ether 
and then lyophilized to yield crude solid that was purified by preparative scale reverse 
phase HPLC using a water/acetonitrile gradient in the presence of 0.1 % TFA. . Expected 
mass: 1939.2 Da, observed mass: 1937.2 Da. 
 
2.4.6 Synthesis of Cys-PAD (CKLAKLAKKLAKLAK-NH2) 
The Cys-PAD (CKLAKLAKKLAKLAK) peptide was assembled using a standard 
Fmoc solid phase peptide synthesis strategy on a Rink amide resin. The protected peptide 
was cleaved from the resin with 92.5 % TFA, 2.5 % TIS, 2.5 % EDT, and 2.5 % H2O. The 
crude product was precipitated and washed with cold diethyl ether. The precipitated 
peptide was then lyophilized, dissolved in HPLC buffer and purified by preparative scale 
reverse phase HPLC using a water/acetonitrile gradient in the presence of 0.1 % TFA. 
Expected mass: 1626.1 Da, observed mass: 1626.6 Da. 
 
2.4.7 Synthesis of TMR-PAD (TMR-CKLAKLAKKLAKLAK-NH2) 
TMR-PAD (TMR-CKLAKLAKKLAKLAK-NH2) was obtained by reaction 
between the Cys-PAD peptide and the fluorophore tetramethylrhodamine-5(6)- 
maleimide. Cys-PAD (0.38 μmol) was dissolved in 25 mM Hepes at pH 7.5, 100 mM 
MESNa, and 20 mM TCEP (0.38 mM final concentration). To this was added the 
fluorophore tetramethylrhodamine-5(6)-maleimide (0.38 μmol). After 36 hours at 4 °C, 
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the reaction was complete and the crude product was purified by preparative scale reverse 
phase HPLC using a water/acetonitrile gradient in the presence of 0.1 % TFA. Expected 
mass, 2108.66, observed mass: 2109.40 Da. 
 
2.4.8 Oxidation of Fl-TATn 
To test whether the thiols present in the Fl-TATn compounds could lead to 
aggregate formation through the formation of intermolecular disulfide bridges, the 
compounds (10 μM in PBS, this concentration reflects the highest concentration used in 
the cell-based assays) were oxidized by bubbling O2 in the media for 1 hour. Formation 
of aggregates of higher molecular weights was monitored by HPLC analysis and mass 
spectrometry. The HPLC profiles and MS spectra of the oxidized Fl-TATn compounds 
were similar to those presented above and to the samples treated with the reducing agent 
TCEP (10 mM), indicating that no intermolecular disulfide bridges formed between the 
Fl-TATn molecules. Instead, intramolecular disulfide bridges might have formed. Given 
the close proximity of the cysteine residues in the Fl-TATn compounds, these 
intramolecular disulfide bonds would have a greater probability of formation than 
intermolecular disulfide bridges. These intramolecular disulfide bridges might however 
not lead to a shift in HPLC retention time. The mass spectrometry analysis was also not 
accurate enough to unequivocally confirm the loss of 2 H that would accompany the 
formation of each disulfide bridge. In the case of Fl-TAT2 and Fl-TAT4, oxidation of the 
cysteines was confirmed by monitoring the reducing activity of the compounds. Fl-TAT2 
and Fl-TAT4 were first reduced with immobilized TCEP in PBS. The TCEP beads were 
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filtered and the solution was immediately added to a solution of Aldrithiol-2 (2,2’-
dithiopyridine, 100 μM). Aldrithiol forms a thiopyridone salt upon reduction and this is 
accompanied by an increase in absorbance at 350 nm. As expected, the reduced Fl-TAT2 
and Fl-TAT4 caused an increase in the absorbance of the solution at 350 nm. In a parallel 
assay, the freshly reduced Fl-TAT2 and Fl-TAT4 were bubbled with O2 as described in the 
previous paragraph. In this case, addition of Aldrithiol did not cause an increase in the 
absorbance 350 nm (the absorbance of fluorescein at 490 nm was measured to confirm 
that the reduced and oxidized Fl-TATn compounds were used at the same concentration). 
These results therefore confirm that the reducing activity of Fl-TAT2 and Fl-TAT4 was 
abolished after the oxidation step, further confirming that intracellular disulfide bonds are 
formed. In the case of Fl-TAT3, one can presume that one intramolecular disulfide bridge 
might form; leaving one cysteine that could potentially form an intermolecular disulfide 
bond. The fact that I did not detect aggregates of high molecular weight might reflect that 
fact that intermolecular disulfide bond formation is sterically unfavorable. Indeed, Fl-
TAT3 had the ability to reduce Aldrithiol-2 even after the oxidation step, confirming that 
a free thiol might remain even after bubbling oxygen (Aldrithiol-2 is a small molecule that 
presumably might have access to this free thiol). However, to unequivocally confirm that 
aggregates of the Fl-TAT3 compound were not involved in the unique delivery properties 
of this compound, the free thiol groups present in the molecule were capped with 
iodoacetamide. These results are described in the next section. 
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2.4.9 Synthesis of Fl-TAT3-(S-CH2-CO-NH2)3 (Fl-TAT3 acetamidated with 
iodoacetamide to block the thiols and prevent disulfide bond formation) 
Fl-TAT3-(S-CH2-CO-NH2)3 was formed after addition of iodoacetamide (50 mM) 
to Fl-TAT3 (1.4 mM) in 6 M GnHCl, 25 mM HEPES, and 50 mM TCEP at pH 8.5. The 
solution was placed on a shaker at room temperature. The reaction was monitored by 
analytical reversed-phase HPLC and MALDI-TOF. After 24 h, the elution peak 
corresponding to Fl-TAT3 had completely disappeared to lead to the formation of a single 
peak corresponding to the product. The product was purified by reverse-phase HPLC. The 
Aldrithiol test described in the previous section was used to confirm that the compound 
formed had no reducing activity and therefore no free thiol (Fl-TAT3 was used as a positive 
control). Yield: 69.3 %. Expected mass: 5718.66 Da, Observed mass: 5722.25 Da. 
 
2.4.10 Live-cell imaging experiments 
HeLa cells were seeded on 8-well chamber glass slide (Lab-TekTM Cat. No. 
177402, 0.8 cm2/well, Nunc International, Naperville, IL) at 3.0 x 104 cells/well in 
Dulbecco’s modified Eagle’s medium supplemented with 10 % FBS and incubated for 24 
h at 37 °C in a humidified atmosphere containing 5 % CO2. For live-cell imaging, cells 
were washed and incubated with Leibovitz’s L-15 Medium and placed under an inverted 
epifluorescence microscope (Model IX81, Olympus, Center Valley, PA) equipped with a 
heating stage maintained at 37 °C. The microscope is configured with a spinning disk unit 
(DSU, Olympus) to perform both confocal and wide-field fluorescence microscopy. 
Images were collected using a Rolera-MGI Plus backilluminated EMCCD camera 
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(Qimaging, Surrey, BC, Canada) mounted on the microscope with UPlanFl 100× / 1.3 NA 
oil, or LCPlan 20× / 0.4 NA objectives. Images were acquired using phase contrast and 
three standard fluorescence filter sets: CFP (Ex = 436±20 nm / Em= 480±40 nm), Texas 
Red (Ex = 560±40 nm / Em= 630±75 nm), and FITC (Ex = 482±35 nm / Em= 536±40 
nm). (Semrock, Rochester, NY). Cells were treated with the different peptides in L-15 
medium. The concentrations of the peptides were determined by measuring the absorbance 
of the fluorescein moiety at 492 nm (ε = 56000 M-1 cm-1 at pH 7.4). For macropinocytosis 
inhibition, cells were first pretreated with 50 μM of amiloride (Sigma, MO) for 30 minutes, 
and then with the peptides while keeping amiloride present. After incubation at 37 °C for 
30 min, the cells were washed with PBS 5 times and the medium was replaced with fresh 
L-15. The integrity of the plasma membrane of the cells was determined by addition of 
the cell-impermeable DNA stain SYTOX® Blue (5 μM, dead cells are stained in less than 
5 min at this concentration). Cells were then placed on the microscope and images were 
acquired in the CFP fluorescence channel for detection of SYTOX® Blue. TMR was 
detected with the Texas Red filter set and Fl with the FITC filter set. Images were 
processed using the SlideBook 4.2 software (Olympus, Center Valley, PA). For the 
delivery of TMR-PAD to live cells reported in Figure 2 and 3, cells were imaged with a 
20X objective by phase contrast and fluorescence imaging for up to 4 h. Ten to twenty 
images were acquired for each experiment. The total number of cells in a given image was 
determined from the phase contrast image while the number of dead cells was determined 
by identifying cells containing a blue fluorescent nucleus stained by SYTOX® Blue. Cell 
viability was determined by first establishing a ratio of dead cells/total number of cells for 
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each sample (1000 cells were counted in each experiments and each experiments were 
repeated 3 times). 
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3. CYTOSOLIC DELIVERY OF PROTEINS AND CELL-IMPERMEABLE SMALL 
MOLECULES INTO LIVE CELLS BY INCUBATION WITH A MULTIVALENT 
ENDOSOMOLYTIC REAGENT OF THE CELL-PENETRATING PEPTIDE TAT*225 
 
3.1 Introduction 
In this chapter, I describe the synthesis and cellular delivery properties of a 
multivalent and branched delivery system consisting of a tetramethylrhodamine-labeled 
dimer of the prototypical CPP TAT, dfTAT. I test the hypothesis that a branched 
multivalent TAT system, for which its synthesis protocol is very simple, would display an 
enhanced endosomolytic activity when compared to TAT. Furthemore, I hypothesize that 
this delivery system could induce the release of cell-impermeable macromolecules trapped 
inside endocytic organelles into the cytosolic space of live cells. Again, this is based on 
the principle that multivalency results in an increase of the CPP's local concentration at 
the sites where the peptide interacts with cellular components (avidity effect)209, 210, 224, 226. 
Here I report that dfTAT penetrates live cells by escaping from endosomes with high 
efficiency. By mediating endosomal leakage, dfTAT also delivers proteins into cultured 
cells after a simple co-incubation procedure. I achieved cytosolic delivery in several cell 
lines and primary cells and observed that only a relatively small amount of material 
remained trapped inside endosomes. Delivery did not require a binding interaction 
between dfTAT and a protein, multiple molecules could be delivered  
*This chapter is reprinted with permission from “Protein delivery into live cells by incubation with an 
endosomolytic agent” by Erazo-Oliveras, A.+; Najjar, K.+; Dayani, L.; Wang, T.-Y.; Johnson, G.A. and 
Pellois, J.-P. Nature Methods 2014, 11 861-867. doi: 10.1038/nmeth.2998. +authors contributed equally. 
Copyright (2014) by Nature Publishing Group. 
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simultaneously, and delivery could be repeated. dfTAT-mediated delivery did not 
noticeably affect cell viability, cell proliferation or gene expression. dfTAT-based 
intracellular delivery should be useful for cell-based assays, cellular imaging applications 
and the ex vivo manipulation of cells. 
 
3.2 Results 
 Protein transduction strategies are extremely useful for the investigation and 
manipulation of cellular processes. For example, proteins labeled with fluorophores, stable 
isotopes or reactive tags and delivered into live cells can, for instance, be used for imaging 
applications or in cellulo structure determination by NMR, respectively136, 227, 228. Despite 
the unique opportunities provided by protein transduction technologies, current protocols 
are often suboptimal229, 230. Proteins fused to a protein transduction domain (PTD) or CPP 
typically use the endocytic pathway as a route of cellular entry8. However, the majority of 
PTD-protein fusions endocytosed by cells typically remain trapped inside endosomes; as 
a result, the amount of protein that reaches the cytosol of cells is low, and the biological 
outcomes achieved are poor138. A possible solution to this problem is to increase the ability 
of proteins to escape from the endocytic pathway. This is possible with membrane-
destabilizing agents that disrupt endosomes222, 231, 232, but to date, the efficiencies of 
available reagents have remained low233, 234. Ideally, a delivery strategy should combine 
efficient endosomal escape, low cell toxicity and convenience. I aimed to develop an 
innocuous endosomolytic agent that efficiently delivers protein cargos into cells. Based 
on the results from chapter two, my working hypothesis is that a trimeric TAT labeled 
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with the fluorophore tetramethylrhodamine (TMR), which I will call tfTAT for trimeric, 
fluorescent TAT, might have enhanced endosomolytic activity compared to that of its 
dimeric and monomeric counterparts, dfTAT and fTAT, respectively. Surprisingly, I show 
that the dimeric delivery system dfTAT efficiently delivers proteins into live cells in 
approximately one hour without affecting cell viability or proliferation. 
 
3.2.1 Synthesis and purification of dfTAT and its monomeric counterparts 
 My synthetic approach consists of assembling multiple fluorescently-labeled TAT 
(fTAT) peptides together by oxidation of free cysteine thiol(s) and formation of disulfide 
bridges. The design of this multivalent branched delivery system is shown in Figure 3-1.  
It is important to point out that the monomeric and dimeric peptides, fTAT and dfTAT, 
were generated first since the synthesis protocol for these peptides was much simpler. As 
a result, I studied their ability to translocate across the plasma membrane and enter the 
cytosolic space of live cells before assessing the penetration activity of the trimeric peptide 
tfTAT. To my surprise, the penetration activity of dfTAT was very high and far surpassed 
my expectations (even expectations for tfTAT). Due to this, the work in this chapter will 
focus only on studies performed using dfTAT and its monomeric counterparts. 
 I used TAT as the template for my design of the dimeric delivery vehicle. The 
fluorescent peptide CK(ε-NH-TMR)-TAT (fTAT) was generated by SPPS using standard 
Fmoc protocols. I introduced a lysine at the N-terminus of TAT bearing a Mtt protecting 
group at the ε NH2.  The lysine side chain protecting group was removed orthogonally 
with 2 % trifluoroacetic acid (TFA) and modified with TMR for fluorescence imaging. I 
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added a cysteine at the N-terminus to permit dimerization by disulfide bond formation 
(Figure 3-1 (top)). Disulfide bonds are relatively stable inside endosomes but are cleaved 
following endosomal escape and upon entry into the reducing cytosolic space of cells229, 
235, 236. TFA cleavage and preparative scale reverse phase HPLC purification afforded 
fTAT (Figure 3-2 (A)). Incubation in oxygenated medium and oxidation of the free 
cysteine thiol of fTAT generated the dimer (CK(ε-NH-TMR)TAT)2 (dfTAT; Figure 3-2 
(B)). Alternatively, the thiol of CK(ε-NH-TMR)TAT was acetamidated to obtain a peptide 
(acfTAT) that cannot dimerize (Figure 3-3) or was reacted with bis(maleimido)ethane to 
obtain a nonreducible dimer (nrdfTAT) (Figure 3-4). dfTAT, acfTAT and nrdfTAT were 
purified by HPLC and their identities were evaluated by MALDI-TOF mass spectrometry 
(Figure 3-3,  3-4 and  3-5). 
 
3.2.2 dfTAT penetrates the cytosol of live cells efficiently 
 I incubated fTAT, acfTAT, dfTAT and nrdfTAT for 1 h with HeLa cells, the mouse 
neuroblastoma cell line Neuro-2a and human primary dermal fibroblasts (HDFs). 
Internalization was first assessed by fluorescence microscopy. acfTAT (1–20 μM) 
localized in a punctate distribution consistent with accumulation of the peptide inside 
endosomes237 (Figure 3-6 (A)). The fluorescence signal of dfTAT was also punctate 
below 2 μM but became distributed in the cytosolic space and nucleus of an increasing 
number of cells at higher concentrations (Figure 3-6 (B) and 3-7). The overall amount  
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Figure 3-1 Branched multivalent CPP system using disulfide bonds: 2nd generation. 
Peptides will be generated using SPPS, which should allow obtaining higher yields than 
before. The branched multivalent system will be generated by a simple oxidation step 
suing a peptide containing one Cys residue (top) or by reacting Aldrithiol-2 with a peptide 
containing two Cys residues and then allowing the product of that reaction to react with a 
peptide containing one Cys residue (bottom).  As shown, the design of the 2nd generation 
branched multivalent system was, in part, inspired by the work shown in chapter 2. 
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Figure 3-2 Chemical structure of fTAT and dfTAT.  (A) fTAT contains the TAT 
sequence, a fluorescently- labeled Lys residue  and  Cys residue (Lys and Cys were 
conjugated to the N-terminus of TAT).  (B) The thiol group in fTAT is oxidized to form a 
disulfide bond and generate dfTAT. The exact mass of each peptide is shown. 
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Figure 3-3 Characterization of acfTAT.  (A) Chemical structure of acfTAT and its exact 
mass. The alkyl amide group on the peptide prevent dimerization in cells (arrow).   (B) 
HPLC chromatogram of pure acfTAT and MALDI-TOF spectrum. 
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Figure 3-4 Characterization of nrfTAT.  (A) Chemical structure of nrfTAT and its exact 
mass. (B) HPLC chromatogram of pure nrfTAT and MALDI-TOF spectrum. The 2153 
peak corresponds to doubly charged nrfTAT. 
 
	 78
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 Characterization of dfTAT. HPLC analysis of reduction reaction of dfTAT 
after addition of the reducing agent tris(2-carboxyethyl)phosphine (TCEP). Pure dfTAT 
was mixed with a solution of TCEP (50 mM) in water and allowed to react for 15 min. 
The HPLC chromatogram shows a peak with rt = 14.3 min and is identical to the retention 
time of pure fTAT. 
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Figure 3-6 Cytosolic delivery of dfTAT in live cells is efficient. (a) Cellular localization 
of acfTAT and dfTAT assessed by fluorescence microscopy. Cells were incubated for 1 h 
with either acfTAT (20 μM) or dfTAT (5 μM), washed and imaged with a 100× objective. 
Monochrome images represent the emission of TMR at 560 nm. Scale bars, 10 μm. (b) 
Comparison of the cytosolic delivery efficiency of acfTAT, fTAT and dfTAT. Cells were 
incubated with acfTAT, fTAT or dfTAT (1–20 μM) for 1 h. The number of cells with 
detectable cytosolic and nuclear fluorescence distribution in microcopy images was 
counted and divided by the total number of cells present (1,000 cells per experiment). (c) 
dfTAT overall uptake in HeLa cells as a function of the concentration of dfTAT present 
in the incubation medium. Cells were incubated with dfTAT (1–10 μM) for 1 h, and 
relative uptake was assessed quantitatively by measuring the bulk fluorescence of cell 
lysates (300,000 cells per experiment). a.u., arbitrary units. The data in b and c represent 
the mean of triplicate experiments and the corresponding s.d. 
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Figure 3-7 Cytosolic and nuclear fluorescence distribution of dfTAT is concentration 
dependent.  HeLa cells were incubated with varying concentration of dfTAT (1, 2, 2.25, 
2.5, 2.75, 3, 4, 5 μM). Cells were washed and imaged. Inverted monochrome images (20X 
obkective) show a dramatic increase in the cytosolic delivery of dfTAT between 2-5 μM. 
Although not shown here, the number of cells in each image is approximately the same as 
determined by bright field imaging. Cells that display a fluorescence punctate distribution 
are not clearly visible under these imaging conditions. Further analysis of these cells using 
100X objective clearly show a fluorescence punctate distribution indicative of peptide 
trapped in endosomes. Scale bars: 50 μm 
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of dfTAT inside cells (in the cytosolic space and endosomes) also increased with the 
concentration of dfTAT administered extracellularly (Figure 3-6 (C)). I delivered dfTAT 
into the cytosolic space and nucleus of additional cell lines and primary intestinal porcine 
epithelial cells (Figure 3-8). In all cases, cells were not stained with SYTOX® Blue, 
indicating that their plasma membrane was not compromised and that the cells imaged 
were alive. 
Similarly to acfTAT, fTAT was localized inside endosomes at up to 10 μM. 
However, at 20 μM, many cells displayed cytosolic fluorescence, indicating that fTAT 
reproduced some of the activity of dfTAT by possibly dimerizing in situ (Figure 3-9). 
Finally, nrdfTAT displayed a cytosolic distribution similar to that obtained with dfTAT 
(Figure 3-10), indicating that the disulfide bond present in dfTAT was not required for 
cytosolic penetration. 
 
3.2.3 dfTAT penetrates cells in a two-step process 
To test whether endosomal escape is involved in delivery of dfTAT, I assessed the 
effects of molecules that influence endocytosis104, 219, 238, 239. Whereas filipin and 
chlorpromazine (inhibitors of caveolae- and clathrin-mediated endocytosis) had little 
effect, amiloride (inhibitor of macropinocytosis) and bafilomycin (vacuolar H+-ATPase 
inhibitor) inhibited the delivery of dfTAT, suggesting that macropinocytosis and 
endosomal acidification are important for cytosolic penetration (Figure 3-11). To assess 
whether endosomal escape could be visualized, dfTAT was incubated with cells for 5 min 
to permit endocytic uptake; cells were washed and then imaged in a pulse-chase  
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Figure 3-8 Delivery of dfTAT was achieved in multiple cell types. HeLa, COLO 316, 
NIH 3T3, HaCaT, Neuro-2a, MCH58, primary HDF and primary IPEC-1 cells were 
incubated with 5 μM dfTAT for 1 h, washed and imaged The fluorescence signal detected 
was in the cytosolic space and nucleus of cells (top panel 100X objective). After imaging 
cells were incubated in a humidified atmosphere containing 5 % CO2 for 24 h, washed and 
imaged. (top panel: 20X objective, bottom panel: 100X  objective) Cell morphology did 
not change after 24 h. Cell viability was assessed by exclusion of the cell-impermeable 
dye  SYTOX® Blue after both 1 h and 24 h. The TMR fluorescence at the 24 h time point 
is different to that obtained at the 1 h time point presumably because of the intracellular 
degradation of the peptide . Scale bars: 20X objective, 50 μm; 100X objective, 10 μm. 
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Figure 3-8 Continued. 
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Figure 3-8 Continued. 
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Figure 3-9 fTAT cellular localization after incubation with live cells depends on its 
concentration in the extracellular media. Inverted monochrome (black = fluorescence 
signal, white = no signal) fluorescence images of HeLa cells incubated with 10 or 20 μM 
of fTAT for 1 h. fTAT displays at fluorescence punctate distribution at 10 μM fTAT (left 
panel) while at 20 μM fTAT shows a significant increase in nthe population of cells 
displaying cytosolic and nuclear fluorescence distribution. Scale bars: 50 μm. 
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Figure 3-10 Delivery of nrdfTAT into live cells. Cells were incubated with nrdfTAT ((i) 
2.5–5 μM and (ii) 5-10 μM*) for 1 h. Fluorescence images (monochrome (white = 
fluorescence signal, black = no signal) 20X image, center panel) show cytosolic delivery 
of nrdfTAT into HeLa cells at both concentrations. SYTOX® Blue (2 μM) was used as 
an indicator of cell death.  Scale bars: 50 μm (inverted monochrome 20X image).  
*The concentration of nrdfTAT was estimated by measuring the absorbance of TMR using 
a spectrophotometer, as described with other peptides. However, nrdfTAT has two TMR 
spaced by a 8.0 Å BMOE linker and such close proximity might affect the extinction 
coefficient of TMR. In order to take this effect into account, a concentration range for 
nrdfTAT was calculated based on the extinction coefficient of free TMR (91,500 mol-
1cm-1) and that of dfTAT (45,500 mol-1cm-1) (dfTAT also has two TMR in close 
proximity).  
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Figure 3-11 Effect of endocytosis inhibitors on the cellular distribution of dfTAT. 
HeLa cells were pretreated with each inhibitor for 20 min, washed and incubated with 5 
μM dfTAT and inhibitor for 1 h. The percentage of cells displaying a cytosolic and nuclear 
fluorescence distribution was quantified as in Figure 3-6 (B). Inset, punctate distribution 
of dfTAT in the presence of bafilomycin (1,000 cells per experiment, experiments were 
performed in triplicates, mean ± s.d. represented). Scale bar: 10 μm. 
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experiment. dfTAT was initially localized in a punctate distribution consistent with that 
of endosomes (100X objective, data not shown). Yet, an increasing number of cells 
displayed a cytosolic distribution at later time intervals. When imaged with a 20X 
objective, cells with a cytosolic distribution were brighter than cells with a punctate 
distribution (this is consistent with TMR being partially self-quenched when dfTAT is 
trapped inside endosomes; Figure 3-12), and this was used to quantify dfTAT’s cytosolic 
penetration as a function of time. Consistent with the notion that dfTAT penetrates the 
cytosolic space after endocytic uptake, the percentage of cells with cytosolic fluorescence 
increased from 4.3 % to 76.9 % over a period of 40 min (Figure 3-13). To further test 
whether dfTAT escapes from endocytic organelles, I incubated cells first with DEAC-K9, 
a fluorescent peptide that accumulates inside endosomes (Figure 3-14)175. After washing, 
cells were incubated with dfTAT. Although only a punctate distribution of fluorescence 
was observed with cells incubated with DEAC-K9 alone, subsequent addition of dfTAT 
led to a bafilomycin-dependent redistribution of the DEAC-K9 signal throughout the 
cytosolic space and nucleus (Figure 3-15). These data indicate that dfTAT accumulates 
inside endosomes already containing DEAC-K9 and that dfTAT endosomal escape is also 
accompanied by the leakage of luminal DEAC-K9. 
 
3.2.4 dfTAT mediated endosomal leakage is very efficient 
 When endocytosed at similar levels, dfTAT escaped endosomes, whereas acfTAT 
did not, indicating that dfTAT is greatly more endosomolytic than acfTAT and is active 
inside endosomes as a dimer rather than as a reduced monomer (Figure 3-16).  
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Figure 3-12 Fluorescence emission spectra of dfTAT (5 μM) before and after 
reduction with the reducing agent TCEP (50 mM). The sample was excited at 556 nm 
and the emission was recorded between 570-750 nm. The emission spectra show that the 
fluorescence emission of dfTAT increases upon reduction of its disulfide bond. This is 
indicative of TMR self-quenching in the context of dfTAT. This evidence suggests that 
TMR fluorescence is quenched inside endosomes where, presumably, the peptide exists 
as a dimer. This behavior displayed by dfTAT allowed me to design the experiment 
performed in Figure 3-12.   
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Figure 3-13 Pulse-chase experiment showing the progressive cytosolic penetration of 
dfTAT. HeLa cells were incubated with dfTAT (5 μM) for 5 min, washed and imaged 
with a 20X objective (TMR fluorescence images are represented as inverted monochrome) 
(a schematic of the protocol is shown on the left). The imaging intervals and corresponding 
percentages of cells with a cytosolic signal are represented. Scale bars: 50 μm. 
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Figure 3-14 Structure and characterization of DEAC-K9. Structure and expected mass 
of DEAC-K9 (top). HPLC analysis and MALDI-TOF mass spectrum of pure DEAC-K9 
(rt = 14.4 min) (expected mass: 1412.97, observed mass: 1415.59) 
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Figure 3-15 dfTAT causes the cytosolic release of molecules trapped inside 
endosomes. Microscopy images showing dfTAT-mediated release of molecules trapped 
inside endosomes; a schematic of the process is included (top). HeLa cells were incubated 
with 5 μM DEAC-K9 for 1 h and washed. Cells were subsequently incubated with 5 μM 
dfTAT for 1 h. Images are represented as inverted monochromes. Scale bars: 10 μm.  
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Figure 3-16 dfTAT displays a high endosomolytic activity when compared to 
acfTAT. HeLa cells were incubated with dfTAT (5 μM) for 5 min and acfTAT (50 μM) 
for 1 h. After 1h, the cells were washed with PBS/heparin, imaged and lysed. The lysis 
buffer used in this experiment contains 2 mM DTT. The bulk fluorescence of cell lysates 
on a 96-well plate was measured using a plate reader. The fluorescence of each sample 
was normalized to total protein content in the cell lysate, as determined by a Bradford 
protein assay. Similarly, the fluorescence of solutions of acfTAT at different 
concentrations (0.1, 0.5, 1, 5 and 10 μM) was measured using a plate reader. A calibration 
curve of the peptide fluorescence intensity v.s. peptide concentration was established. 
These data was used to estimate the average concentration of acfTAT and dfTAT inside 
cells. Data shows higher fluorescence intensity for acfTAT than dfTAT inside cells. These 
data suggests that dfTAT is a dimer inside endosomes and that this peptide is more 
endosomolytic than acfTAT (Model 1).  
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However, the cytosolic fluorescence of dfTAT possibly obscures the signal that 
remains inside endosomes. Under such a scenario, dfTAT endosomal escape would appear 
more dramatic than it really is. To establish more precisely the efficiency with which 
dfTAT mediates endosomal leakage, I co-incubated dfTAT with SNAP-Surface, a cell-
impermeable green fluorophore that can react with the SNAP protein fusion tag240. The 
experiment was performed in cells expressing a SNAP-H2B histone construct so that 
SNAP-Surface 488 would label the nucleus of cells upon delivery, deplete the cytosolic 
signal and reveal the amount of probe remaining trapped inside endosomes. Cells 
incubated with dfTAT and SNAP-Surface 488 displayed a nuclear staining (Figure 3-17), 
whereas cells incubated with SNAP-Surface 488 alone did not (Figure 3-18). Cells with 
a brightly labeled nucleus also contained only a few dim endosomes. Analysis of the 
fluorescence signal indicated that 50–90 % of the fluorophore escaped endosomes. 
 
3.2.5 dfTAT mediated delivery is not deleterious to cells 
 By inducing efficient endosomal leakage, dfTAT might negatively affect cell 
physiology. In addition, endosomal leakage has been previously observed in cells 
undergoing apoptosis241. Endosomal leakage could therefore be either a cause or a 
consequence of cell death. To address these issues, I treated HeLa, MCH58, HDF and 
Neuro-2a cells with dfTAT for 1 h and established viability 1 and 24 h after incubation 
using a SYTOX® Green exclusion assay (Figure 3-19). Viability was >95 % after treating 
cells with 5 μM dfTAT for 1 h—conditions required to achieve cytosolic distribution of 
dfTAT in >80 % of cells. Cell morphology was also unaffected by dfTAT  
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Figure 3-17 Endosomolytic efficiency of dfTAT. HeLa cells expressing SNAP-H2B 
were incubated with 5 μM dfTAT and 5 μM SNAP-Surface 488 (a schematic of the 
protocol followed is shown on the left). Representative fluorescence images (of 50 total) 
of SNAP-Surface are shown (dfTAT is in the inset). The SNAP-Surface 488 signal present 
in the nucleus is indicated as a percentage of the total signal. Scale bars: 10 μm. 
 
 
 
 
 
 
 
	 97
 
 
 
 
Figure 3-18 SNAP-Surface 488 enters cells via endocytosis and does not escape 
endosomes in the absence of dfTAT. (A) HeLa cells were incubated with 5 μM SNAP-
Surface 488 for 1 h, washed and imaged. Inverted monochrome image shows a punctate 
distribution from SNAP-Surface 488 (right panel). (B) HeLa cells were incubated with 5 
μM SNAP-Surface 488 and 2.5 μM dfTAT (a concentration in which dfTAT incubation 
does not result in significant cytosolic release) for 1 h, washed and imaged. Inverted 
monochrome images show SNAP-Surface 488 accumulation in endocytic organelles 
(punctate distribution) (right panel) and colocalization with TMR signal. Bright field 
images show HeLa cells morphology did not change after uptake of SNAP-Surface 488 
and/or dfTAT (right panels). Scale bars: 10 μm. 
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Figure 3-19 dfTAT is not toxic to cells under conditions where efficient endosomal 
escape is achieved. (A) HeLa, MCH58, HDF and Neuro-2a cells were incubated with (1-
50 µM) dfTAT for 1 h. Cell viability was assessed by a SYTOX Green exclusion assay 
1, 24, and 48 h (for HeLa) after incubation (1,000 cells/experiment, experiments in 
triplicates, average and standard deviations represented). (B) Histogram of flow cytometry 
data. HeLa cells were incubated with 5 µM dfTAT or no peptide (control) for 1h, washed 
and then incubated in SYTOX Green (1 µM) for 15 min. Cells were then trypsinized for 
5 min, resuspended in a total of 200 µl of nrL-15, and analyzed by flow cytometry (BD 
Accuri C6 Flow Cytometer). Histograms show that only 2 % and 7.5 % of cells are stained 
with the cell impermeable dye SYTOX Green for untreated and treated cells, 
respectively. 
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Figure 3-20 The cellular localization of acfTAT and dfTAT is different after 
incubation with live cells but cell morphology is not changed. Fluorescence 
(monochrome) and bright field images (100X objective) of HeLa cells incubated with 20 
μM acfTAT (left panel) and 5 μM dfTAT (right panel). The acfTAT peptide displays a 
fluorescence punctate distribution while dfTAT exhibits a cytosolic and nuclear 
fluorescence distribution. Bright field images show no change in HeLa cell morphology 
upon peptide delivery. Scale bar: 10 µm. 
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Figure 3-21 dfTAT-mediated delivery does not significantly affect cell proliferation. 
HeLa, Neuro-2a and HDF cells were incubated with 5 μM dfTAT for 1 h or left untreated. 
Proliferation was assessed using a MTT assay (150,000 cells/experiment, experiments in 
triplicates, mean and standard deviations represented). 
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incubation (Figure 3-20). Likewise, dfTAT incubation did not affect the proliferation 
rates of HDF, HeLa or Neuro-2a cells (Figure 3-21), and cells containing a cytosolic 
fluorescence signal indicative of efficient dfTAT endosomal escape were observed to 
divide normally by microscopy (figure 3-22). 
To characterize the physiological impact of dfTAT cytosolic penetration in greater 
detail, I performed transcriptome analysis on HDF cells incubated for 1 h in nrL-15 
medium with or without 5 μM dfTAT. Cells harvested immediately after dfTAT 
incubation showed 11 transcripts up- or downregulated more than twofold compared to 
those of untreated cells (twofold is used as a significance threshold; 47,321 total transcripts 
detected; Figure 3-23). Only two transcripts were dysregulated in cells incubated in 
DMEM for an additional 1 h and 24 h after treatment with dfTAT (Figure 3-23 and 3-
24). Together, these results indicate that dfTAT has a minimal impact on mRNA 
expression and that cells recover rapidly from dfTAT-mediated endosomal leakage 
(corroborated by quantitative proteomic profile experiments; Figure 3-25). 
If dfTAT perturbs many endosomes during a delivery step, I envisioned that 
endocytic trafficking might be a cellular process likely to be negatively affected following 
peptide incubation. In particular, I reasoned that dfTAT could cause endosomal leakage 
after an initial treatment but fail to be endocytosed or remain trapped inside damaged 
endocytic organelles after a second dfTAT incubation. I therefore tested the stepwise 
delivery of two different molecules (DEAC-K9 and SNAP-Surface 488). Cells were first 
incubated with dfTAT (5 μM) and DEAC-K9 (5 μM) for 1 h. As expected, this incubation 
resulted in the cytosolic distribution of both dfTAT and  
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Figure 3-22 dfTAT-mediated delivery does not significantly affect cell division. 
Microscopy imaging showing that cells containing cytosolic dfTAT divide. HeLa cells 
were incubated with 5 µM dfTAT for 1 h, washed and imaged in a time-lapse experiment. 
Scale bars, 10 μm 
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Figure 3-23 dfTAT-mediated delivery does not significantly affect transcription in 
primary cells. Whole-genome microarray analysis of HDF cells treated with dfTAT. HDF 
cells were treated with 5 μM dfTAT for 1 h and transcriptome analysis was performed 
immediately, 1 h, or 24 h after dfTAT treatment. The plot displays microarray intensity 
values of treated vs. untreated (same incubation steps but without peptide) samples. The 
red lines represent 2-fold intensity change cut-offs and transcripts up or down-regulated 
above these cut-offs are circled for clarity. 
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Figure 3-24 mRNA expression analysis in the presence of staurosporine. (a) In order 
to establish a positive control for the microarray analysis, staurosporin was used to induce 
apoptosis in HDF cells. Cells were treated with staurosporine (0.1 µM) for 1h and mRNA 
levels were analyzed as described in Figure 3. The identity of transcripts related to 
apoptosis that were up-regulated (highlighted in red) and down-regulated (highlighted in 
green) upon treatment with staurosporin are listed. Notably, a total of 1830 transcripts 
were found to be up-or down-regulated out of 47321 transcripts detected. (b) Analysis of 
the microarray intensities of untreated HDF cells vs. those of HDF cells treated with 
staurosporine (0.1 µM) for 1h. The red lines represent the 2-fold cut-offs. (c) Table listing 
the identity of transcripts that are up-regulated (highlighted in red) and down-regulated 
(highlighted in green) in HDF cells incubated with dfTAT (5 µM) and analyzed 
immediately after incubation (1h), or 1h (1h+1h) and 24 h (1h+24h) after incubation. The 
11, 2, and 2 transcripts listed represent the total number of transcripts up or down-
regulated in the 1h, 1h+1h, and 1h+24h samples, respectively. 
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Figure 3-25 Differential in gel electrophoresis (DIGE) proteomic analysis of HDF 
cells treated with dfTAT (5 μM) for 1 h. (a) Representative green and red fluorescence 
overlay of 2D gel of cells treated with or without dfTAT for 1h and incubated in fresh 
media for an additional 1h (1+1h samples, treated sample is labeled with Cy3 and 
untreated with Cy5). Green and red were used as pseudo colors for Cy3 and Cy5 dyes, 
respectively, and a yellow color is indicative of equal fluorescence intensities. (b) Table 
summarizing analysis results obtained from the DIGE using the DeCyder v6.5 suite of 
software tools (GE Healthcare). Data was obtained using a 2 standard deviation model 
(95% confidence). Each pair (treated vs. untreated) were individually analyzed based on 
the normalized volume ratio of each individual protein spot from Cy3- or Cy5- labeled 
sample. 
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DEAC-K9 (data not shown). Twenty minutes later, cells were incubated with dfTAT (5 
μM) and SNAP-Surface 488 (5 μM) for 1 h. Cells treated with dfTAT using this two-step 
protocol displayed cytosolic and nuclear fluorescence of both DEAC-K9 and SNAP-
Surface 488 (Figure 3-26). Delivery of SNAP-Surface 488 did not occur in the absence 
of dfTAT (Figure 3-18) and was inhibited by bafilomycin, consistent with the notion that 
the second delivery step is also mediated by the endosomolytic activity of dfTAT. 
Moreover, the fluorescence of SNAP-Surface 488 examined was comparable to that 
observed when SNAP-Surface 488 was delivered into untreated cells (one-step delivery) 
or simultaneously with DEAC-K9 (Figure 3-27). Together these results establish that 
dfTAT-mediated delivery can be repeated. This suggests that the endocytic route 
employed by dfTAT is not dramatically compromised after dfTAT-mediated endosomal 
leakage. 
 
3.2.6 dfTAT delivers proteins by simple co-incubation 
 To determine whether dfTAT could deliver large proteins into the cytosol of cells, 
I chose EGFP (26 kDa) as a model cargo. Cells were incubated with EGFP and dfTAT for 
1 h and examined by microscopy. EGFP was distributed into the cytosolic space and 
nucleus in more than 90 % of cells without observable toxicity (Figure 3-28). To estimate 
how much fluorescent and folded protein was delivered, cells were counted, harvested and 
lysed. The lysate was analyzed by PAGE, and the fluorescence of EGFP was quantified. 
On the basis of this analysis, approximately 34 μM and 23 μM of EGFP was present per 
HDF and Neuro-2a cell, respectively (Figure 3-29). As imaging  
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Figure 3-26 dfTAT-mediated delivery does not significantly affect endocytosis. 
Microscopy images showing that dfTAT-mediated endosomal escape can be repeated. 
HeLa cells were co-incubated with dfTAT (5 μM) and DEAC-K9 (5 μM) for 1 h (step1) 
(images not shown). After washing, dfTAT (5 µM) and SNAP-Surface 488 (5 μM) were 
co-incubated in the absence (top panel) or presence (bottom panel) of bafilomycin (200 
nM) (step 3). Scale bars: 10 μm. 
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Figure 3-27 Simultaneous delivery of SNAP-Surface 488 and DEAC inside cells using 
a one step protocol. (a) HeLa cells were incubated with 5 μM dfTAT, 5 μM SNAP-
Surface 488 and 5 μM DEAC-K9. Inverted monochrome images show cytosolic and 
nuclear fluorescence localization of dfTAT (red fluorescence), DEAC-K9 (blue 
fluorescence) and SNAP-Surface 488 (green fluorescence). Scale bars: 10 μm. (b)  HeLa 
cells were incubated with 5 μM dfTAT and 5 μM SNAP-Surface 488. Inverted 
monochrome images show cytosolic and nuclear fluorescence localization of dfTAT and 
SNAP- Surface 488. Scale bars: 10 μm.  (c) HeLa cells were first incubated with 5 μM 
dfTAT and 5 μM DEAC-K9 for 1 h. Cells were then washed, incubated with 5 μM SNAP-
Surface 488 for 1 h and imaged. In one hand, inverted monochrome images show cytosolic 
and nuclear localization of TMR and DEAC but, in the other hand, SNAP-Surface 488 
display a fluorescence punctate distribution. Scale bar: 10 μm. 
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Figure 3-28 Delivery of intact and functional EGFP using co-incubation with dfTAT. 
Microscopy imaging showing that dfTAT delivers EGFP into the cytosol of live cells. 
HeLa, Neuro-2a and HDF cells were co-incubated with EGFP (10 μM) and dfTAT (5 μM) 
for 1 h. Scale bars: 100X objective, 10 μm; 20X objective, 100 μm. 
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Figure 3-29 Quantitation of the concentration of EGFP delivered into the cytosol of 
HDF and Neuro-2a. HDF and Neuro-2a cells were co-incubated with dfTAT (5 µM) and 
EGFP (10 µM) for 1 h. After 1 h, cells were washed with PBS/heparin and lysed. The cell 
lysate was treated with nucleases and an aliquot of 27 µL was analyzed by PAGE (top 
right panel). Similarly, samples of known EGFP concentrations (determined by measuring 
absorbance at 488 nm and using an extinction coefficient of 55,000 mol-1cm-1) were 
analyzed by PAGE (top left panel). A fluorescence imager was used to measure the EGFP 
fluorescence intensity from the cell lysates and EGFP calibration samples. Silver staining 
was used to detect all proteins in the lysate. A calibration curve of EGFP fluorescence 
intensity vs. EGFP concentration was established and used to estimate the average 
concentration of EGFP in the cell lysates. The data obtained was used to calculate the 
concentration of EGFP per cell. Important numbers: Cell number on well: 79,600 
(determined by flow cytometry); Cell volume: 2000 µm3  (bionumbers.hms.harvard.edu.) 
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confirmed that a large fraction of EGFP escaped endosomes (Figure 3-28), one can expect 
micromolar concentrations of proteins to be delivered in the cytosolic space of cells. To 
determine whether dfTAT needs to interact with a particular protein in order to 
successfully deliver it, I characterized the binding of dfTAT to EGFP. No fluorescence 
resonance energy transfer (FRET) between dfTAT and EGFP could be detected under 
conditions used for cellular incubation assays (Figure 3-30). Similarly, no interaction 
between dfTAT and EGFP could be detected by native gel electrophoresis (Figure 3-31). 
In contrast, dfTAT and BSA were found to interact in this assay (presumably through 
electrostatic interactions). Interestingly, addition of BSA (or fetal bovine serum or 
heparin) to cell incubation medium reduced the cytosolic penetration of dfTAT in a 
concentration-dependent manner (Figure 3-32). 
To further confirm that functional proteins can penetrate cells upon incubation 
with dfTAT, I tested delivery of Cre recombinase. In this assay, Cre induces 
recombination of a loxP-STOP-loxP sequence upstream of the EGFP-encoding gene of a 
reporter plasmid156. Therefore, cells transfected with the reporter plasmid express EGFP 
when Cre recombinase penetrates cells and excises the STOP signal sequence. Cells 
treated with TAT-Cre (1 μM) and dfTAT (5 μM) expressed EGFP (Figure 3-33), but the 
percentage of EGFP+ cells was greater in the presence of dfTAT (47 %) than in the 
presence of fTAT or when TAT-Cre was incubated alone (<5 %). 
I also delivered FITC–anti-ATP5A, a fluorescently-labeled antibody that 
recognizes the α-subunit of the mitochondrial ATP synthase. Cells treated with FITC–
anti-ATP5A (20 μg/ml) and dfTAT (5 μM) contained green fluorescent tubular  
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Figure 3-30 dfTAT and EGFP do not interact when co-incubated. (a) Fluorescence 
emission spectrum of EGFP (1 μM) (donor FRET pair) (EGFP, Ex/Em 488/508 nm) 
excited at 488 nm. The spectrum show an intense emission peak at around 510 nm and a 
small shoulder peak around 548 nm (b) Fluorescence emission spectrum of a solution of 
EGFP (1 μM) and dfTAT (5 μM) (acceptor FRET pair) (TMR, Ex/Em 556/580 nm) 
excited at 488 nm. The spectrum shows an intense emission peak at around 510 nm and a 
small shoulder peak around 548 nm. The contribution of TMR to the EGFP fluorescence 
spectrum (crossover fluorescence) was determined by measuring the fluorescence 
emission of a solution of dfTAT (5 µM) excited at 488 nm (not shown). The spectrum of 
the solution with EGFP and dfTAT is almost identical to the spectrum of EGFP alone 
(TMR fluorescence crossover signal was subtracted). (c) Fluorescence emission spectrum 
of ligated EGFP-CK(TMR). Using expressed protein ligation, EGFP was chemically 
ligated to CK(TMR) as described to produce EGFP-CK(TMR)7. EGFP-CK(TMR) was 
used a positive control for the FRET signal. Upon excitation at 488 nm, a dramatic increase 
in fluorescence between 560-630nm is observed (fluorescence max approximately 580 
nm), indicative of a FRET signal due the close proximity between fluorophores. This 
increase in fluorescence intensity was not observed in the spectrum in part b) (indicative 
of no interactions between EGFP and dfTAT). Emission of all samples was scanned from 
500 to 650 nm. 
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Figure 3-31 dfTAT and EGFP do not interact. (a) Native gel electrophoresis was used 
to determine binding interaction between dfTAT and EGFP. Samples were prepared by 
incubating dfTAT (5 μM) with either EGFP (10 µM) or BSA (10 µM, protein with a pI = 
4.7, used as a positive control) in nrL-15 for 30 min at 37 °C (pH 7.0, representing the pH 
of the extracellular milieu of the cell and pH 5.0 representing the lower pH that exists 
along the endocytic pathway). dfTAT alone, EGFP alone and BSA alone at the same 
concentration and pH were loaded on the same gel as controls. Fluorescence images of the 
gel were acquired using a Typhoon scanner. Green fluorescent bands corresponding to 
EGFP and a red fluorescence band correspond to dfTAT fluorescence. Red fluorescent 
bands corresponding to both dfTAT and BSA indicated binding between peptide and 
protein. In contrast, dfTAT fluorescence is not detected in bands corresponding to EGFP, 
indicating absence of binding. An image of the Commassie stained native gel is also 
shown (top left corner). (b) Coomassie staining, red fluorescence, and green fluorescence 
images of samples of dfTAT and EGFP at varying concentration and analyzed by native 
gel electrophoresis. Similar results were obtained with dmEGFP (EGFP not containing 
cysteine residues, data not shown). 
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Figure 3-32 Effect of BSA, heparin and FBS on dfTAT cell penetration  (a) Co-
incubation of dfTAT with BSA results in a decrease in the percentage of cells displaying 
cytosolic release of dfTAT. HeLa cells were co-incubated with 5 µM dfTAT and 10 µM 
BSA for 1h. Cells show a punctate distribution of the peptide (monochrome 100X image) 
indicative of peptide being trapped in endocytic vesicles. In comparison, HeLa cells 
incubated with dfTAT (5 μM) alone show a homogenous cytosolic and nuclear 
distribution of peptide in a majority of cells. (b) Effect of FBS and heparin on dfTAT 
mediated cellular. HeLa cells were incubated with 5 μM dfTAT and heparin (1-100 
µg/mL) or FBS (0.1-10%) for 1 h. Cells were washed and imaged. The % cells with 
cytosolic and nuclear distribution was calculated as described in Figure 1(b). Scale bars: 
10 µm.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 117
 
 
 
 
	 118
 
Figure 3-33 Delivery of intact and functional Cre-recombinase using co-incubation 
with dfTAT. Assay showing that dfTAT improves the delivery of TAT-Cre. HeLa cells 
transfected with a plasmid containing egfp upstream of a loxP-STOP-loxP sequence were 
incubated for 1 h with either fTAT (5 µM) or dfTAT (5 µM) in the presence of TAT-Cre 
(1 µM).  EGFP+ cells that result from successful TAT-Cre delivery were visualized and 
counted by microscopy (confirmed by flow cytometry). Scale bars: 100 µm. 
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structures (Figure 3-34). Colocalization with the blue fluorescent mitochondrial marker 
pTagCFP-mito confirmed that these structures were mitochondria (Figure 3-35 (A)). 
Cells treated with FITC–anti-IgG, an antibody that does not target mitochondria, did not 
stain tubular structures (Figure 3-35 (B)). These experiments confirmed that dfTAT can 
deliver a functional antibody into live cells. 
The transcription factor HOXB4 can penetrate cells, activate transcription and 
induce hematopoietic stem cell expansion, either by itself or when fused to TAT242-244. I 
was therefore interested in determining whether dfTAT, by promoting cytosolic delivery, 
would enhance the transcriptional activity of this protein. NIH 3T3 cells were transfected 
with a vector containing the luciferase gene under a HOXB4-inducible promoter and with 
a β-galactosidase reporter as internal control. Cells were incubated with HOXB4 or TAT-
HOXB4, in the absence or presence of dfTAT, for 1.5 h. I assessed the expression of 
luciferase by measuring the luminescence of cell lysates (normalized to β-galactosidase 
activity, luciferase induction represents a ratio of treated versus untreated cells). HOXB4 
and TAT-HOXB4 (200 nM) alone induced a 2.2- and 5.0-fold increase in luciferase 
activity, respectively (Figure 3-36). In contrast, addition of dfTAT (3 μM) led to 53.1- 
and 307.4-fold luciferase induction, respectively. Neither dfTAT alone nor dfTAT 
incubated with TAT-mCherry led to the induction of luciferase, indicating that luciferase 
expression was dependent on the presence of HOXB4. 
Although increasing the transcriptional output of HOXB4 is valuable, precisely 
controlling the level and activity of HOXB4 inside cells is important to achieve desirable 
biological outcomes245. Because dfTAT appears to act independently of the molecules  
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Figure 3-34 Delivery of an intact and functional antibody using co-incubation with 
dfTAT. Microscopy imaging showing that dfTAT mediates the delivery of an antibody. 
HeLa cells were co-incubated with FITC-anti-ATP5A (20 µg/mL) and dfTAT (5 µM) for 
1 h. FITC-anti-ATP5A (green) is delivered in the cytosol of cells and stains tubular 
mitochondria (more clearly visible in zoomed-in image). Absence of SYTOX® Blue 
staining indicates that the cells imaged do not have a compromised plasma membrane. 
Black arrows point to tubular mitochondria. Scale bars: 100X objective, 10 µm; zoomed-
in image, 2 µm. 
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Figure 3-35 The FITC-anti-ATP5a antibody co-localizes with a fluorescently labeled 
mitochondrial protein expressed in live cells after dfTAT-mediated delivery. (a) Cells 
expressing TagCFP-mito (left) were imaged using the FITC and CFP filters. Tubular 
mitochondria were clearly observed only in the CFP channel. In a separate experiment, 
dfTAT (5 µM) and FITC-anti-ATP5A (20 µg/mL) were incubated for 1 h with cells 
expressing TagCFP-mito. The inverted monochrome images show co-localization of 
FITC-anti-ATP5A (FITC channel) and TagCFP-mito (CFP channel). Scale bars: 2 µm. 
(b) To confirm that the mitochondrial staining is specific to FITC-anti-ATP5A, an 
antibody without an intracellular epitope, FITC-anti-IgG, was delivered with dfTAT. 
FITC-anti-IgG (20 µg/mL) and dfTAT (5 µM) were incubated with cells for 1 h. Inverted 
monochrome images show a homogenous cytosolic fluorescence distribution (top). In 
contrast, cells that were incubated with FITC-anti-ATP5A show fluorescence in tubular 
structures (bottom). Scale bars: zoom-in image, 2 µm; 100X objective, 10 µm. 
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Figure 3-36 dfTAT mediated delivery of HoxB4 and TAT-HoxB4 improves the 
expression of a luciferase reporter. NIH 3T3 transfected with a HoxB4-dependent 
luciferase reporter were incubated for 1.5 h with either HoxB4 or TAT-HoxB4 (200 nM) 
in presence or absence of dfTAT (3 μM). TAT-mCherry (200 nM) and dfTAT (3 μM) 
serve as negative controls (400,000 cells/experiment, experiments in duplicate). 
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used for co-incubation in my assays, I hypothesized that it might be possible to titrate the 
amount of protein that penetrates cells by varying the protein concentration in the medium 
while keeping dfTAT concentration constant. Under this scenario, the efficiency of 
endosomal escape should remain unaffected, but the amount of material released from 
endosomes should change. Initial experiments with DEAC-K9 showed that the amount of 
fluorescent peptide delivered inside cells could be titrated using this protocol (Figure 3-
37 and 3-38). Consistent with these results, luciferase induction was proportional to the 
concentration of HOXB4 in the medium (Figure 3-39). 
 
3.3 Discussion 
 By mediating endosomal leakage, dfTAT is remarkably efficient at delivering 
proteins and peptides into the cytosol of cells. Delivery is efficient because the amount of 
material that reaches the cytosol is substantial and the amount trapped inside endosomes 
is relatively low, and because cytosolic delivery occurs in most cells present in a sample. 
Endosomal escape appears to take place in most cells once dfTAT, which is intrinsically 
more endosomolytic than monomeric TAT, reaches a threshold concentration within 
endosomes. Future studies aimed at establishing the roles played by the two copies of the 
peptide TAT and of the fluorophore TMR, as well as their respective arrangement, should 
provide more molecular details about the activity of dfTAT. Establishing where dfTAT 
escapes from the endocytic pathway should also provide valuable insights regarding its 
endosomolytic activity, which will be the focus of my next chapter. Notably, the 
membrane of endosomes can be lysed by fluorescently  
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Figure 3-37 The amount of DEAC-K9 delivered in the cytosol and nucleus of live 
cells can be titrated. HeLa cells were incubated with dfTAT (5 μM) and increasing 
amounts of DEAC-K9 (1, 2.5, 5, 10, 20 μM). The fluorescence intensity of cells displaying 
cytosolic release was assessed by microscopy (representative 20X images are shown using 
a pseudocolored colorscale: blue=lowest intensity, red=highest intensity) and by 
measuring to the bulk fluorescence of cell lysates (microscope: 1,000 cells/experiment, 
fluorometer: 300,000 cells/experiment; experiments in triplicates, average and standard 
deviations represented). Scale bars: 10 μm 
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Figure 3-38 Determination of the amount of DEAC-K9 delivered into cells. HeLa cells 
were incubated with dfTAT (5 µM) and different concentrations of DEAC-K9 (1, 2.5, 
5,10 and 20 µM) for 1 h. Cells were washed with PBS/heparin, imaged and lysed. The 
bulk fluorescence of cell lysates containing DEAC-K9 was measured using a fluorometer. 
Similarly, the fluorescence of solutions of DEAC-K9 at different concentrations (0.01. 
0.1, 1, 10 and 100 µM) was measured using a fluorometer. A calibration curve of DEAC-
K9 intensity vs. DEAC-K9 concentration was established. These data was used to estimate 
the average concentration of DEAC-K9 inside cells. Data shows a linear increase in the 
amount of DEAC-K9 delivered inside cells (top right panel). Consistent with these data, 
fluorescence images that show an increase in the fluorescence signal in the cytosol cells 
with increasing concentrations o DEAC-K9 incubated in the media (top left panel, and 
Figure 3-37). 
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Figure 3-39 The induction of luciferase expression by dfTAT-medited delivery of 
HoxB4 into cells can be controlled. NIH 3T3 cells were co-incubated with HoxB4 (25-
200 nM) and dfTAT (3 µM) and luciferase induction was measured as described in a 
(400,000 cells/experiment, experiments in duplicate). 
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labeled cell-penetrating peptides upon light irradiation175, 246. dfTAT trapped inside 
endosomes (for example, after incubation at 2 μM) can indeed leak out of endosomes 
when TMR is continuously excited for several seconds (data not shown). Yet, all delivery 
experiments reported herein were performed in a dark room with a dim red light. The 
excitation of dfTAT, when required for fluorescence microscopy, was also minimized to 
less than 300 ms in all images shown. Overall, I conclude that the endosomal leakage 
mediated by dfTAT is light independent. 
A remarkable aspect of dfTAT-mediated delivery is the minimal cellular responses 
associated with the efficient endosomal leakage observed. This is surprising because 
endosomal lysis can be extremely toxic by causing the rapid release of calcium into the 
cytosol of cells178. In addition, the leakage of endolysosomal proteases could contribute to 
toxicity247-250. Yet, I observed that cells were not only viable but also healthy. These results 
are presumably valid for only the one hour dfTAT incubation used in my assays. 
Continuous endosomal leakage induced by particulate wear debris induces inflammatory 
responses and apoptosis251. dfTAT could therefore promote similar effects if administered 
to cells for long incubation times. Notably, membrane repair mechanisms have also been 
shown to mask the effect of debris-induced endosomal leakage251. This, in turn, could also 
explain why dfTAT-mediated delivery is relatively innocuous under the conditions tested. 
dfTAT delivers cell-impermeable molecules displaying diverse structures and 
properties. DEAC-K9, like dfTAT, is highly positively charged, and the isoelectric points 
(pI) of Cre (9.4), and HOXB4 (9.8) are also not suggestive of favorable electrostatic 
interactions with dfTAT. EGFP, a protein with a lower pI (6.2), does not appreciably 
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interact with dfTAT in vitro. It is therefore likely that dfTAT does not need to interact 
with a given protein outside the cell or within the lumen of endosomes to achieve cytosolic 
delivery of that protein. Instead, interactions that occur between dfTAT and a protein with 
low pI such as BSA are inhibitory. Similar inhibitory effects between arginine-rich cell-
penetrating peptides and negatively charged species have been observed203, 252. 
The co-incubation protocol used herein allows several cargos to be delivered 
simultaneously. Alternatively, delivery can be performed in successive steps, without 
complex sample preparations and, as exemplified by the delivery of SNAP-Surface 488 
or FITC–anti-ATP5A, is ideally suited for imaging applications. In addition, co-
incubation provides the opportunity to titrate the extracellular concentration of target 
molecules independently of dfTAT. The amount of protein delivered to the cytosol and 
the biological output achieved can in turn be modulated. Although my approach is likely 
not optimal for in vivo delivery of biologics, it could offer several advantages over existing 
reagents for delivery to tissue cultures and the ex vivo manipulation of cells. 
 
3.4 Materials and methods 
3.4.1 Peptide design, synthesis and purification 
 All peptides were synthesized in-house on the rink amide MBHA resin 
(Novabiochem) by solid-phase peptide synthesis (SPPS) using standard Fmoc protocols. 
Fmoc-Lys(Mtt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Gln(Trt)-OH and Fmoc-Cys(Trt)-OH (Novabiochem) were used to assemble the peptides. 
Reactions were carried out in a SPPS vessel at room temperature using a stream of dry 
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N2 to provide agitation. Fmoc deprotection was performed by addition of piperidine in 
dimethylformamide (DMF) (Fisher) (20 %, 10 mL) to the Fmoc-peptide resin (0.30 
mmol). Deprotection reactions were carried out once for 5 min (1 × 5 min) and 1 × 15 min 
with a washing step in between reactions. Amino acid coupling reactions were carried out 
for 4 h with a mixture of Fmoc-amino acid (1.2 mmol), HBTU (Novabiochem) (0.44 g, 
1.1 mmol) and di-isopropylethylamine (DIEA) (Sigma) (0.51 mL, 3.0 mmol) in DMF. 
Upon completion of the reactions, the resin was washed with DMF and dichloromethane 
(DCM) (Fisher). For DEAC-K9, the DEAC fluorophore (AnaSpec) was coupled to the N 
terminus of the peptide after coupling of the ninth Fmoc-Lys(Boc)-OH using a mixture of 
DEAC, HBTU and DIEA (4, 3.9 and 10 molar equivalents (eq) with respect to the peptide) 
in DMF. The reaction was carried out overnight using a stream of dry N2 to provide 
agitation. For CK(ε-NH-TMR)TATG (fTAT), the Mtt protecting group at the ε-amino 
group of Lys on CK(ε-NH-Mtt)TATG was cleaved with 2 % trifluoroacetic acid (TFA) 
(Fisher) and 2 % tri-isopropylsilane (TIS) (Sigma) in DCM, and the resin was washed 
with DCM and DMF. A mixture of TMR, HBTU and DIEA (4, 3.9 and 10 eq with respect 
to the peptide) in DMF was added to the resin, and the reaction was carried out overnight 
using dry N2 to provide agitation. Following Fmoc-deprotection and peptide assembly, the 
resin was washed with DCM and dried in vacuo. The resin was then treated with TFA 
containing 2.5 % H2O, 2.5 % TIS and 2.5 % ethanedithiol (EDT) (Sigma) for 3 h at room 
temperature to achieve global deprotection and cleavage from the resin. The crude peptide 
products were precipitated and washed with cold anhydrous Et2O (Fisher). The 
precipitates were resuspended in water and lyophilized. The products obtained were then 
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resuspended in 0.1 % aqueous TFA/acetonitrile. The peptides were analyzed and purified 
by reverse-phase HPLC. HPLC analysis was performed on a Hewlett-Packard 1200 series 
instrument and an analytical Vydac C18 column (5-μm particle size, 4 mm × 150 mm). 
The flow rate was 1 mL/min, and detection was at 214 nm and 550 nm. Semi-preparative 
HPLC was performed on a Vydac C18 10 × 250–mm column. The flow rate was 4 
mL/min, and detection was at 214 nm and 550 nm. All runs used linear gradients of 0.1% 
aqueous TFA (solvent A) and 90% acetonitrile, 9.9 % water and 0.1% TFA (solvent B). 
The correct identity of the peptides was confirmed by MALDI-TOF performed with a 
Shimadzu/Kratos instrument (AXIMA-CFR). fTAT expected mass was 2,041.17; 
observed mass was 2,040.66. DEAC-K9 expected mass, 1,412.97; observed mass, 
1,415.59. 
 
3.4.2 Synthesis of acetamidated C(S-CH2CONH2)K(ε-NH-TMR)TATG (acfTAT) 
 C(S-CH2CONH2)K(ε-NH-TMR)TATG was formed after addition of 
iodoacetamide (Sigma) (0.275 mg, 1.49 μmol) to CK(ε-NH-TMR)TATG (148 μg, 0.074 
μmol) in 25 mM HEPES, pH 7.5, under an atmosphere of N2. The product was purified 
using analytical reverse-phase HPLC. Expected mass (MALDI-TOF), 2,098.19; observed 
mass, 2,096.31. 
 
3.4.3 Generation of dfTAT by dimerization of CK(TMR)TATG (fTAT) 
 dfTAT was formed by dissolving (0.3 mg, 1.5 × 10−4 mmol) fTAT in aerated 
phosphate buffer saline (PBS), pH 7.4 (5 mL). Oxygen dissolved in the buffer acted to 
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oxidize the thiol groups on the peptides and form a disulfide bond. The reaction was 
allowed to react overnight until completion (100 % yield according to HPLC analysis). 
The product was purified using analytical reverse-phase HPLC. Expected mass (MALDI-
TOF), 4,080.34; observed mass, 4,084.21. 
 
3.4.4 Generation of nrdfTAT using fTAT 
 Two fTAT peptides linked by the bis(maleimido)ethane (BMOE) (Pierce) linker 
(nrdfTAT) was formed by reacting pure fTAT (0.202 mg, 0.099 μmol) with BMOE (0.011 
mg, 0.0496 μmol) for 3 h in PBS buffer, pH 7.2, under an atmosphere of N2. The product 
was purified using analytical reverse-phase HPLC. Expected mass (MALDI-TOF), 
4,313.39; observed mass, 4,303. 
 
3.4.5 Cloning, overexpression and purification of TAT-Cre, TAT-mCherry, HOXB4 
and TAT-HOXB4 
 The pTriEx-HTNC plasmid encoding His-tagged TAT-NLS-Cre (TAT-Cre) 
protein was purchased from Addgene. The TAT-Cre gene was then cloned into pTXB1 
vector and transformed into Escherichia coli BL21 (DE3) cells (Agilent Technologies). 
The protein was expressed and purified as described253. Briefly, TAT-Cre was expressed 
with 1 mM IPTG at 37 °C for 3 h. TAT-Cre was then purified to homogeneity using a Ni-
NTA resin (Qiagen) and cation-exchange chromatography (HiTrap SP HP) (GE 
Healthcare). 
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pTXB1-TAT-mCherry was obtained by inserting the TAT DNA sequence into the 
pTXB1-mCherry plasmid. The oligonucleotides with sequences 5′-TAT GGG TCG TAA 
AAA ACG TCG TCA GCG TCG TCG TGG TCA-3′ and 3′-ACC CAG CAT TTT TTG 
CAG CAG TCG CAG CAG CAC CAG TAT-5′ (Integrated DNA Technologies) coding 
for the TAT sequence, which contain NdeI sites, were annealed to generate dsDNA. The 
pTXB1-mCherry plasmid was cut with NdeI (New England Biolabs) and ligated with TAT 
dsDNA. The pTXB1-TAT-mCherry plasmid was transformed into BL21 (DE3) cells, and 
protein expression was induced with 1 mM IPTG at 16 °C for 24 h. Cells were harvested 
and resuspended in lysis buffer containing 20 mM Tris-Cl (pH 7.5) and 200 mM NaCl. 
After cell lysis by sonication and high-speed centrifugation at 15,000 r.p.m. (rotor radius: 
23 cm) for 1 h, the soluble fraction was applied to chitin resin (New England Biolabs) pre-
equilibrated with lysis buffer and incubated overnight at 4 °C (the protein contains a C-
terminal intein-chitin binding domain purification tag). The resin was washed with ten 
column volumes of lysis buffer. The protein was cleaved from the resin by incubating the 
beads with 1 column volume of cleavage buffer supplemented with 100 mM 2-
mercaptoethanesulfonic acid and for 24 h at 4 °C. The protein was further purified using 
cation-exchange chromatography. 
EGFP was cloned, expressed and purified as previously described254. The double-
mutant EGFP (dmEGFP) was obtained by introducing the mutations (C49S, C71V) in the 
EGFP plasmid using site-directed mutagenesis. Because dmEGFP does not contain any 
Cys residue, this protein is unable to form a disulfide bond with fTAT. In all assays, results 
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obtained with EGFP were similar to those obtained with dmEGFP. In the text, both EGFP 
and dmEGFP are therefore referred to as EGFP for simplicity. 
The pTAT-HA-HOXB4 vector was generously provided by G. Sauvageau 
(Montreal University). His6-HOXB4 was produced by cloning the HOXB4 gene into pET-
28a. Briefly, the HOXB4 cDNA was first amplified from pTAT-HA-HOXB4 by using 
primers designed to introduce the NdeI and XhoI sites at the 5′ and 3′ ends, respectively 
(5′-GGC ATT CAT ATG GCT ATG AGT TCT TTT TTG ATC AAC TCA- 3′; 5′-GGT 
CAG TCT CGA GCT AGA GCG CGC GGG G-3′) (IDT). The PCR fragment was then 
inserted into the corresponding NdeI and XhoI sites of the 6xHis-tag vector, pET-28a. The 
fidelity of the reading frame was confirmed by sequencing. The procedure for the 
purification of both TAT-HOXB4 and HOXB4 is similar and has been previously 
described244. Briefly, BL21 (DE3) cells were transformed with either pTAT-HA-HOXB4 
or pET28a-HOXB4 and induced at 37 °C for 5 h with 1 mM IPTG. The pelleted cells were 
lysed by sonication in buffer A (8 M urea, 20 mM HEPES, 200 mM NaCl, pH 8.0). 
Lysates, which were obtained via high-speed centrifugation (14,000 r.p.m., 30 min at 22 
°C), were then adjusted to 10 mM imidazole and incubated with Ni-NTA agarose beads 
for 60 min at room temperature. The nickel beads were then washed with buffer A 
containing 20 mM and 40 mM imidazole to eliminate the presence of any nonspecific 
products, and bound proteins were subsequently eluted with 100 mM and 250 mM 
imidazole in buffer A. Eluates from both concentrations of imidazole containing the 
proteins of interest (i.e., TAT-HOXB4 or HOXB4) were loaded on a HiTrap SP HP 
column at 4 °C in buffer B (4 M urea, 20 mM HEPES, 50 mM NaCl, pH 6.5) and eluted 
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on the FPLC in a single-step at 4 °C with buffer C (20 mM HEPES, 1 M NaCl, pH 8.0). 
Both proteins were immediately desalted by diluting with 20 mM HEPES (pH 8.0) and 
concentrated using centrifugal filter units with 10K MWCO (EMD Millipore), divided 
into aliquots and flash frozen at –80 °C. Protein concentrations were determined using the 
Bradford protein assay (Bio-Rad). 
 
3.4.6 Cell lines 
 HeLa (ATCC CCL-2), HaCat255 (obtained from J. Massagué, Memorial Sloan-
Kettering Cancer Center), NIH 3T3 (ATCC CRL-1658), COLO 316256 (obtained from R. 
Burghardt, Texas A&M University), HDF (ATCC PCS-201-010), Neuro-2a (ATCC CCL-
131) and MCH58257 (obtained from E. Shoubridge, Montreal Neurological Institute and 
Hospital) were grown in Dulbecco's minimum essential medium (DMEM) (Fisher) 
supplemented with 10% fetal bovine serum (FBS) (Fisher) and 1× penicillin/streptomycin 
(P/S) (Fisher) and kept at 37 °C in a humidified atmosphere containing 5 % CO2. Intestinal 
porcine epithelial cells (IPEC-1, obtained from G. Wu, Texas A&M University) were 
cultured in growth medium containing DMEM, 10 % FBS, insulin (5 μg/mL; Sigma), 
hydrocortisone (1 μg/mL; Sigma), EGF (5 ng/mL; BD Biosciences) and 1× P/S and kept 
at 37 °C in a humidified atmosphere containing 5% CO2258. Cultures were tested 
for Mycoplasma contamination using the PCR Mycoplasma Test Kit II (PromoKine). 
HeLa cells were profiled using STR, by ATCC before purchase, but other cell lines were 
not. 
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3.4.7 Delivery of peptides inside live cells 
 Cells were seeded in eight-well dishes so that the cells were 80–90 % confluent 
after 48 h. Each well was washed three times with PBS and Leibovitz's L-15 medium that 
did not contain the amino acid cysteine (nonreducing L-15, nrL-15). The medium (nrL-
15) used for incubation lacks cysteine to avoid reduction of the disulfide bond of dfTAT. 
Cells were then incubated with different concentrations of the acfTAT, fTAT, dfTAT or 
nrdfTAT at 37 °C for 5–60 min. Cells were washed three times with PBS and nrL-15 and 
placed on an inverted epifluorescence microscope (Model IX81, Olympus) equipped with 
a heating stage maintained at 37 °C. Images were collected using a Rolera-MGI Plus back-
illuminated electron-multiplying charge-coupled device (EMCCD) camera (Qimaging). 
Images were acquired using bright-field imaging and three standard fluorescence filter 
sets: CFP (excitation (Ex) = 436 ± 10 nm/emission (Em) = 480 ± 20 nm), RFP (Ex = 560 
± 20 nm/Em = 630 ± 35 nm) and FITC (Ex = 488 ± 10 nm/Em = 520 ± 20 nm). The 
fluorescence intensities of different cells were measured with the SlideBook 4.2 software 
(Olympus), and the average fluorescence intensity was determined for each condition. Our 
laboratory has previously reported that cell-penetrating peptides labeled with fluorophores 
such as TMR can photosensitize membranes and cause endosomal leakage upon light 
irradiation175, 246. To minimize the role played by light irradiation in the activities reported 
herein, I performed all delivery experiments under conditions of minimal light irradiation 
(dark room with dim red light). When fluorescence imaging was required, probes (for 
example, SNAP-Surface 488 and EGFP) were imaged before dfTAT images were 
acquired. dfTAT was also excited for only a maximum of 300 ms. In contrast, the light 
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dose required to observe light-induced endosomal leakage was typically 10- to 20-fold 
greater than that used for imaging. For experiments performed with Cre and HOXB4, cells 
were not imaged and not exposed to light during delivery (cells incubated with HOXB4 
were never exposed to light, and cells incubated with Cre were imaged 12 h after 
incubation). 
 
3.4.8 Delivery of peptides and proteins inside live cells by co-incubation with dfTAT 
 HeLa, HDF and Neuro-2a cells were seeded in eight-well dishes, grown and 
washed as described in the prior section. Cells were then co-incubated with 5 μM delivery 
peptide and with the cargo at the corresponding concentration for 1 h at 37 °C. Cells were 
washed three times with PBS and nrL-15 and placed on the microscope. Images were 
acquired as described before. For transfection and expression of SNAP-H2B and TagCFP-
mito, plasmids were mixed with Lipofectamine 2000 reagent in opti-MEM medium and 
incubated at room temperature for 30 min. The DNA complex was added to previously 
seeded HeLa cells (80 % confluent) on an eight-well dish, and cells were kept at 37 °C for 
24 h. After 24 h, the wells were washed three times with PBS and nrL-15 before 
performing the delivery experiments using the SNAP-Surface 488, FITC goat anti-mouse 
IgG (Life Technologies, Cat. No. F2761) or mouse monoclonal FITC–anti-ATP5A 
(Abcam ab119688). The SNAP-Surface 488 fluorescence is known to be quenched (80 
%) before reacting with the SNAP fusion tag240. Consequently, I considered the signal of 
SNAP-Surface 488 to be 80 % quenched when the molecule is trapped inside endosomes 
or distributed in the cytosol of cells, but fully fluorescent when localized in the nucleus of 
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cells (where it reacts with SNAP-H2B). To estimate the amount of SNAP-Surface 488 
that escapes from endosomes after dfTAT-mediated delivery, I analyzed the SNAP-
Surface 488 fluorescence signal obtained after imaging using the SlideBook software. The 
total signal intensity of the cytoplasmic region was multiplied by 5 and compared to the 
total signal intensity of the nuclear region. 
 
3.4.9 Quantitative determination of peptide and macromolecule uptake inside cells 
 HeLa cells were seeded in a 48-well dish, grown and washed as described above. 
For the peptide uptake experiment, each well was incubated for 1 h with varying 
concentration of acfTAT, fTAT or dfTAT (range: 5–25 μM peptide concentration). For 
the titration experiment, cells were incubated with dfTAT (5 μM) and varying 
concentration of DEAC-K9 (range: 1–20 μM) or EGFP (10 μM) for 1 h. Cells were then 
washed with PBS with heparin (1 mg/mL) and nrL-15 and imaged. To lyse cells, I 
removed nrL-15 from the wells, and a total of 100 μl of lysis buffer (50 mM Tris, pH 7.5, 
2 mM EDTA, 2 mM DTT, 0.1 % Triton X-100) were incubated with cells for 5 min 
(alternatively, cells were trypsinized and counted as described in the flow cytometry 
section). Cells were scraped off the dish, and the cell lysate was pipetted into a 1.5-mL 
microcentrifuge tube and centrifuged at 13,000 r.p.m. for 25 min (rotor radius: 8.4 cm). 
For uptake measurement, 70 μl of supernatant were collected and placed in a 96-well plate. 
The fluorescence emission intensity was measured using a plate reader equipped with a 
fluorescence module (Ex = 525 nm, Em = 580–640 nm) (GloMax-Multi+ Detection 
System, Promega). Alternatively, 80 μL of supernatant were diluted to a total volume of 
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100 μl, and the bulk fluorescence was measured using a SLM-8000C fluorometer (Ex = 
435 nm, Em = 465–475 nm) (SLM Instruments). Fluorescence intensities were normalized 
to total protein concentration in each well (determined by Bradford protein assay, wherein 
10 μl of each cell lysate is added to 200 μl of a 1× protein assay reagent and then incubated 
at room temperature for 30 min; absorbance at 600 nm is measured using the plate reader). 
To determine the amount of EGFP uptake, I mixed cell lysates (27 μl) with 3 μl of 5× 
SDS-PAGE loading buffer lacking DTT and analyzed them by SDS-PAGE (the sample 
was not boiled so as to avoid EGFP unfolding; SDS-PAGE does not unfold EGFP, as 
described in 259 ; DTT was not included to avoid cleavage of the disulfide bond that might 
form between fTAT and EGFP). Calibration curves were established for EGFP and 
DEAC-K9 by analyzing samples of known concentrations using SDS-PAGE gel and 
fluorescence, respectively. All experiments were performed in triplicate. 
 
3.4.10 Quantitative analysis of TAT-HOXB4 and HOXB4 delivery with fTAT and 
dfTAT using a luciferase reporter 
The murine fibroblast cell line (NIH 3T3, stably transfected with the E2A-PBX 
vector), the luciferase reporter vector, pML (5xHOX/PBX; contains a promoter with 
binding sites for HOXB4 and PBX) and the β-gal internal control vector used in the 
following studies were kindly provided by P. Zandstra (University of Toronto). The cells 
were initially cultured in 100-mm dishes at 37 °C with 5 % CO2 in DMEM supplemented 
with 10% FBS. For experimental purposes, however, cells were seeded in 24-well plates 
at a density of 5 × 104–6 × 104 cells per well for 24 h. Subsequently, cells were 
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cotransfected with 0.8 μg/ml of pML (5xHOX/PBX) and of the β-gal internal control 
vector using Lipofectamine 2000. Twelve hours post transfection, cells were washed and 
incubated with TAT-HOXB4 or HOXB4 (both at 200 nM, unless, otherwise noted; see 
below) with or without fTAT or dfTAT in nrL-15 for 90 min. Some cells were also 
incubated with TAT-mCherry (200 nM) with and without the peptides. After incubation, 
all cells were washed with PBS and lysed according to the manufacturer's protocol for the 
reporter lysis buffer (RLB) (Promega). For titration experiments, the same protocol was 
followed, with the exception that HOXB4 concentrations were varied (25, 50, 100, 150 
and 200 nM). In order to quantitate the luciferase reporter activity, I added 100 μl of 
luciferase assay reagent (Promega) to 20 μl of cell lysate and bioluminescence was 
immediately measured using a SpectraMaxL luminometer (Molecular Devices). For the 
purposes of measuring transfection efficiency, 180 μl of β-gal assay buffer were mixed 
with 20 μl of cell lysate in a 96-well plate and incubated at 37 °C for 30 min. The β-gal 
assay buffer is composed of 75 % 0.1 M sodium phosphate, pH 7.5, 24 % o-nitrophenyl 
β-D-galactopyranoside (ONPG made at a concentration of 4 mg/mL in 0.1 M sodium 
phosphate) (Sigma) and 1% 100-fold solution (10 % 1 M magnesium chloride solution, 
32 % β-mercaptoethanol and 58 % distilled water). Absorbance was then measured at 450 
nm using the plate reader. As the absorption spectrum of the chromophore (TMR) 
conjugated to the peptide used in this study overlaps with that of β-gal, 20 μl of cell lysate 
containing the peptide were also diluted with 180 μl of the lysis buffer, and absorbance 
values obtained at 450 nm were subtracted from those of the β-gal. The luciferase activity 
of all samples was determined as a ratio of the luciferase activity to the β-gal activity, and 
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the fold-increase in luciferase activity was established by normalizing the luciferase 
activity of each sample to that of cells, which were transfected but had no protein 
delivered. 
 
3.4.11 Cell viability assays 
In order to determine cells that had compromised plasma membranes, I treated 
cells with SYTOX® green (SYTOX® blue in some cases) and Hoechst (Invitrogen). 
SYTOX® dyes are cell impermeable and stain the DNA of cells with compromised plasma 
membranes. The Hoechst dye is cell permeable and stains the DNA of all cells. Images 
were acquired using the green and blue filter. The green and blue images were used to 
count cells with a blue- or green-stained nucleus. ImageJ was used to count the dead 
(green) and total cells (blue). Cytotoxicity was determined from the ratio of SYTOX® 
green–positive cells/total number of cells. An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was performed to determine the effect of the peptide 
on cell proliferation. Cells were seeded in a six-well dish, grown and washed as described 
above. One well from the dish was incubated with 5 μM dfTAT at 37 °C for 1 h. A second 
well was left untreated and served as control. Cells were washed three times with PBS and 
nrL-15. Cells were trypsinized and seeded into 96-well dishes containing 200 μl of 
DMEM. The cells were then allowed to attach to the bottom of the dish for 12 h. The MTT 
assay was then performed at specific time points to measure cell proliferation. The DMEM 
was removed and replaced with 100 μl of nrL-15, and 10 μl of a 12 mM MTT stock 
solution were added to the wells. The 96-well dish was incubated at 37 °C for 4 h. After 
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the incubation, 100 μl of a 10 mM SDS-HCl solution were added to each well. The solution 
was mixed thoroughly by pipetting up and down and was incubated for 13 h. After the 
incubation each sample was mixed, and the absorbance at 600 nm was measured. Controls 
included a negative control where 10 μl MTT was added to 100 μl of nrL-15 alone (no 
cells). A second control consisted of cells treated with the delivery peptide but to which 
no MTT was added to subtract the contribution of TMR from the measured absorbance. 
The absorbance of the negative control was subtracted from all samples. The final time 
point measurement for each cell type corresponded to 100 % cell confluency. 
 
3.4.12 Whole-genome microarray analysis 
HDF cells were cultured in 24-well dishes and incubated with nrL-15 (untreated 
cells), nrL-15 supplemented with dfTAT (5 μM, treated cells) or nrL-15 supplemented 
with staurosporine (0.1 μM) for 1 h. Cells were trypsinized immediately after washing 
with PBS or nrL-15 (1-h time point). Alternatively, cells were trypsinized after 1 h (1 h + 
1 h) or 24 h (1 h + 24 h) incubation in 10 % FBS/DMEM. Cells were removed from each 
well by gentle pipetting and spun down at 12,000 r.p.m. for 4 min at 4 °C. The cell pellets 
were preserved in 1 mL Trizol (Ambion, Life Technologies) and shipped frozen to the UT 
Southwestern microarray facility, where total RNA was extracted and analyzed on an 
Illumina Human HT-12 v4 sequencer using reported protocols 
(https://microarray.swmed.edu/protocols/protocol/illumina-gene-expression-probe-
labeling). 
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3.4.13 Differential in gel electrophoresis (DIGE) proteomic analysis 
HDF cells were treated with or without dfTAT as described in the whole-genome 
microarray analysis assay. A volume of 150 μl of lysis buffer (10 mM Tris, pH 7.5, 1 % 
CHAPS and 1× protease inhibitor cocktail) was added to each well. After 5 min, the 
solution was transferred to an Eppendorf tube, and 20 μl of nuclease cocktail were added 
to the cell lysates and incubated on ice for 30 min. The lysate was spun down at 13,000 
r.p.m. for 10 min at 4 °C. The supernatant was saved, and an aliquot was used in Bio-Rad 
protein assay for quantification of total protein in the cell lysates. Methanol-chloroform 
precipitation was performed on the remaining sample260. All DIGE experiments were 
performed with pH 3–10 NL gradients. Each sample (~50 μg of protein) was resuspended 
in 30 μl of labeling buffer (7 M urea, 2 M thiourea, 4 % CHAPS, 30 mM Tris, 5 mM 
magnesium acetate). All samples were individually labeled with Cy3 or Cy5 (GE 
Healthcare) for 30 min on ice and in the dark (200 pmol), after which the reaction was 
quenched by the addition of 10 mM lysine for 10 min followed by the addition of an equal 
volume of 2× rehydration buffer (7 M urea, 2 M thiourea, 4 % CHAPS, 4 mg/mL DTT). 
The combined samples were brought up to 250 μl with 1× rehydration buffer (7 M urea, 2 
M thiourea, 4 % CHAPS, 2 mg/mL DTT, 0.5 % IPG buffer, pH 3–10). All strips were 
subjected to isoelectric focusing for 25,000 V h, according to manufacturers' 
recommendations. DIGE-associated instrumentation was manufactured by GE 
Healthcare. Electrophoresis instrumentation was from Hoefer. Cy2/3/5-specific 16-bit 
data files were acquired at 100-μm resolution separately by dye-specific excitation and 
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emission wavelengths using a Typhoon Trio Variable Mode Imager in a manner that 
greater than 90% of the proteins were in the linear range of detection. 
 
3.4.14 Determination of dfTAT and EGFP interaction by FRET 
Fluorescence emission spectra were obtained using an SLM-8000C fluorometer 
upgraded with the Phoenix package (ISS) and Vinci v.1.6 PC software (ISS). The 
experiments were conducted using a quartz cuvette at room temperature. The samples 
were excited at 488 nm (slit width = 1 mm), and the fluorescence emission was scanned 
from 500 to 650 nm (slit width = 1 mm). All samples (1 μM EGFP or dmEGFP and 5 μM 
dfTAT) were prepared using nrL-15. A 12% native gel was run using Tris-glycine running 
buffer at 100 mV for 2 h. Samples containing dfTAT (5 or 10 μM) were co-incubated with 
either varying concentration of dmEGFP (10–20 μM) or BSA (10 μM) in nrL-15 (pH 5.0 
and 7.0) for 30 min at 37 °C before gel loading. Fluorescence images of dfTAT and EGFP 
bands on the gel were detected using a fluorescence scanner (Typhoon, GE Healthcare). 
(dfTAT fluorescence detection: Ex, 568 nm; Em, 620 nm. EGFP fluorescence detection: 
Ex, 488 nm; Em, 525 nm.) Gels were then stained with Coomassie blue. 
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4. dfTAT MEDIATES CYTOSOLIC DELIVERY OF PROTEINS, PEPTIDES AND 
CELL-IMPERMEABLE SMALL MOLECULES INTO CELLS BY PROMOTING 
INTRACELLULAR UPTAKE THROUGH ENDOCYTOSIS AND BY MEDIATING 
ENDOSOMAL ESCAPE FROM LATE ENDOSOMES 
 
4.1 Introduction 
In chapter two and three I showed that branched and multivalent CPPs of the 
peptide TAT can penetrate live cells198. Furthermore, my results show that, in cases where 
cytosolic penetration was successful, the multivalent CPPs delivery efficiency was higher 
than their monomeric counterparts198, 222. These improved endosomolytic delivery agents 
can be used to deliver different cargos such as: antibodies, transcription factors, peptides 
and cell-impermeable small molecules inside cells. These deliveyr agents, specifically 
dfTAT, display very high endosomolytic activity. Interestingly and to my surprise, this is 
not accompanied by high cell toxicity. The molecular details involved in dfTAT 
penetration and high endosomolytic activity remain unknown.  
In this chapter, I describe the mechanism of cell penetration involved in the 
delivery of cargos into the cytosolic space of cells of a highly endosomolytic branched 
and multivalent CPP, dfTAT. I test the hypothesis that dfTAT reaches the cytosolic space 
of cells after dfTAT cellular uptake by endocytosis, trafficking through the endocytic 
pathway and dfTAT-mediated escape from late endosomes. Futhermore, I hypothesize 
that dfTAT-mediated endosomal escape depends on the presence of a negatively-charged 
phospholipid found only in late endosomes inside cells, BMP. I formulated my hypothesis 
	 145
based on evidence showing that the TAT peptide can bind negatively-charged 
phospholipids and can cause disruption of membranes containing BMP in vitro72, 131, 141, 
142. Moreover, it has been shown that TAT monomer reaches the cytosolic space after it 
escapes from endocytic organelles found late in the endocytic pathway103. Here I report 
that dfTAT requires to be transported to endocytic vesicles found late in the endocytic 
pathway to escape and reach the cytosolic space. I demonstrate that dfTAT does not escape 
from early endosomes or lysosomes and instead, like TAT, it appears to escape from late 
endosomes. I achieved cytosolic delivery in cells that were incubated with an inhibitor 
than blocks transport from endosomes to the trans-Golgi network (TGN), retro-2. This 
suggests that dfTAT does not reach the cytosolic space via retrograde transport. On the 
other hand, delivery was blocked by an antibody that accumulates in the lumen of late 
endosomes and binds BMP, anti-BMP. This result suggests that dfTAT interacts with 
BMP in order to escape from late endosomes. 
 
4.2 Results 
4.2.1 Transport of dfTAT to endocytic organelles found late in the endocytic pathway 
is required for endosomal escape 
 In chapter three I showed that dfTAT penetrates cells via a two-step process. First, 
dfTAT is taken up by cells by endocytosis (macropinocytosis been the major mechanism). 
This step leads to entrapment of dfTAT inside endocytic vesicles and trafficking along the 
endocytic pathway. Subsequently, dfTAT escapes from the endocytic pathway and enters 
the cytosolic space of cells. The exact exit point where dfTAT escapes remains unknown. 
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 In order to establish where dfTAT escapes from the endocytic pathway, I decided 
to block endocytic transport at specific points using known molecular biology tools. To 
do this, I incubated dfTAT with cells expressing dominant negative-Rab5 (DN-Rab5) or 
dominant negative Rab7 (DN-Rab7). Rab proteins are part of a group of regulators that 
control endosome biogenesis, endosome maturation and trafficking261. Expression of DN-
Rab5 and DN-Rab7 arrests transport of cargos at a specific step by blocking the maturation 
of endocytic vesicles to early endosomes and late endosomes, respectively (Figure 4-1)262-
266. When dfTAT (3 μM) was incubated with cells expressing DN-Rab5 and DN-Rab7 
penetration of dfTAT into the cytosolic space was inhibited dramatically. While the 
population of untreated (non transfected cells, “dfTAT alone”) cells showed 57.6 % 
cytosolic fluorescence distribution, cells expressing DN-Rab5 and DN-Rab7 displayed 8.1 
% and 6.9 % cells with cytosolic fluorescence distribution, respectively (Figure 4-2 and 
4-3). Most cells expressing DN-Rab5 and DN-Rab7 showed a punctate fluorescence 
distribution consistent with the peptide being trapped inside endosomes (Figure 4-4).  
Disruption of the endocytic pathway using inhibitors or, as in this case, DN-Rab 
proteins can cause a negative feedback where uptake/endocytosis is affected. Expression 
of DN-Rab5 and DN-Rab7 could lead to a decrease of dfTAT intracellular uptake, which 
in turn can decrease dfTAT endosomal escape due to a decrease in the amount of dfTAT 
inside endosomes. To confirm that reduction of the % cells with cytosolic dfTAT  
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Figure 4-1 Model of endocytic trafficking and dfTAT inhibition of transport 
mediated by DN-Rab5 and DN-Rab7. In principle, dfTAT transport to early endosomes 
and subsequent vesicles will be blocked by expression of DN-Rab5. On the other hand, 
transport of dfTAT to late endosomes and lysosomes will be block by expression of DN-
Rab7.  
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Figure 4-2 Expression of DN-Rab5 and DN-Rab7 in live cells inhibits dfTAT 
endosomal escape. Assay showing that dfTAT endosomal escape is significantly reduced 
by expression of DN-Rab5 and DN-Rab7. Untreated (dfTAT alone) HeLa cells or 
transfected cells with a plasmid containing rab5q79l and and rab7q67l genes were 
incubated for 1 h with dfTAT (3 µM). Cells displaying cytosolic dfTAT fluorescence 
distribution that result from successful dfTAT delivery were visualized and counted by 
microscopy. Scale bars: 10X objective, 100 µm. 
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Figure 4-3 Quantitative analysis of dfTAT penetration in live cells expressing DN-
Rab5 and DN-Rab7. Cells were incubated with dfTAT (3 μM) for 1 h. The number of 
cells with detectable cytosolic and nuclear fluorescence distribution in microcopy images 
was counted and divided by the total number of cells present (1,000 cells per experiment).  
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Figure 4-4 Expression of DN-Rab5 and DN-Rab7 causes dfTAT to remain trapped 
inside endocytic vesicles. Untreated (dfTAT alone) HeLa cells or transfected cells with a 
plasmid containing rab5q79l and and rab7q67l genes were incubated for 1 h with dfTAT 
(3 µM). Cells were visualized as before. Scale bars: 100X objective, 10 µm 
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fluorescence distribution was not a consequence of a reduction in the amount of dfTAT 
endocytosed, I measured dfTAT intracellular uptake. Cells expressing DN-Rab5 and DN-
Rab7 did not show a significant difference in the amounts of dfTAT uptake when 
compared to non transfected cells (Figure 4-5). This confirms that the reduction in the % 
cells with cytosolic fluorescence distribution is not due to a decrease in dfTAT uptake. 
These data altogether indicate that dfTAT, after been endocytosed, has to be transported 
to endocytic organelles found late in the endocytic pathway (late endosomes or lysosomes) 
to achieve endosomal escape and enter the cytosolic space of cells. 
 
4.2.2 dfTAT does not cause leakage of a peptide that accumulates inside lysosomes 
 At this point, penetration of dfTAT into the cytosolic space of cells appears to 
require transport into late endosomes or lysosomes or both. These endocytic organelles 
are two potential candidates for the exit point of dfTAT from the endocytic pathway. To 
determine if dfTAT can escape from lysosomes, I will test the dfTAT-mediated release of 
DEAC-K9 into the cytosolic space of cells using fluorescence microscopy (as performed 
in chapter 3). DEAC-K9 is a fluorescently-labeled cell-impermeable peptide that gets 
endocytosed by the same pathway as dfTAT175, 225. However, unlike dfTAT, DEAC-K9 
cannot escape from the endocytic pathway by itself and so it remains trapped inside 
endosomes after incubation with cells. In chapter 3, I showed that after incubation of cells 
with DEAC-K9 and a quick wash (1 min), incubation with dfTAT causes leakage of 
DEAC-K9 from endosomes into the cytosolic space of cells (Figure 3-15). My rationale 
is that if dfTAT escapes from lysosomes it could mediate the release of  
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Figure 4-5 Quantitative analysis of dfTAT intracellular uptake in cells expressing 
DN-Rab5 and DN-Rab7. Cells were incubated with dfTAT (3 μM) for 1 h, and relative 
uptake was assessed quantitatively by measuring the bulk fluorescence of cell lysates 
(300,000 cells per experiment). a.u., arbitrary units. The data represent the mean of 
triplicate experiments and the corresponding s.d. 
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DEAC-K9 from lysosomes to the cytosolic space. Interestingly, I was able to detect co-
localization of DEAC-K9 with LysoTracker® Green, a marker of lysosomes, after 
incubating cells with the peptide (10 μM) for 1 h, washing and imaging after only 30 min 
(Figure 4-6). As observed before, incubation of cells with dfTAT, after a quick wash (1 
min), caused leakage of DEAC-K9 from endosomes (Figure 4-7, left panel). On the 
contrary, dfTAT did not cause leakage of DEAC-K9 when the latter was allowed to 
tr8affic along the endocytic pathway and accumulate inside lysosomes for 2 h following 
an 1 h incubation and wash (Figure 4-7, right panel). Moreover, the punctate 
fluorescence signal of DEAC-K9 co-localized with LysoTracker® Green (data not shown) 
suggesting it remained trapped inside endosomes. One possibility is that dfTAT escapes 
from lysosomes (late endosomes as well, late endosomes being the major exit point) in an 
inefficient manner, to an extent that cannot be detected from the release of DEAC-K9 by 
fluorescence microscopy, because most of the peptide is degraded by proteases in 
lysosomes. To test this possibility, I used a protease-resistant version of dfTAT made out 
of D-amino acids, D-dfTAT. Like dfTAT, D-dfTAT penetrates cells efficiently (data not 
sown). Incubation of D-dfTAT with cells that had been pre-incubated with DEAC-K9 did 
not cause leakage of DEAC-K9 from lysosomes (same protocol used earlier was followed) 
(Fig 4-8). Together, these findings suggest that transport of dfTAT to lysosomes and 
lysosomal leakage are not required for dfTAT endosomal escape. It is possible that dfTAT 
reaches this organelle but possibly it is degraded before it can disrupt the membrane of 
lysosomes. 
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Figure 4-6 DEAC-K9 cellular localization following cellular uptake and endocytic 
trafficking. Cells were incubated with DEAC-K9 (10 μM) for 1 h, washed and imaged 
after 30 min. DEAC fluorescence signal is shown in magenta and LysoTracker® Green 
signal is shown in green. Co-localization is displayed as white (highlighted inside square). 
Scale bars: 10 µm. 
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Figure 4-7 dfTAT does not mediate leakage of DEAC-K9 from lysosomes. HeLa cells 
were incubated with 10 μM DEAC-K9 for 1 h and washed. Cells were subsequently 
incubated with 5 μM dfTAT, after 1 min or 2 h, for 1 h. Images are represented as inverted 
monochromes. Scale bars: 10 μm. 
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Figure 4-8 D-dfTAT does not mediate leakage of DEAC-K9 from lysosomes. HeLa 
cells were incubated with 10 μM DEAC-K9 for 1 h and washed. Cells were subsequently 
incubated with 5 μM D-dfTAT, after 1 min or 2 h, for 1 h. Images are represented as 
inverted monochromes. Scale bars: 10 μm. 
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4.2.3 Retro-2, an inhibitor of retrograde transport, does not block penetration of 
dfTAT into the cytosolic space of cells 
 Until this point, penetration of dfTAT into the cytosolic space appears to require 
transport into late endosomes. dfTAT could be escaping from the endocytic pathway by 
causing leakage of late endosomes. On the other hand, dfTAT endosomal escape could 
proceed from the Golgi apparatus (Golgi) or the endoplasmic reticulum (ER) via the TGN 
after transport of dfTAT to late endosomes267. There is evidence showing that toxins and 
viruses utilize this pathway to reach the cytosolic space of cells267-269. Interestingly, both 
modes of endosomal escape described require transport to late endosomes. To establish if 
retrograde transport is involved in dfTAT endosomal escape I will block retrograde 
transport using retro-2. Retro-2 is a molecule known to protect cells against ricin-mediated 
cell death (ricin transports from early endosomes to the TGN) and infection by viruses 
like SV40 (SV40 transports from late endosomes to the TGN) by blocking transport from 
endosomes to the TGN270, 271. It is important to mention that retro-2 blocks retrograde 
transport but not endosome maturation (retro would not block transport to late 
endosomes)270. I pre-incubated cells with retro-2 (20 μM) for 30 min, washed and 
incubated with dfTAT (3 μM). After incubation, dfTAT escaped from endosomes and 
showed a cytosolic fluorescence distribution (Figure 4-9). Moreover, the % of cells with 
dfTAT fluorescence distribution did not change when compared to untreated cells (Figure 
4-10). Furthermore, intracellular uptake of dfTAT was not affected by incubation with 
retro-2 (Figure 4-11). These findings suggest that  
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Figure 4-9 dfTAT does not escape from the endocytic pathway via retrograde 
transport. HeLa cells were pre-incubated with 20 µM for 30 min and washed. 
Subsequently, cells were co-incubated with dfTAT (3 µM) and retro-2 (20 µM) for 1 h 
washed and imaged. Scale bars: 10 μm. 
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Figure 4-10 Quantitative analysis of dfTAT penetration in live cells incubated with 
retro-2, an inhibitor of retrograde transport. Cells were pre incubated with retro-2 (20 
µM) and washed. Subsequently, cells were co-incubated with dfTAT (3 μM) and retro-2 
(20 µM) for 1 h. The number of cells with detectable cytosolic and nuclear fluorescence 
distribution in microcopy images was counted and divided by the total number of cells 
present (1,000 cells per experiment).  
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Figure 4-11 Quantitative analysis of dfTAT intracellular uptake in cells pre-
incubated with retro-2. Cells were pre-incubated with retro-2 (20 µM) and washed. 
Subsequently, cells were co-incubated with dfTAT (3 μM) and retro-2 (20 µM) for 1 h 
and relative uptake was assessed quantitatively by measuring the bulk fluorescence of cell 
lysates (300,000 cells per experiment). a.u., arbitrary units. The data represent the mean 
of triplicate experiments and the corresponding s.d. 
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dfTAT does not utilize retrograde transport to escape from the endocytic pathway and 
enter the cytosolic space of cells.  
 
4.2.4 Penetration of dfTAT into the cytosolic space is blocked by an antibody against 
BMP 
 So far, all the data I have shown points at late endosomes as the exit point for 
dfTAT endosomal escape. It is well established that the TAT peptide binds to negatively-
charged phospholipids and can disrupt membranes containing phosphatidylserine (Pdt-
Ser) and BMP72, 141, 142. Moreover, TAT has been shown to cause lipid mixing and leakage 
of molecules encapsulated in liposomes containing BMP131. Late endosomes are enriched 
with the negatively-charged peptide BMP. Interestingly, BMP is found only in late 
endosomes inside cells152, 153. Therefore, I decided to establish the role of BMP in dfTAT 
endosomal escape. To do this, I utilized anti-BMP, an antibody known to bind BMP and 
accumulate in late endosomes after uptake by fluid-phase endocytosis128, 130, 152, 272. Anti-
BMP has been shown to block infection of vesicular stomatitis virus (VSV), a virus that 
requires transport to late endosomes to cause infection, presumably by interfering 
selectively with late endosome/BMP functions130. Long pre-incubation of cells with anti-
BMP (50 μg/mL, for 18 h) led to a significant decrease in the % of cells with dfTAT 
cytosolic fluorescence distribution (Figure 4-12, left panel). While 57.6 % of untreated 
cells (dfTAT alone) displayed a cytosolic fluorescence distribution, only 5.2 % of cells 
pre-incubated with anti-BMP (anti-BMP, 18 h incubation) displayed a cytosolic 
fluorescence distribution  
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Figure 4-12 Incubation of live cells with anti-BMP inhibits dfTAT endosomal escape. 
Cells were pre-incubated with anti-BMP (50 µg/mL) or anti-IgG (50 µg/mL) for 18 h, 
washed, co-incubated with anti-IgG (50 µg/mL) or anti-BMP (50 µg/mL) and dfTAT (3 
µM) for 1 h. Cells displaying cytosolic dfTAT fluorescence distribution that result from 
successful dfTAT delivery were visualized and counted by microscopy. Scale bars: 10X 
objective, 100 µm. 
 
 
 
	 163
(Figure 4-13). Interestingly, the intracellular uptake of dfTAT was not significantly 
affected by incubation with anti-BMP (Figure 4-14) Moreover, the majority of treated 
cells showed a punctate fluorescence distribution consistent with dfTAT being trapped 
inside endosomes (Figure 4-15, left panel). To show that inhibition was not an indirect 
effect of antibody incubation, cells were pre-incubated with anti-IgG (50 μg/mL, for 18 h) 
(anti-IgG has no known effect on endosome/BMP function). Incubation with anti-IgG 
showed no significant change in the % of cells with dfTAT cytosolic fluorescence 
distribution when compared to untreated cells (Figure 4-12 (right panel) and 4-13). 
Interestingly, treatments of cells with both, anti-BMP and anti-IgG, did not have a 
significant effect on intracellular uptake of dfTAT, even though the observe dfTAT 
penetration activity differed greatly between treatments (Figure 4-14). Long incubation 
with anti-BMP has been shown to affect endosome morphology, endosome dynamics and 
localization and trafficking of proteins associated with endosome function128, 153, 273, 274. 
To confirm that inhibition of dfTAT penetration was not due to changes in the endocytic 
pathway, cells were incubated with anti-BMP for only a short time. Similarly as before, 
incubation with anti-BMP (50 μg/mL, for 30 min) led to a significant decrease in the % of 
cells with dfTAT cytosolic fluorescence distribution. I observed only 6.6 % of cells 
showed penetration of dfTAT into the cytosolic space (Figure 4-13). Moreover, dfTAT 
fluorescence signal co-localized with WT GFP-Rab7, a marker of late endosomes275, 276 
(Figure 4-16). The latter shows that incubation of anti-BMP does not block transport of 
dfTAT to late endosomes. Altogether, these data suggests that dfTAT 
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Figure 4-13 Quantitative analysis of dfTAT penetration in live cells pre-incubated 
with anti BMP. Cells were pre incubated with anti-BMP (50 µg/mL) and washed. 
Subsequently, cells were co-incubated incubated with dfTAT (3 μM) and anti-BMP (50 
µg/mL) for 1 h. The number of cells with detectable cytosolic and nuclear fluorescence 
distribution in microcopy images was counted and divided by the total number of cells 
present (1,000 cells per experiment).  
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Figure 4-14 Quantitative analysis of dfTAT intracellular uptake in cells pre-
incubated with anti-IgG and anti-BMP. Cells were pre-incubated with antibodies (50 
µg/mL) for the specified time and washed. Subsequently, cells were co-incubated with 
dfTAT (3 μM) and antibodies (50 µg/mL) for 1 h and relative uptake was assessed 
quantitatively by measuring the bulk fluorescence of cell lysates (300,000 cells per 
experiment). a.u., arbitrary units. The data represent the mean of triplicate experiments 
and the corresponding s.d. 
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Figure 4-15 Incubation of cells with anti-BMP causes dfTAT to remain trapped 
inside endocytic vesicles. Cells were pre-incubated with anti-BMP (50 µg/mL) or anti-
IgG (50 µg/mL) for 18 h, washed, co-incubated with anti-IgG (50 µg/mL) or anti-BMP 
(50 µg/mL) and dfTAT (3 µM) for 1 h. Cells were imaged as before. Scale bars: 100X 
objective, 10 µm 
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Figure 4-16 dfTAT cellular localization in cells pre-incubated with anti-BMP. Cells 
expressing WT GFP-Rab7 were pre-incubated with anti-BMP (50 µg/mL) for 30 min and 
washed. Subsequently, cells were co-incubated with dfTAT (3 μM) and anti-BMP (50 
µg/mL) for 1 h, washed and imaged after 30 min. dfTAT fluorescence signal is shown in 
red and GFP-Rab7 signal is shown in green. Co-localization is displayed as yellow 
(highlighted inside square). Scale bars: 10 µm. 
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endosomal escape requires transport to late endosomes and productive interactions 
between dfTAT and BMP. 
 
4.3 Discussion 
By mediating endosomal leakage, dfTAT escapes from the endocytic pathway 
after entering cells via macropinocytosis. The ability of dfTAT to escape from endosomes 
seems to require transport into late endosomes. Disruption of dfTAT transport to late 
endosomes using DN-Rab5 and DN-Rab7 proved to be effective at inhibiting dfTAT 
endosomal escape and shows that dfTAT endosomal escape does not take place from early 
endosomes. The latter phenomenon associated with dfTAT endosomal escape was true 
even in conditions where the amount of dfTAT endocytosed by cells expressing DN-Rab 
proteins (“treated cells”) was similar than untreated cells.  This clearly shows that high 
peptide cellular uptake is not sufficient to cause endosomal escape. Further suggesting that 
transport to these vesicles (late endosomes) is a key step in the mechanism of dfTAT cell 
penetration. 
The ability of dfTAT to escape the endocytic pathway was also blocked when anti-
BMP, an antibody known to bind and disrupt BMP dynamics, was incubated with cells 
and allowed to accumulate in late endosomes prior to treatment of dfTAT with cells. 
Interestingly, transport of dfTAT to late endosomes was detected in cells treated with anti-
BMP.  Previous data shows that dfTAT endosomal escape requires transport to late 
endosomes.  Furthermore, this evidence hints that once the peptide reaches these BMP-
enriched vesicles effective interactions between dfTAT and BMP are required for dfTAT 
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endosomal escape. This is consistent with evidence showing that TAT can disrupt 
membranes containing BMP and cause leaky fusion (in a BMP concentration dependent 
manner) more efficiently than with membranes that do not contain this phospholipid. 
Future experiments will be performed to investigate, in much more detail, the interactions 
between dfTAT and BMP and its ability to disrupt membranes that resemble different 
endocytic organelles including the membranes of intraluminal vesicles found inside late 
endosomes.           
 A remarkable aspect of dfTAT-mediated delivery is the minimal effect it has on 
cellular processes such as: cell division, transcription and endocytosis after achieving 
efficient endosomal leakage (as discussed before in chapter 3). It is known that endosomal 
lysis can be extremely toxic, in part, due to rapid release of calcium, from endocytic 
vesicles, into the cytosol of cells178. In addition, the leakage of endolysosomal proteases 
could contribute to toxicity247-250. Interestingly, dfTAT does not cause the release of a cell 
impermeable peptide, DEAC-K9, which was allowed to accumulate inside lysosomes. The 
latter suggests that dfTAT does not cause leakage of lysosomes, does not cause leakage of 
lysosomal proteases into the cytosolic space of cells and does not escape from these 
vesicles. This evidence could explain, in part, the observation that cells are not only viable 
but also healthy after dfTAT-mediated endosomolysis. However, these results are 
presumably only valid for the incubation conditions used in my assays. For example, 
continuous endosomal leakage induced by particulate wear debris (discussed also in 
chapter 3) have shown to induce inflammation and apoptosis251. Therefore, dfTAT 
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treatment could be detrimental to cells if administered for long incubation times. Future 
experiments will be performed to address these concerns. 
 
4.4 Materials and methods 
4.4.1 Peptide design, synthesis and purification 
 All peptides were synthesized in-house on the rink amide MBHA resin 
(Novabiochem) by solid-phase peptide synthesis (SPPS) using standard Fmoc protocols. 
Fmoc-Lys(Mtt)-OH, Fmoc-D-Lys(Dde)-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-Lys(Boc)-
OH, Fmoc-Gly-OH, Fmoc-D-Gly-OH,  Fmoc-Arg(Pbf)-OH, Fmoc-D-Arg(Pbf)-OH,  
Fmoc-Gln(Trt)-OH, Fmoc-D-Gln(Trt)-OH, Fmoc-Cys(Trt)-OH and Fmoc-D-Cys(Trt)-
OH (Novabiochem) were used to assemble the peptides (D-amino acids were used to 
generate the D peptide versions). Reactions were carried out in a SPPS vessel at room 
temperature using a stream of dry N2 to provide agitation. Fmoc deprotection was 
performed by addition of piperidine in dimethylformamide (DMF) (Fisher) (20 %, 10 mL) 
to the Fmoc-peptide resin (0.30 mmol). Deprotection reactions were carried out once for 
5 min (1 × 5 min) and 1 × 15 min with a washing step in between reactions. Amino acid 
coupling reactions were carried out for 4 h with a mixture of Fmoc-amino acid (1.2 mmol), 
HBTU (Novabiochem) (0.44 g, 1.1 mmol) and di-isopropylethylamine (DIEA) (Sigma) 
(0.51 mL, 3.0 mmol) in DMF. Upon completion of the reactions, the resin was washed 
with DMF and dichloromethane (DCM) (Fisher). For DEAC-K9, the DEAC fluorophore 
(AnaSpec) was coupled to the N terminus of the peptide after coupling of the ninth Fmoc-
Lys(Boc)-OH using a mixture of DEAC, HBTU and DIEA (4, 3.9 and 10 molar 
	 171
equivalents (eq) with respect to the peptide) in DMF. The reaction was carried out 
overnight using a stream of dry N2 to provide agitation. For CK(ε-NH-TMR)TATG 
(fTAT), the Mtt protecting group at the ε-amino group of Lys on CK(ε-NH-Mtt)TATG 
was cleaved with 2 % trifluoroacetic acid (TFA) (Fisher) and 2 % tri-isopropylsilane (TIS) 
(Sigma) in DCM, and the resin was washed with DCM and DMF. For the D version of 
CK(ε-NH-TMR)TATG (ck(ε-NH-TMR)tatg, D-fTAT), the Dde protecting group at the ε-
amino group of Lys on ck(ε-NH-Dde)tatg was cleaved with 2 % hydrazine monohydrate 
in DMF (25 mL/g of resin). To couple and label the peptides with TMR, a mixture of 
TMR, HBTU and DIEA (4, 3.9 and 10 eq with respect to the peptide) in DMF was added 
to the resin, and the reaction was carried out overnight using dry N2 to provide agitation. 
Following Fmoc-deprotection and peptide assembly, the resin was washed with DCM and 
dried in vacuo. The resin was then treated with TFA containing 2.5 % H2O, 2.5 % TIS and 
2.5 % ethanedithiol (EDT) (Sigma) for 3 h at room temperature to achieve global 
deprotection and cleavage from the resin. The crude peptide products were precipitated 
and washed with cold anhydrous Et2O (Fisher). The precipitates were resuspended in 
water and lyophilized. The products obtained were then resuspended in 0.1 % aqueous 
TFA/acetonitrile. The peptides were analyzed and purified by reverse-phase HPLC. HPLC 
analysis was performed on a Hewlett-Packard 1200 series instrument and an analytical 
Vydac C18 column (5-μm particle size, 4 mm × 150 mm). The flow rate was 1 mL/min, 
and detection was at 214 nm and 550 nm. Semi-preparative HPLC was performed on a 
Vydac C18 10 × 250–mm column. The flow rate was 4 mL/min, and detection was at 214 
nm and 550 nm. All runs used linear gradients of 0.1% aqueous TFA (solvent A) and 90% 
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acetonitrile, 9.9 % water and 0.1% TFA (solvent B). The correct identity of the peptides 
was confirmed by MALDI-TOF performed with a Shimadzu/Kratos instrument (AXIMA-
CFR). fTAT and D-dfTAT expected mass was 2,041.17; dfTAT observed mass was 
2,040.66. D-fTAT observed mass was 2,042.77 DEAC-K9 expected mass, 1,412.97; 
observed mass, 1,415.59. 
 
4.4.2 Generation of dfTAT and D-dfTAT by dimerization of CK(TMR)TATG 
(fTAT) or ck(TMR)tatg (D-fTAT) 
 dfTAT and D-dfTAT was formed by dissolving (0.3 mg, 1.5 × 10−4 mmol) fTAT 
or D-fTAT in aerated phosphate buffer saline (PBS), pH 7.4 (5 mL). Oxygen dissolved in 
the buffer acted to oxidize the thiol groups on the peptides and form a disulfide bond. The 
reaction was allowed to react overnight until completion (100 % yield according to HPLC 
analysis). The product was purified using analytical reverse-phase HPLC. dfTAT and D-
dfTAT expected mass, 4,080.34; dfTAT observed mass, 4,084.21; D-dfTAT observed 
mass 4,078.87 
 
4.4.3 Cell lines 
 HeLa (ATCC CCL-2) were grown in Dulbecco's minimum essential medium 
(DMEM) (Fisher) supplemented with 10% fetal bovine serum (FBS) (Fisher) and 1× 
penicillin/streptomycin (P/S) (Fisher) and kept at 37 °C in a humidified atmosphere 
containing 5 % CO2. Cultures were tested for Mycoplasma contamination using the PCR 
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Mycoplasma Test Kit II (PromoKine). HeLa cells were profiled using STR, by ATCC 
before purchase. 
 
4.4.4 Delivery of peptides inside live cells 
 Cells were seeded in eight-well dishes so that the cells were 80–90 % confluent 
after 48 h. Each well was washed three times with PBS and Leibovitz's L-15 medium that 
did not contain the amino acid cysteine (nonreducing L-15, nrL-15). The medium (nrL-
15) used for incubation lacks cysteine to avoid reduction of the disulfide bond of dfTAT 
or D-dfTAT. Cells were then incubated with dfTAT or D-dfTAT (using a specified 
concentration) at 37 °C for 1 h. Cells were washed three times with PBS and nrL-15 and 
placed on an inverted epifluorescence microscope (Model IX81, Olympus) equipped with 
a heating stage maintained at 37 °C. Images were collected using a Rolera-MGI Plus back-
illuminated electron-multiplying charge-coupled device (EMCCD) camera (Qimaging). 
Images were acquired using bright-field imaging and three standard fluorescence filter 
sets: CFP (excitation (Ex) = 436 ± 10 nm/emission (Em) = 480 ± 20 nm), RFP (Ex = 560 
± 20 nm/Em = 630 ± 35 nm) and FITC (Ex = 488 ± 10 nm/Em = 520 ± 20 nm). The 
fluorescence intensities of different cells were measured with the SlideBook 4.2 software 
(Olympus), and the average fluorescence intensity was determined for each condition. Our 
laboratory has previously reported that cell-penetrating peptides labeled with fluorophores 
such as TMR can photosensitize membranes and cause endosomal leakage upon light 
irradiation175, 246. To minimize the role played by light irradiation in the activities reported 
herein, I performed all delivery experiments under conditions of minimal light irradiation 
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(dark room with dim red light). When fluorescence imaging was required, probes (for 
example, DEAC-K9 and LysoTracker® Green) were imaged before dfTAT and D-dfTAT 
images were acquired. dfTAT and D-dfTAT were also excited for only a maximum of 300 
ms. In contrast, the light dose required to observe light-induced endosomal leakage was 
typically 10- to 20-fold greater than that used for imaging. 
 
4.4.5 Determination of dfTAT cell localization and quantitative determination of 
dfTAT endosomal escape in cells expressing DN-Rab5 and DN-Rab7 
HeLa cells were seeded in eight-well dishes, grown and washed as described in the 
prior section. Cells expressing DN-Rab5 or DN-Rab7 were incubated with 3 μM dfTAT 
for 1 h at 37 °C. Cells were washed three times with heparin/PBS and nrL-15. Images 
were acquired as described before. For transfection and expression of DN-Rab5 
(Rab5(Q79L)) and DN-Rab7 (Rab7(Q67L)), plasmids (purchased from addgene) were 
mixed with Lipofectamine 2000 reagent in opti-MEM medium and incubated at room 
temperature for 30 min. The DNA complex was added to previously seeded HeLa cells 
(70-80 % confluent) on an eight-well dish, and cells were kept at 37 °C for 18 h. After 18 
h, the wells were washed three times with PBS and nrL-15 before performing the delivery 
experiments using dfTAT. Cells displaying a cytosolic/nuclear fluorescence distribution 
was established to determine the % of cells with cytosolic/nuclear dfTAT fluorescence 
distribution and divided by the total number of cells in the well, as determined from bright 
field images (~2000 cells were counted in each experiments).  
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4.4.6 Delivery of DEAC-K9 inside live cells with dfTAT or D-dfTAT 
 HeLa were seeded in eight-well dishes, grown and washed as described in the prior 
section. Cells were incubated with 10 μM DEAC-K9 for 1 h at 37 °C. Cells were washed 
three times with heparin/PBS and nrL-15 and placed on the heating stage maintained at 
37 °C. The delivery peptide was incubated with cells quickly after or 2 h after washing the 
cells for 1 h at 37 °C. Cells were washed three times with heparin/PBS and nrL-15 and 
LysoTracker® Green (250 nM) was added.  Images were acquired as described before. 
 
4.4.7 Quantitative analysis of dfTAT delivery in cells incubated with anti-BMP 
HeLa cells were seeded in eight-well dishes, grown and washed as described in the 
prior section. Cells were incubated with 50 µg/mL purified mouse monoclonal anti-BMP 
(6C4) (Echelon Biosciences, Cat. No. Z-PLBPA) for 30 min (short incubation) or 18 h 
(long incubation) at 37 °C. Cells were washed three times with heparin/PBS and nrL-15 
and placed on the heating stage maintained at 37 °C. dfTAT (3 µM) was incubated with 
cells for 1 h at 37 °C. Cells were washed three times with heparin/PBS and nrL-15. Images 
were acquired as described before. Cells displaying a cytosolic/nuclear fluorescence 
distribution was established to determine the % of cells with cytosolic/nuclear dfTAT 
fluorescence distribution and divided by the total number of cells in the well, as 
determined from bright field images (~2000 cells were counted in each experiments). 
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4.4.8 Quantitative determination of peptide uptake inside cells 
 HeLa cells were seeded in a 48-well dish, grown and washed as described above. 
For the DN-Rab5 and DN-Rab7 and anti-BMP or FITC mouse anti-human IgG (Abcam 
99772) experiments cells were incubated with dfTAT (specified concentration) after 
transfection and incubation with antibody, respectively. For the retro-2 experiment, cells 
were incubated with dfTAT (specified concentration) after incubating cells with retro-2 
(20 µM) for 30 min as described before in (270). Cells were then washed with PBS with 
heparin (1 mg/mL) and nrL-15 and imaged. To lyse cells, I removed nrL-15 from the 
wells, and a total of 100 μL of lysis buffer (50 mM Tris, pH 7.5, 2 mM EDTA, 2 mM 
DTT, 0.1 % Triton X-100) were incubated with cells for 5 min. Cells were scraped off the 
dish, and the cell lysate was pipetted into a 1.5-mL microcentrifuge tube and centrifuged 
at 13,000 r.p.m for 25 min (rotor radius: 8.4 cm). For uptake measurement, 70 μl of 
supernatant were collected and placed in a 96-well plate. The fluorescence emission 
intensity was measured using a plate reader equipped with a fluorescence module (Ex = 
525 nm, Em = 580–640 nm) (GloMax-Multi+ Detection System, Promega). Fluorescence 
intensities were normalized to total protein concentration in each well (determined by 
Bradford protein assay, wherein 10 μl of each cell lysate is added to 200 μL of a 1× protein 
assay reagent and then incubated at room temperature for 30 min; absorbance at 600 nm 
is measured using the plate reader). All experiments were performed in triplicate. 
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5. CONCLUSION 
 
 Due to the enhanced functional activity observed from specific molecules that exist 
in nature (viruses, antibodies), I propose that multivalency can be used to increase the 
delivery activity of monomeric CPPs. In chapter two, I generated a series of multivalent 
peptide constructs of the CPP TAT to establish the effect of multivalency in CPP delivery 
and to study the mechanism of multivalent CPP penetration. I observed a significant 
increase in the endosomolytic activity of the CPP TAT after conjugating TAT-thioester to 
a scaffold peptide containing n number of LysGly repeats (n =3) and displaying multiple 
copies of this CPP. This trimeric endosomolytic agent was able to deliver intact functional 
molecules into the cytosolic space of live cells, including a bioactive cell-impermeable 
peptide that can cause apoptosis. Interestingly, a dimeric version of this multivalent 
peptide construct could not escape from endosomes while a tetrameric version was not 
able to reach the cytosolic space of cells due to unproductive plasma membrane binding. 
The results revealed that although multivalency is an effective strategy to increase the 
endosomolytic activity of CPPs increasing the number of CPP copies display in the 
delivery agent does not always translate to increase in delivery activity. However, this 
phenomenon may vary between multivalent CPPs displaying different sequences and 
structures and might not be true for other multivalent CPPs. Yet, finding just the right 
number of CPPs that will lead to the highest achievable delivery activity is key to generate 
improved delivery agents.  
	 178
The synthesis protocol for these multivalent delivery agents was difficult and 
produced low yields. Furthermore, the amount of delivery agent required to study and 
establish the mechanism of penetration involved in multivalent CPP-mediated 
macromolecule delivery, which was my main goal, was high.  For this reason I set out to 
develop a new delivery agent that displayed highly efficient endosomolytic activity but 
that, at the same time, was simple to generate in high yields. In chapter three, I observed 
that a dimeric-branched multivalent delivery agent of the CPP TAT, dfTAT, penetrated 
live cells by escaping from endosomes with remarkable high efficiency (dfTAT can be 
produced by simple disulfide bond formation in high yields). Moreover, I found that 
dfTAT escaped the endocytic pathway and entered the cytosolic space of cells more 
efficiently that its monomeric counterpart even when both peptides where present inside 
endocytic vesicles at the same amounts. Consequently, I was able to directly establish for 
the first time that displaying multiple copies of a CPP can increase its endosomolytic 
activity. Furthermore, dfTAT delivered different proteins including a fluorescent protein, 
EGFP, an enzyme, Cre-recombinase, a mitochondrial antibody, anti-ATP5A and a 
transcription factor, HoxB4 using a simple co-incubation protocol. Delivery was achieved 
in multiple cell types including primary cells and I observed that only a few molecules 
remained trapped inside endosomes. Interestingly, I was able to deliver multiple molecules 
inside cells simultaneously and more than once and the amount of cargo delivered could 
be controlled. Remarkably, noticeable negative effects on cell viability, cell proliferation 
or transcription did not accompany the herculean endosomolytic activity displayed by 
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dfTAT. These results revealed that dfTAT offers several advantages over existing delivery 
agents. 
Throughout my studies, I aimed to better understand the mechanism of multivalent 
CPP penetration. In chapter four, I observed that dfTAT penetration was blocked after 
expression of DN-Rab5 and DN-Rab7 in cells. This result revealed that dfTAT does not 
escape from early endosomes and that it has transport and reach endocytic vesicles found 
late in the endocytic pathway to escape from endosomes. I found that dfTAT could not 
cause leakage of DEAC-K9, which accumulates inside lysosomes. This result revealed 
that dfTAT does not escape from lysosomes. Furthermore, this shows that dfTAT 
presumably does not cause leakage of lysosomal proteases. This, in part, can explain the 
observed low cytotoxicity associated with dfTAT endosomolysis. Finally, I showed that 
dfTAT penetration is blocked by an antibody that accumulates in late endosomes, binds 
and disrupts BMP dynamics, anti-BMP. This result revealed that both transport to late 
endosomes and interactions between BMP and dfTAT are necessary for penetration of 
dfTAT inside live cells. The collective of insights herein provides a basis for the design 
of improved delivery agents that could prove useful for the delivery of molecules. 
Moreover, the delivery agents shown here, specially dfTAT, could be very useful for 
delivery of molecules into tissues, manipulation of cells in a culture (cell reprogramming), 
the study of cell processes in live cells (cell-based assays) and cell imaging applications. 
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